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Abstract 
The objective was to explore the role of GPR41 (FFAR3) and GPR43 
(FFAR2) in colonic physiology and potential involvement in appetite control. 
The expression of SCFA receptors mRNA across the longitudinal axis of 
healthy mice, pig and human colon were found to be similar. 
Immunohistochemistry revealed FFAR2 and FFAR3 to be localised to flask 
shaped cells deep in colonic crypts and were identified as open type 
enteroendocrine cells by co-localisation with chromogranin A, a classical 
marker of enteroendocrine cells using both pig and human colon tissue. 
Further co-localisation studies with pig colonic tissue showed the SCFA 
receptors are co-localised with serotonin (enterochromaffin cells), and the 
satiety peptides, peptide YY (PYY) and glucagon like peptide 1 (GLP-1), 
indicative of enteroendocrine L cells. Impact of dietary fibre was assessed 
using colonic tissue collected from pigs fed a fermentable carbohydrate diet 
were compared to a control diet of less fermentable carbohydrate. Results 
demonstrate steady state SCFA concentrations exist in the colonic lumen, 
explained by enhanced uptake of SCFA due to an increased expression of 
SCFA transporter (MCT1). Dietary fibre was found to have minimal impact on 
relative abundance of the SCFA receptors mRNA across the longitudinal axis 
of pig colon. However, evaluation of the satiety peptides, PYY and pro-
glucagon (precursor of GLP-1) mRNA have revealed a statistical significant 
increase in PYY but not pro-glucagon mRNA. Subsequently, attention was 
focused toward use of in-vitro models to explore SCFA receptors in appetite 
control. Initial in-vitro experiments assessed activity profile of SCFA receptors 
and evaluated chemical tools used to differentiate between FFAR2 and 
FFAR3. Murine ‘GLUTag’ and human ‘NCI-H716’ in-vitro models of 
enteroendocrine ‘L cells’ were characterised and SCFA induced GLP-1 
secretion evaluated.  10mM butyrate and 10µM 4-CMTB induced GLP-1 
release. RNA interference was used in attempt to knockdown FFAR2 in NCI-
H716 cells to evaluate SCFA sensor’s involvement in GLP-1 release. In 
summary, luminal SCFA may stimulate SCFA receptors of enteroendocrine 
cells releasing peptides; GLP-1, PYY or serotonin to co-ordinate gut motility 
and appetite. 
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Anatomy of the human colon 
Anatomy of the large intestine 
The colon is the last organ of the alimentary canal. It has a horseshoe shape 
with an average length of 1.5m and an average diameter of 7.5cm, around 
three times larger than the small intestine. The large intestine is found within 
abdominal cavity supported by a serous membrane known as the 
peritoneum. The posterior peritoneum anchors the colon to the abdominal 
wall while the visceral peritoneum attaches to the colon. This double layered 
membrane is considered the mesenteric organ supplying nerves, blood and 
lymphatic vessels. This continuous structure is often referred to as the 
mesocolon defined by its attachment to anatomical regions of the colon 
which can be separated into three sections; the caecum, the colon - the 
ascending, transverse, descending and sigmoid colon - and the rectum 
(Martini. 2006; Tortora and Derrickson. 2012).  
The terminal ileum connects the small intestine to the large intestine through 
the ileocaecal sphincter found at the medial surface of the caecum. This is a 
pouch-like structure, approximate 6cm in length and quite variable in size. 
Found attached at the posteromedial surface is the vermiform appendix 
approximately 9cm in length. The mesoappendix supports this structure 
connecting it to the ileum and caecum. From the superior border of the 
caecum, the ascending colon raises 12-20cm up the right lateral-posterior 
wall of abdominal cavity. At the inferior surface of the liver the colon takes a 
sharp left at the right colonic (hepatic) flexure marking the beginning of the 
transverse colon measuring ≈50cm in length (Martini. 2006; Tortora and 
Derrickson. 2012). 
The greater omentum separates the transverse colon from the abdominal 
wall, while the transverse mesocolon provides support across the anterior 
surface of the abdomen above the small intestine. At its end is another sharp 
turn, the left colonic (splenic) flexure. The descending colon runs vertically, 
approximately 25cm down the left side of the abdomen firmly attached to the 
abdominal wall to the iliac foss, forming the sigmoid flexure. Approximately 
15cm in length, the sigmoid colon has a characteristic S shape passing 
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posterior to the bladder connecting the descending colon to the rectum. The 
final portion of the colon measures 15-20cm in length descending anterior to 
the coccyx. The last 2-3cm gives rise to columns of Morgagni which meet 
transverse folds marking the end of the functional colon through the anus. An 
orifice tightly controlled by internal and external sphincters (Martini. 2006; 
Tortora and Derrickson. 2012). 
Anatomy of pig colon  
The colon is 21% of the total length of the pig intestine with an average 
length of five meters and a capacity of approximately ten litres in pigs 
weighing 100kg (Kararli. 1995). The caecum is well-defined with capacity 
between 1.5 to 2.2L (Frandson, et al. 2009). Positioned in front of the left 
kidney it is a blind sac that connects to the colon near the ileocaecal junction. 
Similar to humans all regions of the pig colon is sacculated but like ruminants 
the ascending colon is made up of a series of coils, the proximal, spiral and 
distal loops that are collectively referred to as the spiral colon. The spiral loop 
has a cone shape connecting to the transverse colon in the upper quadrant 
of abdominal cavity. Crossing the left side of the abdomen it reaches the 
distal colon running backward towards the rectum to terminate at the anus 
(Frandson, et al. 2009; Dyce. 2010). 
 
Anatomy of the mouse colon 
The large intestine is comprised of the caecum, colon and rectum. The 
caecum a well-defined blind sac with a kidney-like shape positioned in the 
lower abdominal cavity without an attached appendix. Its two openings are 
close together connecting the ileum and colon. The mouse colon is neither 
coiled nor sacculated divided into ascending, transverse and descending 
colon. The ascending colon rises from the caecum to reach the stomach 
pylorus. A short transverse colon connects to the descending colon running 
towards the posterior body cavity exiting through a short rectum at the anus 
(Jackson, et al. 1975; Cook. 1965). 
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The thin-thickness of the colonic wall is comprised of four histological tissue 
layers; the apical mucosa, the muscularis mucosae, the submucosa, the 
muscularis externa and the surrounding serosa. Structure and function of 
each layer will now be explained independently. 
Histology of the colonic wall 
 
 
 
 
 
 
 
 
 
Figure 1.1: A diagrammatic illustration of the histological structures of 
the colonic wall (adapted from Tortora and Derrickson. 2012) 
Mucosa 
The colonic mucosa is devoid of projecting villi making it much thinner than 
the mucosa of the small intestine. This mucous membrane functions as a 
barrier against luminal content. An epithelial layer is in direct contact with 
luminal content and is supported by the underlying lamina propria. The 
lamina propria is a loose network of connective tissue containing blood and 
lymphatic vessels transporting absorbed nutrients to other sites in the body. 
Scattered throughout are large lymphatic nodules containing immune cells of 
the mucosa-associated lymphatic tissue for defence against disease. 
Connective tissue of the lamina propria binds to the underlying muscularis 
mucosae (Martini. 2006; Tortora and Derrickson. 2012). 
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Muscularis mucosae 
The muscularis mucosa separates the lamina propria of the mucosa from the 
submucosa. This structure is a thin layer of circular smooth muscle 
surrounded by a thin layer of longitudinal smooth muscle responsible for 
agitating the mucosae to expose the apical epithelial cells to the luminal 
content (Martini. 2006; Tortora and Derrickson. 2012). 
 
Submucosa 
The submucosa is an intermediate collection of loose connective tissue 
between the muscularis mucosa (interior) and muscularis externa (exterior). 
In the submucosa nutrients are absorbed by blood and lymphatic vessels. 
Scattered throughout are a number of large lymphoid nodules like those of 
the lamina propria of the mucosa. Also, a collection of nerves fibres are 
present that form the plexus of Meissner, the submucosal plexus of the 
enteric nervous system (Martini. 2006; Tortora and Derrickson. 2012). 
 
Muscularis externa 
The muscularis externa is a prominent feature of the colon. The muscularis 
usually consists of a layer of circular smooth muscle encased in a layer of 
longitudinal smooth muscle, but not in the colon. Instead three bands of 
longitudinal smooth muscle form the taenia coli that run beneath the serosa 
across the entire length of the colon. The muscular tone of the taenia coli can 
form a series of pouches in the colonic wall called haustra (observed in 
human and pig colon). These structures are formed by a series of internal 
folds in the colonic mucosa that allow expansion and elongation of the colon 
during bacterial fermentation and also accommodate the passage of colonic 
content (Young, et al. 2006). Contractions of the muscularis are mostly 
controlled by the plexus of Auerbach, the myenteric plexus of the enteric 
nervous system localised between these muscle layers. The outer layer is 
longitudinal muscle that is coated by the connective tissue of the serosa 
(Martini. 2006; Tortora and Derrickson. 2012). 
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Serosa 
The serosa is part of the visceral peritoneum that adjoins to the mesentery, 
attaching the organ to the abdominal wall. This serous membrane consists of 
an outer layer of mesothelium surrounding loose connective tissue supplying 
blood, lymphatic vessels and nerves to the attached colon. In humans a 
feature of the colonic serosa is the presence of numerous tear shaped 
pouches of fat that attach to the underlying taenia coli known as epiploic 
appendages (Martini. 2006; Tortora and Derrickson. 2012). 
 
Enteric nervous system 
The enteric nervous system is considered the brain of the gut consisting of 
approximately 400-600 million neurons in man (Furness, et al. 2014), within a 
set of two intrinsic nerve plexus. The plexus of Auerbach (myenteric plexus) 
mostly controls gut motility while the plexus of Meissner (submucosal plexus) 
responds to luminal content. These plexus are comprised of motor, sensory 
and interneurons. Motor neurons regulate gut motility by the myenteric 
plexus, and regulate secretory cells of mucosal epithelium via the 
submucosal plexus. Sensory neurons within the submucosal plexus function 
as stretch and chemoreceptors that are activated by arrival of luminal 
content, stimulating afferent neural signals to the brain through the vagus 
nerve. Local communication between motor and sensory neurons occurs 
through interneurons, forming a bridge between the two plexi. The enteric 
nervous system is mostly self-functional but is also regulated by the 
autonomic nervous system through parasympathetic nerve fibres of the 
vagus nerve and the sacral spinal cord. Stimulation enhances the actions of 
the enteric nervous system to increase secretions and gut motility. Opposing 
effects are mediated through inhibitory actions of sympathetic nerve fibres 
from thoracic and upper lumber regions (Martini. 2006; Tortora and 
Derrickson. 2012). 
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The colonic epithelium has a flat surface devoid of villi. It covers the entire 
inner surface of the large intestine with an abundance of finger-like 
invaginations known as the glands of Lieberkühn. These intestinal crypts 
span deep into the colonic mucosa surrounded by connective tissue of the 
lamina propria. The intestinal epithelium is renewed throughout life, once 
every five to seven days. In humans the chemical and physical insults from 
luminal content cause loss of up to 10
Histology and organisation of the colonic epithelium 
11
During growth into adulthood colonic crypts divide to accommodate growth of 
the organ (Totafurno, et al. 1987). In adulthood, human colonic crypt 
dynamics have shown crypt fission to occur once in every 30-40 years 
(Baker, et al. 2014). As a functional unit, colonic crypts have a stereotypical 
structure divided into three compartments; the crypt base, mid crypt and the 
crypt apex. Localised at the crypt base are intestinal pluripotent stem cells 
that divide to give rise to two daughter cells, a replacement stem cell and a 
nascent transit-amplifying (TA) cell. Dividing in an outward direction nascent 
TA cells are highly proliferative undergoing several cell divisions in the 
transit-amplification zone below the mid crypt. Migrating upward toward the 
crypt apex to differentiate into mature cells of the epithelium of two classes 
either absorptive cells or those producing secretions (Barker, et al. 2007). 
 epithelial cells each day. To maintain 
integrity of the physical barrier, it is essential that lost cells are replaced by 
new cells via epithelial homeostasis (Barker, et al. 2007).  
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Stem cells 
Intestinal stem cells are drivers of epithelial homeostasis and regeneration. 
These are self-renewing cells responsible for generating the cell lineages 
giving rise to the intestinal epithelium; each crypt contains 4-6 stem cells. 
Adult stem cells reside within a stem cell niche at the crypt base surrounded 
by crypt base columnar (CBC) stem cells. The stem cell niche has not been 
as well defined in the colon as in the small intestine which is regulated by 
signals from neighbouring cells and intestinal nutrients (Barker, et al. 2014). It 
has been observed that a ‘reserve’ stem cell population located at the +4 
position from the crypt base is recruited after injury supporting regeneration 
of the CBC stem cell population (Buczacki, et al. 2013).  Stem cell 
localisation in colonic crypts were demonstrated using a specific biomarker 
known as Leu-rich repeat containing G protein coupled receptor 5, LGR5 
(Barker, et al. 2007). 
 
Colonic stem cell division is much slower than in the small intestine which 
allows complete renewal of the epithelium every three to five days. In the 
ascending colon stem cells generate 90 cells crypt-1 every 19 hours but 
becomes more rapid in the descending colon giving rise to 190 cells crypt-1
 
 
every 15 hours. Stem cell dynamics in colonic crypts have been studied in-
silico using mathematical models to produce cell lineage reconstruction and 
in-vivo using approaches involving organoids and lineage tracing methods 
(Reizel, et al. 2011; Barker, et al. 2007). An update in adult intestinal stem 
biology is has been provided in a recent review (Barker. 2014). 
There are at least seven cell types present within the intestinal epithelium 
derived from CBC stem cells. However, only four are usually considered. 
These include absorptive cells (enterocytes / colonocytes) and cells of the 
secretory lineage: goblet cells, enteroendocrine cells and paneth cells. The 
colonic epithelium has a greater abundance of goblet cells than the small 
intestinal epithelium and also lack paneth cells. Lesser cell types include cup 
cells, tuft cells and M cells (Gerbe, et al. 2012) 
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Figure 1.2: An illustration of the colonic crypt structure and cell 
lineages that maintain colonic epithelial homeostasis (adapted from 
Barker. 2014). 
Absorptive cells (Colonocytes) 
The predominant cell type of the colonic epithelium is absorptive colonocytes. 
Collectively, these form a single-cell thick protective barrier across the entire 
surface of the colon. This forms a network of polar cylindrical columnar cells 
with microvilli on their luminal membrane to maximise contact with luminal 
content for absorption. The hallmark of colonocytes is the tight junction 
complexes between adjoining cells (Nusrat, et al. 2000). This forms a 
semipermeable barrier at the apical epithelial intercellular junction acting as 
an interface for nutrient and electrolyte absorption while restricting the 
passage of pathogens (Nusrat, et al. 2000). Recently, the zinc receptor 
(ZnR/GPR39) has been shown to be vital for crypt cell proliferation and 
differentiation of colonocytes (Cohen, et al. 2014). 
 
 
Secretory and absorptive cells 
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Goblet cells 
The cup-like shape goblet cells increase in numbers across the entire length 
of the intestine with highest densities localised to the rectum. The cell type is 
responsible for synthesis and secretion of high molecular weight 
glycoproteins known as mucins. When secreted, they mix with water, 
electrolytes and molecules of the immune system to form a 150μm thick 
mucus layer immediately above the epithelium. This functions as a physical 
protective barrier between luminal content and underlying epithelium 
preventing epithelial dehydration, a lubricant defence against mechanical 
damage during bulk movement of digesta. It also provides a medium for 
absorption of low molecular weight molecules, such as nutrients, and 
prevents the passage of pathogenic microbes (Specian and Oliver. 1991). 
Goblet cell biomarkers include MUC2 and the more recently identified 
bestrophin-2 (Ito, et al. 2013). 
 
Enteroendocrine cells  
Enteroendocrine cells have a characteristic bottle-like appearance localised 
to intestinal crypts. Scattered throughout the intestine are at least ten 
enteroendocrine cell-types, together secreting over twenty different 
hormones (Rehfeld. 2014). Collectively, they are considered the largest 
endocrine system in the human body although they only account for less than 
1% of gut epithelial cells. Their localisation within the gastrointestinal tract 
and their secretory peptides are used as their classification system (Rindi, et 
al. 2004; Gunawardene, et al. 2011). They are defined as either closed-type 
or open-type enteroendocrine cells. Open-type cells possess finger-like 
projections that reach the luminal epithelium and are considered nutrient 
sensing cells of the gut. Closed-type cells are not exposed to luminal content 
but respond to mechanical, neural or paracrine factors (Sternini, et al. .2008). 
Classification and functions of colonic enteroendocrine cells were recently 
discussed in a review by Gunawardene et al (2011). Chromogranin A (ChA) 
was identified as the classical biomarker of enteroendocrine cells (Facer, et 
al. 1985), while more recently neurogenin 3 (Bjerknes and Cheng. 2006) and 
insulin-like peptide encoded by the INSL5 gene were identified 
(Thanasupawat, et al. 2013). 
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Figure 1.3: Overview of the enteroendocrine cell sub-populations of 
different regions of the intestine, hormones released and their 
physiological functions (
Populations 
adapted from Furness, et al. 2013). 
Secretory Peptide 
(Abbreviation) Localisation  Physiological Functions 
G-cells Gastrin (G) Stomach 
Stimulates 
Hunger (Appetite control) 
Growth hormone release 
A cells 
subtypes 
Ghrelin 
(GHRL) Stomach 
Stimulates 
Gastric acid secretion 
ECL cells Histamine (HIST) Stomach 
Stimulates 
Gastric acid secretion 
P cells Leptin (LEP) Stomach 
Stimulates 
Satiety (Appetite control) 
D-cells Somatostatin (SST) 
Stomach 
Small Intestine 
Inhibits 
gastric acid release 
S-cells Secretin (SEC) 
Proximal 
Small Intestine 
Stimulates 
 bicarbonate release 
I-cells 
(Subtypes) 
Cholecystokinin 
(
Proximal 
CCK) Small Intestine 
Stimulates 
Gall bladder contractions 
Pancreatic enzyme 
secretions 
K-cells 
subtypes 
Gastric inhibitory 
peptide Proximal 
(GIP) Small Intestine 
Stimulates 
Insulin Secretion 
M-cells Motilin (MTL) Small Intestine Gastrointestinal motility 
N cells (
Neurotensin Small and 
colon NT) 
Inhibits 
Intestinal contractions 
L-cells 
(subtypes) 
Glucagon-like 
peptide 1 
(GLP-1) 
Distal small 
Intestine and 
colon 
Stimulates 
Carbohydrate uptake, 
Insulin secretion 
 Satiety (Appetite Control) 
EC-cells Serotonin (5-HT) 
Stomach 
Small Intestine 
and colon 
Stimulates 
Motility and secretions 
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Ghrelin 
Hormones involved in appetite control 
Ghrelin is a twenty eight amino acid peptide primary synthesised by X/A-like 
cells of the gastric fundus (Kojima et al. 1999), although present elsewhere in 
the gastrointestinal tract (Date, et al. 2000). Stimulation of ghrelin-producing 
neurons in the hypothalamus causes ghrelin induced growth hormone 
secretion from the anterior pituitary; both peptides are recognised by growth 
hormone secretagogue (GHS) receptors (Kojima et al. 1999). Kojima and 
Kangawa (2005) provide extensive history of ghrelin structure and function. 
In the fasting state circulating levels of ghrelin peak before a meal and 
decrease in proportion to nutritional intake, returning to normal levels within 
sixty minutes (Cummings, et al. 2001; Callahan, et al. 2004). An inverse 
relationship exists between ghrelin levels and body weight, rising after 
weight-loss (Cummings et al. 2002). However, fasting levels in obesity are 
below levels of lean individuals and after a meal circulating levels do not 
return to baseline levels (Le Roux, et al. 2005). Ghrelin influences food intake 
in the central nervous system through the arcuate nucleus of the 
hypothalamus and the brainstem through the vagus nerve (Date, et al. 2002; 
Kirsz and Zieba. 2011). Furthermore, it has recently been proposed that 
ghrelin primes intestinal L cells for nutrient induced GLP-1 secretion 
(Gagnon, et al. 2014). Other effects of ghrelin include adiposity, enhanced 
growth hormone secretion; stimulate the hypothalamo-pituitary-adrenal axis, 
stomach motility, gastric secretions and inhibition of insulin secretion, cardiac 
protection and vasodilation (Korbonits et al. 2004; Van Der Lely, et al. 2004). 
Several in-vitro models are available to study ghrelin secretion including; the 
human thyroid medullary carcinoma cell line, TT cells (Kanamoto, et al. 
2001), the gastric carcinoid cell line, ECC10 cells (Kishimoto, et al. 2003), 
kidney derived cell line, NRK-49F cells (Mori, et al. 2000), and cardiomyocyte 
cell line, HL-1 cells (Iglesias, et al. 2004). 
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Cholecystokinin 
Cholecystokinin (CCK) was the first appetite suppressing hormone to be 
implicated in appetite control (Gibbs, et al. 1973; Kissileff et al. 1981). In 
humans synthesis occurs in a number of tissues but in the intestine CCK is 
localised to enteroendocrine I cells (Buffa, et al. 1976). Bioactive forms of 
CCK are formed from tissue specific post-translational modifications of 
selective cleavage of pro-CCK derived from a 115 amino acid precursors. All 
active forms possess a conserved heptapeptide at the amidated C-terminus, 
CCK-8 is predominant in nervous tissue whereas CCK-58, CCK-33 and 
CCK-22 are synthesised in enteroendocrine I cells (Rehfeld, et al. 2003; 
2008). Following food intake CCK is released into the circulatory system to 
increase concentrations from 1pM to between 5 to 8pM (Liddle et al. 1985), 
detected by two GPCR distributed throughout the central nervous system 
and the gut, CCK-AR and CCK-BR (Huppi, et al. 1995). 
 
Functionally, CCK causes gall bladder contractions, stimulates somatostatin 
secretion and short-term appetite suppression. A recent study has 
demonstrated an enrichment of the short chain fatty acid receptors, FFAR2 
and FFAR3 in I cells of the duodenum (Sykaras, et al. 2012). However, 
previous studies demonstrated CCK secretion is dependent on free fatty acid 
length (McLaughlin, et al. 1998; McLaughlin, et al.  1999). Subsequent 
studies have shown CCK secretion to occur through activation of FFAR1 
(Liou, et al. 2011) and FFAR4 (Tanaka, et al. 2008). Therefore it was 
proposed that SCFA receptor expression be localised at the base of 
duodenal I cells responding SCFA signals delivered by the blood. However, 
their exact localisation within these cells remains to be determined (Sykaras, 
et al. 2012). The G cell derived hormone gastrin is structurally related to CCK 
and recognised by CCK-B receptors on the gastric mucosa (Rehfeld, et al. 
2004). An in-vitro model of CCK secretion is the murine STC-1 cell line 
(Chang, et al. 1994). 
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Glucose-dependent insulinotropic polypeptide 
Glucose-dependent insulinotropic polypeptide, also known as gastric 
inhibitory polypeptide (GIP), is a forty two amino acid hormone formed by 
prohormone convertase 1/3 mediated cleavage of a 153 amino acid pro-GIP 
forming GIP and C-terminal peptide, transcribed from the GIP gene 
(Ugleholdt, et al. 2006). The hormone is expressed throughout the proximal 
intestine with most predominant localisation occurring in enteroendocrine K-
type cells of the duodenum and jejunum. Also enteroendocrine K/L-type cells 
are found throughout the small intestine capable of secreting both GIP and 
GLP-1 (Mortensen, et al. 2003; Theodorakis, et al. 2006). Stimulation of GIP 
secretion was thought to be mediated through nutrient absorption with 
glucose and fat being the most potent stimulators of GIP secretion (Fushiki, 
et al. 1992). However, more recently it was shown that sensing of nutrients 
by cell surface nutrient receptors present on the intestinal endocrine cells 
provoke secretion of GIP (Jang, et al. 2007). 
 
In humans, circulating levels of GIP rise from 0.06-0.10nmol/L to 0.2-0.5 
nmol/L after a meal (Baggio and Drucker. 2007). Bioactive GIP (1-42) has a 
half-life of seven minutes in healthy individuals (Deacon, et al. 2000). 
Dipeptidyl peptidase IV (DPP-IV) cleaves an alanine residue at position 2 to 
yield GIP (3-42), an inactive form of GIP found within circulation (Kieffer, et 
al. 1995), and elimination occurs through the kidneys (Meier, et al. 2004). 
Bioactive GIP elicits its effects through the GPCR, GIP receptors (GIPR). GIP 
primarily functions as an incretin peptide supporting GLP-1 in the modulation 
of pancreatic β-cell physiology. Other physiological actions include 
lipogenesis in adipose tissue, progenitor cell proliferation in the brain and 
enhancement of bone formation while suppressing resorption (Baggio and 
Drucker. 2007). 
 
 
 
 Chapter One 
15 
Glucagon like peptide 1 
Glucagon like peptide 1 (GLP-1) is one of several hormones derived from a 
precursor, 180 amino acid pro-glucagon that is cleaved by pro-hormone 
convertase 1-3 (PC1-3). In the intestine, GLP-1 is localised to 
enteroendocrine L-type cells of the distal ileum and colon. Although synthesis 
also occurs within α-cells of the pancreas and neurons of the solitary nucleus 
in the brain. In the gut and neurons, post-transcriptional processing of the 
preproglucagon gene by PC1 and PC3 generates, glicentin, oxyntomodulin, 
intervening peptide 2, GLP-1 and glucagon like peptide 2, GLP-2 (See review 
by Wren and Bloom. 2007). 
Following a meal, circulating levels of GLP-1 increase within 10-15 minutes in 
proportion to the amount of food consumed reaching maximal levels within 
40 minutes, 15-50 pmol-1
Many forms of GLP-1 exist in circulation including inactive forms secreted 
from enteroendocrine L cells, GLP-1 (1-37) and GLP-1 (1-36) NH
 (Holst. 2007). The L-cell density within the proximal 
intestine is reported sufficient to cause the early increase in GLP-1 secretion 
(Theodorakis, et al. 2006). Later a second peak occurs possibly due to 
nutrient induced GLP-1 secretion from L-cells of the distal ileum and colon. 
More than fifty percent of secreted GLP-1 is inactivated before entering the 
blood circulation by dipeptidyl peptidase-4 (DPP-IV) present on endothelial 
cells and the lining of blood vessels and as a soluble form in the blood 
circulation (Hansen, et al. 1999). 
2 and 
biologically active forms, GLP-1 (7-37) and GLP-1 (7-36) NH2, the latter 
being the most prominent in the human circulatory system (Orskov, et al. 
1994). These have a half-life of approximately two minutes before the 
proteolytic enzyme DPP-IV cleaves at an alanine residue at position 2 
generating inactive GLP-1 (9-37) and GLP-1 (9-36) NH2 (Hansen, et al. 
1999). The importance of this hormone is highlighted by its conserved nature 
across mammalian species and the presence of its recognition GPCR 
(GLP1-R) localisation to appetite controlling centres of the brain, arcuate 
nucleus and the nucleus of the solitary tract. GLP-1 is both important for 
appetite suppression and for controlling circulating levels of glucose. These 
physiological effects are widespread; locally GLP-1 reduces gastric emptying, 
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regulates pancreatic β-cell physiology, and enhances proliferation while 
reducing apoptosis. As an incretin peptide, GLP-1 enhances insulin secretion 
and promotes insulin biosynthesis while lowering glucagon secretion. In 
addition to this the production of glucose in the liver is reduced while uptake 
in peripheral muscle and adipose tissue is enhanced (Baggio and Drucker. 
2007). Beyond glucose homeostasis GLP-1 enhances cardiac function and 
offers cardioprotection and neuroprotection (Baggio and Drucker. 2007). 
Evidence has shown that several in-vitro models exist capable of secreting 
GLP-1 to include murine GLUTag cells (Brubaker, et al. 1998), and human 
NCI-H716 cells (Reimer, et al. 2001). 
Oxyntomodulin  
Oxyntomodulin (OXM) is a thirty seven amino acid formed during post-
transcriptional processing of pro-glucagon secreted from enteroendocrine L-
type cells (Irwin and Flatt. 2013). Similar to GLP-1, OXM shares the ability to 
suppress appetite and reduce food intake in humans, supported by observed 
reduction in circulating levels of ghrelin (Cohen, et al. 2003). This hormone 
shares recognition with the GPCR, GLP1 receptor displaying ability to 
function as low potent incretin peptide (Maida, et al. 2008). Although OXM 
has lower affinity than GLP-1(7-36) for GLP-1R, both function as competitive 
full agonists activating differential signal cascades to elicit different 
physiological responses (Koole, et al. 2010). Allosteric modulation of GLP-1R 
has been shown to enhance the ability of OXM to function as an incretin 
peptide (Willard, et al. 2012). 
Peptide YY 
Peptide YY (PYY) was first isolated from the pig intestine (Tatemoto. 1982). It 
is synthesised within intestinal L-cells, as a thirty six amino acid peptide, PYY 
(1-36), increasing in expression across the longitudinal axis of the colon 
reaching highest levels in the rectum (Adrian, et al. 1985). After secretion into 
circulation the N-terminal tyrosine-proline residues are cleaved by DPP-IV to 
form PYY (3-36), the predominant form of PYY in circulation (Grandt, et al. 
1994). The full length peptide PYY (1-36) is localised to areas of the brain 
(Gelegen, et al. 2012). Circulating levels of PYY are low before a meal but 
increase within fifteen minutes of food consumption and peak in less than two 
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hours. Peak levels are proportional to calories ingested and can remain 
elevated for up to six hours (Batterham, et al. 2003), with ability to 
suppressing appetite. The STC-1 cell line is the only in-vitro model recorded 
to secrete PYY following stimulation (Geraedts, et al. 2009). 
Leptin 
Leptin is a 167 amino acid product of the obese gene (Zhang, et al. 1994). 
The hormone is an adipokine secreted from adipose tissue and is found in 
blood circulation at levels proportional to fat mass (Friedman and 
Halaas.1998). For example in one study concentrations were measured in 
lean individuals at 7.5 ± 9.3 ng ml-1 increasing to 31.3 ± 24.1 ng ml-1
Serotonin 
 in obese 
subjects suggestive of leptin insensitivity (Considine, et al. 1996). Leptin 
crosses the blood brain barrier to be recognised by leptin receptors localised 
to hypothalamic nuclei such as the arcuate nucleus and the paraventricular 
nucleus (Cowley, et al. 2001). The critical role that this peptide has in 
appetite control is highlighted by its deficiency correlating with severe obesity 
(Friedman and Halaas. 1998). Leptin receptors are expressed within 
peripheral tissues and lingual taste buds (Kawai, et al. 2000), and in the 
enteroendocrine L-cells of the gastrointestinal tract where leptin has been 
shown to stimulate GLP-1 secretion (Anini and Brubaker. 2003). 
Serotonin (5-hydroxytryptamine, 5-HT) is often considered a neurotransmitter 
of the central nervous system. However, over 90% of serotonin synthesis, 
storage and secretion originate from the enterochromaffin (EC) cells 
dispersed throughout the intestinal epithelium (Costedio, et al. 2007). 
Interestingly, recent studies have identified that the intestinal microbiota 
regulates host serotonin biosynthesis (Yano, et al. 2015), through actions of 
short chain fatty acids (Reigstad, et al. 2015). Biosynthesis involves uptake of 
dietary tryptophan and conversion by tryptophan hydroxylase and the 
ubiquitous amino acid decarboxylase. EC cells sense and respond to luminal 
content by provoking serotonin secretion and activation of intrinsic and 
extrinsic neurons (Bertrand and Bertrand. 2010). Activation of serotonin 
receptors influence intestinal secretion, motility sensation and regulate food 
intake and cell growth (Hasler. 2009). 
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Figure 1.4: An illustration of regional derived gut hormones and 
physiological functions (top), and the half-life of hormone activity in 
minutes within the circulatory system.  
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The human colon has a mucosal surface area of ≈2000cm
Colonic physiology 
2
Mechanisms of water and electrolyte transport 
 and an even 
greater absorptive surface area due to colonic crypts (Edmonds. 1971). 
Approximately, 90% of the 1.5-2.0 litres of ileal effluent entering the colon 
every day are absorbed (Debongnie and Phillips.1978). Since electrolyte 
absorption is accompanied with uptake of water, it is considered the rate 
limiting step in water absorption (Sandle. 1998). In the intestine, several 
transporters are tightly coupled to water absorption; 1) the small intestinal 
sodium-dependent glucose transporter 1 (SGLT1), 2) the sodium-hydrogen 
exchanger 3 (NHE3) and 3) the chloride-bicarbonate exchanger in the colon. 
In the colon, NHE3 is responsible for the majority of Na+ absorption across 
the apical brush border membrane. A process controlled by sodium-hydrogen 
exchanger regulatory factor family members, NHERF1 and/or NHERF2. 
Development of an in-vitro model to study Na+ absorption enabled the roles 
of NHERF1 and NHEF2 to be investigated. Knockdown studies by RNA 
interference revealed: 1) stimulation of NHE3 by epithelial growth factor 
requires NHEF1, and 2) NHERF2 is responsible for cGMP-dependent protein 
kinase II and calcium-dependent inhibition of NHE3, whilst 3) both NHEF1 
and NHEF2 are involved in cAMP-dependent inhibition of NHE3 (Sarker, et 
al. 2011). Na+ absorption is made electroneutral by absorption of Cl- ions via 
chloride-bicarbonate exchanger (SLC26A3), accompanied by release of 
HCO3- into the colon. HCO3- secretion also occurs through HCO3- 
conductance (Tang, et al. 2009), and accompanies absorption of short chain 
fatty acids (SCFA) from the colonic lumen via SCFA-HCO3- exchanger, the 
predominant mechanism for HCO3-
Several transporters are also localised to the basal-lateral membrane that are 
involved in absorption and secretion of electrolytes (Bachmann, et al. 2011). 
Na
 secretion in the mammalian colon 
(Vidyasagar, et al. 2005).  
+ and HCO3- ions are taken up from surrounding interstitial fluid via 
sodium-hydrogen exchanger 1 (NHE1) regulated by binding of carbonic 
anhydrase II (Li, et al. 2006), and also the Na+ HCO3- symporter, SLC4A4  
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(Barmeyer, et al. 2013), whilst Cl- ions are taken up in exchange for release 
of HCO3- ions by the Cl- HCO3-
Potassium (K
 exchanger, SLC4A2 (Gawenis, et al. 2010). 
+) is most abundant ion in the human body reaching 
concentrations between 3.5mM - 5.0mM in blood circulation and interstitial 
fluid surrounding tissues, while inside cells concentration is approximately 
75mM. To ensure normal cell function it is vital that this concentration 
gradient is maintained. To provide an overview of how the K+ concentration 
gradient is controlled, localised at the baso-lateral membrane are sodium-
potassium ATPase that mediate exchange of Na+ (inside cell) for K+ (outside 
cell), also sodium-potassium-chloride co-transporters mediate uptake of Na+, 
K+, and Cl- ions into epithelial cells (Boron, et al. 2005). As a recycling 
pathway, K+ export occurs across the baso-lateral membrane by K+ 
conductance (Aziz, et al. 2002). Furthermore, at the apical membrane K+ is 
released through BK channels (Sausbier, et al. 2006) and reabsorbed by 
hydrogen-potassium ATPase to maintain K+ homeostasis (Horisberger. 
2001). Overall, this tight control of K+ concentration provides a favourable 
electrochemical gradient for secretion of Cl- and HCO3- ions through 
conductance via CFTR, and stimulates K+ secretion via BP channels and Na+ 
absorption through apical Na+
Interestingly, in a recent study, K
 channels (Heitzmann and Warth. 2008).  
+ channels were found localised to a small 
population of goblet cells in the human colon whereas Cl- secretion was 
found to ordinate from a dominant population of colonocytes expressing 
CFTR at the luminal membrane (Linley, et al. 2014). Furthermore, bestrophin 
family member 2 (best2) and sodium-bicarbonate co-transporter, NBCn1, 
were found localised exclusively to the baso-lateral membrane of goblet cells 
(Yu, et al. 2010; Singh, et al. 2013). Evidence has also emerged that normal 
mucous formation requires cAMP-dependent HCO3- release, Ca2+ mediated 
mucin secretion (Yang, et al. 2013), and functional CFTR channels 
(Gustafsson, et al. 2012). However, the HCO3-
 
 transporter localised to the 
apical membrane of goblet cells remains unknown (Bachmann and Seidler. 
2011). 
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Figure 1.5: An illustration of proposed mechanisms involved in fluid 
absorption and secretion across the colonic epithelium. At the luminal 
membrane, Na+ absorption primarily occurs through Na+ H+ exchanger 3 
(NHE3) but also through electrogenic Na+ channels (ENaC), promoting 
electrogenic secretion of K+  through BK channels and electrogenic Cl- 
secretion through luminal cAMP-activated cystic fibrosis transmembrane 
conductance regulator (CFTR) channels. While luminal H+ K+ ATPases are 
involved in K+ reabsorption. Luminal secretion of HCO3- and absorption of Cl- 
ions are associated with anionic exchangers (such as AE4, SLC26(A3/A6)). 
Furthermore, HCO3- and/or Cl- secretion have been associated with SCFA- 
absorption involving exchangers. At the basolateral membrane, Na+ and 
HCO3- absorption occurs via a symporter (NBC), K+ uptake is mediated by 
Na+ K+ ATPase and Na+ K+ 2Cl- co-transporters, such as NKCC1 (the main Cl- 
uptake mechanism). Furthermore, K+ conductance facilitates K+ efflux 
through multiple channels, while efflux of Cl- occurs through CIC-2 channels 
(Adapted from Sandle and Hunter. 2010). In regard to SCFA transport, SCFA 
uptake across the luminal membrane has been proposed to occur through 
diffusion, a Na+ dependent symporter (SMCT1), and H+ dependent symporter 
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(MCT1). Apical SCFA efflux is an active process involving breast cancer 
resistance protein (BCRP),  while efflux across the baso-lateral membrane is 
carrier mediated involving H+ 
 
dependent symporters, MCT1, MCT4 and 
MCT5 (Adapted from Gill and Dudeja. 2011). 
Colonic microflora and SCFA production 
One hundred trillion micro-organisms consisting of in excess of 1000 different 
bacterial species reside in our gut with the colonic content possessing 1012 
bacteria gram-1
 
 (Chapman. 2001). Each day fifteen grams of bacteria are 
removed comprising of approximately fifty percent of faecal material, 
replaced by bacterial proliferation in the proximal colon (Tappenden and 
Deutsch. 2007). The most abundant bacterial species residing in the colon 
include the bacteriodes, bifidobacterium, eubacteria and propionibacterium 
(Hill. 1995). Each day between 20-60 grams of dietary fibre is consumed 
evading digestion and absorption in the small intestine. This reaches the 
colon as an energy source for our symbiotic microflora, utilised via colonic 
fermentation (Cummings. 1981). Most are saccharolytic bacteria yielding 
SCFA and gases. Some colonic bacteria are proteolytic utilising certain 
proteins, peptides and glycoproteins precursors to yield branched SCFA, 
phenols, amides and gases such as carbon dioxide, methane, hydrogen 
(Robertfroid. 2005). 
SCFA production is dynamic and is influenced by changes in microflora 
populations, diet, absorption, and utilisation of bacterial synthesis and 
transport of water (Dass, et al. 2007). In-vitro fermentation studies have 
shown differential profiles of SCFA production in-vivo in response to different 
sources and types of dietary fibres (Wisker, et al. 1998; Vong and Stewart. 
2013). The two most prominent butyrate producers account 10-20% of total 
bacterial content, these are faecalibacterium prausnitzii of clostridium cluster 
IV (Miquel, et al. 2013), and eubacterium rectale, a rosburia species from 
clostridial cluster XIVa. The microbiology of butyrate production has been 
reviewed (Pryde, et al. 2002; Louis and Flint. 2009). Recently, genes 
involved in bacterial butyrate synthesis pathways such as butyryl CoA, 
acetate CoA-transferase and butyrate kinase have all proven useful targets 
for detection of butyrate producers (Louis, et al. 2010; Vital, et al. 2013). 
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Figure 1.6: A diagrammatic illustration of colonic microbiota derived SCFA production 
(Adapted from Tappenden and Deutsch. 2007; and Louis, et al. 2014)23 
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Short chain fatty acid (SCFA) 
SCFA are weak carboxylic acids (pKa ≈ 4.8) known as monocarboxylates of 
one to six carbon chain length. The major three SCFA, acetate, propionate 
and butyrate account for 95% of total SCFA production (Bergman. 1990). A 
similar SCFA ratio (3:1:1) exists between species with average faecal SCFA 
concentrations reaching 40mM acetate: 15mM propionate: 14mM butyrate 
(Fernandes, et al. 2014). Each day ≈300mM SCFA are generated by colonic 
fermentation with around 90% being rapidly absorbed across the luminal 
membrane through transport mechanisms (see figure 1.5). Interestingly, 
SCFA account for between 5-10% of total human energy demand (McNeil. 
1984; Topping and Clifton. 2001).   
Chain Length Monocarboxylate Structure pKa 
1 Formate (formic acid) 
  
3.55 
2 Acetate (acetic acid) 
 
4.56 
3 Propionate (propionic acid) 
 
4.67 
4 Butyrate (butyric acid) 
 
4.63 
5 Valerate (valeric acid) 
 
4.64 
6 Hexanoate (hexanoic acid) 
 
4.63 
 
Figure 1.7: Structure and pKa of monocarboxylates  
(Adapted from Fukushima 1995) 
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SCFA transport and metabolism 
Transport of SCFA across the colonic mucosal epithelium has been 
proposed to occur through non-ionic passive diffusion (Sellin. 1999) and 
carrier mediated transport involving anionic exchangers (Vidyasagar, et al. 
2005; Cuff, et al. 2002; Ganapathy, et al. 2008). However, at physiological 
conditions (pH = 7.4) essential for microbial fermentation of dietary fibre 
(Daly, et al. 2012), SCFA (pKa ≈ 4.8) are predominantly in their anion form 
(SCFA-
Proposed SCFA carrier mediated transport mechanisms across the apical 
membrane include: a 1) SCFA
). Therefore, SCFA are primarily absorbed through carrier mediated 
transport mechanisms (see figure 1.5), evident in studies by observed 
saturation kinetics (Cuff, et al. 2002; Miyauchi, et al. 2004). 
- / HCO3- exchanger (Vidyasagar, et al. 2005), 
an 2) electroneutral H+ coupled monocarboxylate transporter 1, MCT1 (Cuff, 
et al. 2002), and 3) an electrogenic Na+
Butyrate contributes significantly to health maintenance of colonic mucosa as 
a major source of energy for colonocytes (Chapman. 2001), while both 
propionate and acetate enters the circulatory system via the portal vein 
 coupled monocarboxylates 
transporter 1, SMCT1 (Miyauchi, et al. 2004; Ganapathy, et al. 2008). 
SMCT1 has been shown to be localised to the apical epithelium of mouse 
colon using immunohistochemistry (Gopal, et al. 2007). However, studies 
have shown MCT1 expression on the apical membrane of the polarised 
Caco-2 cell line (Hadjiagapiou, et al. 2000), and luminal membrane vesicles 
isolated from pig and human colon tissue (Ritzhaupt, et al.1998). 
Furthermore, MCT1 has been localised to the luminal membrane of human 
colonic tissue (Thibault, et al. 2007) and equine colon (Nedjadi, et al. 2014). 
Interestingly, it has also been shown butyrate and propionate upregulate 
MCT1 expression and butyrate transport in a dose-dependent manner as 
shown in-vitro (Cuff, et al. 2002) and in pig intestine (Haenen, et al. 2013). 
SCFA efflux into the intestinal lumen occurs through breast cancer resistant 
protein, BCRP (Goncalves, et al. 2011). While monocarboxylates members 
MCT1, MCT4 and MCT5 are considered responsible for efflux at the baso-
lateral membrane (Gill, et al. 2005). 
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influencing gluconeogenesis in the intestine (de Vadder, et al. 2014) and 
hepatic tissue (den Besten, et al. 2014). Metabolism of propionate primarily 
occurs in the liver through a vitamin B12
Physiological functions of the SCFA 
 dependent pathway generating the 
precursor of the TSA cycle, succinyl-CoA, while acetate is utilised by the liver 
or peripheral tissues by conversion to Acetyl-CoA, precursor of lipogenesis 
(Cummings, et al. 1987). Interestingly, it has been shown that SCFA protect 
against high fat diet induced obesity via a peroxisome proliferator-activated 
receptor (PPAR) γ-dependent switch from lipid synthesis to utilisation in 
hepatic and adipose tissue (den Besten, et al. 2015). In peripheral blood 
circulation SCFA levels are in micromolar concentrations; butyrate (1-3μM), 
propionate (4-5μM) with acetate normally measured at 100-150μM can reach 
250-400μM after drinking alcohol (Siler, et al. 1999).  
SCFA have numerous functions many occurring through epigenetic gene 
regulation through histone deacetylases (HDAC) inhibition (Schilderink, et al. 
2013). The most potent is butyrate with ability to modulate genes involved in 
cell proliferation, differentiation and apoptosis (Daly and Shirazi-Beechey. 
2006), and self-regulate genes encoding HDAC enzymes through a TP53 
pathway (Li and Li. 2014).  
In normal colonic physiology, these effects are beneficial helping to maintain 
the intestinal barrier function through the promotion of epithelial homeostasis 
(Hamer, et al. 2008). These effects include upregulating tight junction 
assembly to enhance barrier integrity (Peng, et al. 2009), promoting MUC2 
synthesis and production thus developing the protective mucous layer 
(Hatayama, et al. 2007). Nutrient recovery is enhanced by upregulating 
apical sodium channels to promote water and sodium absorption (Zeissig, et 
al. 2007), and upregulating MCT1 expression to enhance SCFA uptake (Cuff, 
et al. 2002). 
SCFA are immune regulators suppressing colonic inflammation by inhibiting 
nuclear factor κB which regulates genes involved in early inflammatory 
responses (Inan, et al. 2000), upregulating nuclear peroxisome proliferator-
activated receptor γ (PPARγ) and inhibiting interferon γ signalling (Schwab, et 
 Chapter One 
27 
al. 2007; Klampfer, et al. 2003). SCFA-induced extracellular signals promote 
colonic macrophages and dendritic cells to induce differentiation of colonic 
regulatory T cells (Singh, et al. 2014). Butyrate acts to directly induce colonic 
regulatory T cell differentiation (Furusawa, et al. 2013) and induce immune 
cell chemotaxis (Maslowski, et al. 2009; Vinolo, et al. 2011). In addition, 
SCFA are anti-carcinogenic inhibiting proliferation and promoting apoptosis in 
a dose-dependent manner (Peng, et al. 2007), an effect not observed in 
cancerous cell lines, termed the butyrate paradox (Comalada, et al. 2006). 
Secretion of hormones from enteroendocrine cells in response to SCFA have 
been implicated to be involved in enhanced mucosal blood flow (Dass, et al. 
2007), with differential effects on intestinal motility (Fukumoto, et al. 2003; 
Hurst, et al. 2014). At the extra-intestinal level SCFA contribute to appetite 
control through stimulation of leptin secretion from adipose tissue (Xiong, et 
al. 2004), and by directly stimulating centres in the brain involved in appetite 
control (Frost, et al. 2014). 
G-protein coupled receptors (GPCR) are a superfamily of plasma membrane 
bound proteins with over 800 encoded within the human genome 
(Fredriksson, et al. 2003). 50% of GPCR function as sensory receptors 
responding to odorants, nutrients, light and hormones (Alexander, et al. 
2013). Important structural differences exist between GPCR that enable 
detection of thousands of chemical and physical stimuli. Structurally, GPCR 
are a single polypeptide with an extracellular domain (N-terminus), an 
intracellular domain (C-terminus) and an intermediate seven α-helical 
transmembrane domain, connected by three extracellular loops (ECL1-3) and 
three intracellular loops (ICL1-3) that form a ringed shaped central core 
(Alexander, et al. 2013). Protein tertiary interactions between helices provide 
structural stability vital for their functionality.  
G-protein coupled receptors  
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Structure of G-protein coupled receptors  
The length of GPCR polypeptides vary between 311 to 1490 amino acid 
residues with largest variations occurring at the N-terminus (879 amino acids) 
and C-terminus (371 amino acids), the ECL1-3 are also variable in size, 36-
154 residues. Further GPCR stability is provided by disulphide bonding 
between two conserved cysteine residues within the ECL-1-3. Some GPCR 
possess a forth intracellular loop (ICL4) formed by insertion of a cysteine 
residue in the plasma membrane at the C-terminal domain, a site of 
palmitoylation. Functionally, conserved cysteine residues of ECL1 and ECL2 
provide a site of disulphide bonding providing structural stability, vital for 
trafficking of functional receptors to the cell membrane. The N-terminus and 
ECL of most GPCR possess sites for N-glycosylation for trafficking receptors 
to the cell membrane (Tuteja N. 2009). 
The extracellular N-terminal domain is the site of recognition for orthosteric 
agonists for all GPCR except the rhodopsin family.  The intracellular domains 
are less well defined but are involved with downstream signalling and 
receptor desensitisation. GPCR desensitisation is a common feature 
impairing functionality through phosphorylation by second messenger 
dependent protein kinases and GPCR kinases, the later promoting receptor 
internalisation via β-arrestin (Ferguson. 2001). 
Ligand-GPCR interactions 
The GPCR structure conformation has a dynamic nature with some receptors 
demonstrating constitutive activity which can be exploited to identify ligands 
(Chalmers and Behan. 2002). Ligand-GPCR interactions can occur at an 
orthosteric binding pocket (site of endogenous ligand activity) inducing 
conformational changes that cause partial or full activity (agonists), partial or 
full inverse activity (inverse agonists) or inhibitory activity (antagonists) 
(Rang, et al. 2007) Ligand-GPCR interactions may also target an allosteric 
binding pocket causing conformational changes to act as a direct agonist or 
may also function as positive or negative allosteric modulators. The diversity 
of ligand-GPCR interactions and potential conformational states 
communicate with cytoplasmic membrane G-proteins that raise numerous 
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intracellular signal cascades that control physiological and cellular responses 
(Wootten, et al. 2013; Smith, et al. 2011). 
GPCR classification 
The frequently used A-F system was the first classification system to be 
introduced organising all GPCR in vertebrates and invertebrates into six 
classes based on sequence homology; Rhodopsin-like receptors (Class A), 
Secretin receptors (Class B), Glutamate receptors (Class C), Pheromone 
receptors (Class D), cAMP receptors (Class E) and Frizzled/smoothened 
receptors (Class F) (Kolakowski. 1994). However, this system takes into 
account GPCR not found in humans making class D (pheromones) and class 
E (cAMP receptors) redundant (Fredriksson, et al. 2003). Today an 
overlapping GPCR classification system is used based on the GRAFS 
scheme dividing vertebrate GPCR into five categories; Glutamate (Class C), 
Rhodopsin (Class A), Adhesion (Class B), Secretin and Frizzled receptors 
(Fredriksson and Schioth. 2005). 
In order of size, the Rhodopsin family is the largest, with the majority of 
sensory GPCR belonging to this family with many more remaining GPCR 
orphans. Approximately half of modern pharmaceutical drugs target 
members of this family, with 40 GPCR implicated in regulation of body weight 
(Schioth. 2006). The relatively compact ligand recognition site is found within 
the seven transmembrane helical bundles. Examples of this family include 
odorant receptors, bitter taste receptors (T2R family) and the SCFA receptors 
(GPR109A, FFAR2 and FFAR3). 
 The Adhesion family consists of more than 30 receptors. All possess a 
large extracellular N-terminus with a conserved GPCR proteolysis site within 
an auto-proteolysis-inducing (GAIN) domain enabling auto-proteolytic 
cleavage upon activation (Paavola and Hall. 2012). For example Type IV 
collagen activates GPR126 (Paavola, et al. 2014). 
The Glutamate family has over 20 receptors (Alexander, et al. 2013) 
which all share a fundamental property of receptor dimerization and possess 
the feature of an extracellular N terminal ligand binding Venus flytrap domain. 
Ligand examples include the heterodimers of sweet and umami taste 
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receptors (T1R1-3) and the homo dimers involved in calcium sensing, CaSR 
(Riccardi and Maldonado-Perez. 2005; Brennan, et al. 2014). 
The smaller categories include the Secretin family encoded for by 15 genes 
within the human genome. Nine receptors respond to structurally related 
polypeptide hormones to include the gut derived hormones, glucagon like 
peptide 1 (GLP-1), glucagon like peptide 2 (GLP-2) and gastric inhibitory 
peptide (GIP). The Frizzled family is the smallest consisting of frizzled 
protein, 1-10 and Smoothened (Alexander, et al. 2013). 
GPCR intracellular signals 
These G-proteins are membrane bound heterotrimeric guanine nucleotide 
binding proteins consisting of Gα and Gβγ subunits, encoded for by 16α, 5β, 
and 12γ subunit genes in humans (Reimann et al. 2012). Several of these 
genes express splice variants which together account for over 1500 variants 
of Gαβγ trimers that are known to exist (Wess. 1998). In the resting state G-
protein trimers are unattached to GPCR, although anchored to the 
membrane they are freely diffusible across the plane of the membrane. 
Ligand-GPCR interaction cause intracellular conformation changes to recruit 
the trimer complex to promote GDP/GTP-dependent dissociation of G-protein 
trimers into active Gα and Gβγ initiating intracellular signals. Although once 
considered inactive it is now proposed that the Gβγ
However, classification of G-proteins continues to be based on downstream 
targets of the G
 complex activates effector 
pathways that control GPCR activity (Dupre, et al. 2009). 
α G-proteins (Wess. 1998). These downstream signalling 
cascades constitute four Gα subunit families. 1) Gαs: stimulates adenylyl 
cyclase to elevate intracellular cAMP production (serotonin receptor). 2) Gαi: 
inhibits adenylyl cyclase to decrease intracellular cAMP production (opioid 
receptors). 3) Gαq: stimulates phospholipase C to generate diacylglycerol and 
inositol trisphosphate which activates protein kinase C and triggers calcium 
release from intracellular stores (amine receptors). 4) Gα12/13 couples to Rho 
GTPase pathways (Bishop and Hall. 2000; Reimann, et al. 2012). Signal 
transduction is terminated by re-association of Gαβγ complex following a 
 Chapter One 
31 
GαGTP-GDP hydrolysis reaction. A short history of the G-proteins is provided 
in a recent review (Milligan and Kostenis. 2006). 
Our perception of sweet, bitter and umami taste are controlled by GPCR 
nutrient receptors while salt and sour are mediated by ion channels. Recent 
progress has suggested the ability of the gastrointestinal tract to monitor 
luminal content through chemo-sensations of specialised enteroendocrine 
cell types enriched with GPCR (Reimann, et al. 2012). Interestingly, tuft cells 
were recently identified as a distinct cell lineage with potential to function as 
chemo-sensory cells of the gut (Gerbe, et al. 2011). 
GPCR: nutrient receptors in the gastrointestinal tract 
The luminal environment in the intestine is dynamic altering in response to 
food consumption. The sensing of available nutrients induces signalling 
pathways that cause intestinal adaptation to optimise nutrient consumption 
(Dailey. 2014). In the small intestine glucose is sensed by sweet receptors 
(T1Rs) coupling to the Gα protein, gustducin intracellular signalling cascades 
via cAMP and PKA enhancing expression of the intestinal sodium-glucose 
cotransporter 1 (SGLT1) (Dyer, et al. 2007; Margolskee, et al. 2007). 
Similarly, short-term activation of butyrate receptor GPR109A has recently 
been shown to upregulate MCT1 (Borthakur, et al. 2012). 
In recent years, nutrient induced hormone secretion has been shown to occur 
through certain GPCR using in-vitro models and confirmed using RNA 
interference technologies and knockout mouse models. Examples of nutrient 
induced GLP-1 secretion include activation of TGR5 by bile acids (Kim, et al. 
2014), capsaicin induced stimulation of TRPV1 (Wang, et al. 2012), and long 
chain fatty acid induced stimulation of GPR119 (Lauffer, et al. 2009), and 
SCFA induced FFAR2 activation (Tolhurst, et al. 2012). 
Following GPCR stimulation on enteroendocrine cells secretory peptides are 
recognised by GPCR, locally, on nerve endings, while others target GPCR at 
distant sites by entering the circulatory system. Investigations are made 
difficult due to their low abundance with cell identification requiring the aid of 
tissue fixation to enable staining while in-vitro models are useful for 
performing functional studies (Tolhurst, et al. 2012).  
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SCFA receptors  
In 1997, random sequencing identified a family of orphan GPCR positioned in 
tandem on chromosome 19 downstream from cluster differential 22 (CD22), 
locus q13.1 of the human and mouse genomes, identified as GPCR; GPR40, 
GPR41, GPR42 and GPR43 (Sawzdargo, et al. 1997). Several groups later 
simultaneously identified the endogenous ligands for these receptors as free 
fatty acids with efficacy dependent on carbon chain length, hence their name 
as the free fatty acid receptor family. In 2003, GPR41 (FFAR3) and GPR43 
(FFAR2) were identified as short chain fatty acid (SCFA) receptors (Brown, et 
al. 2003; Le Poul et al. 2003). The two receptors were found to share 
common monocarboxylates with carbon chain lengths one to six as ligands, 
unresponsive to esters and amide groups (Brown, et al. 2003).  
 
The FFAR family is conserved in mammals with the exception of GPR42 
found absent from the rodent genome (Liaw and Connolly. 2009). GPR42 is 
considered an inactive FFAR3 pseudogene but salvaging of all six single 
nucleotide polymorphisms or just R174W was shown sufficient to rescue 
activity (Brown, et al. 2003). Interestingly, it has been suggested that GPR42 
is active in over 70% of the human population (Liaw and Connolly. 2009). 
SCFA receptors are not limited to FFAR2 and FFAR3. The niacin receptor, 
GPR109A has been shown to be responsive to millimolar concentrations of 
butyrate (Thangaraju, et al. 2009), and two odorant GPCR, murine O1FR78 
and human OR51E2 have been identified as SCFA receptors (Pluznick, et al. 
2013). However, interest in this thesis was focused on elucidating the roles of 
FFAR2 and/or FFAR3 contribution to appetite control. 
 
 
 
 
 
 
 
 Chapter One 
33 
Pharmacology of SCFA receptors, FFAR2 an FFAR3 
Sequence homology between SCFA receptors were identified in early studies 
with FFAR3 sharing 52% similarity and 43% identity to FFAR2 (Brown, et al. 
2003). Activation was found to occur in the range of high micromolar to low 
millimolar SCFA concentrations with distinct SCFA activity profiles between 
FFAR2 and FFAR3. Although dependent on the methodology used the 
activity profile was summarised at FFAR2; C2=C3=C4>C2>C5>C1 and 
FFAR3; C3>C4>C5>C6>C2 while C1 had no activity at FFAR3 (Le Poul, et 
al. 2003). FFAR2 was demonstrated to couple to both Gq and Gi/o G-protein 
families, while FFAR3 was found to only couple with the pertussis toxin 
sensitive G-protein Gi/o 
In 2008, positively charged residues were found to be conserved in the 
transmembrane domains 5, 6 and 7 of the FFAR family identifying their 
importance in recognition of the carboxylic acid group of endogenous ligands 
within the orthosteric binding pocket (Stoddart, et al. 2008). The importance 
of these residues was highlighted for acetate by site directed mutation 
analysis demonstrating the role of the conserved D(E)RY motif. FFAR2 
contains a Glu-Arg-Tyr motif while FFAR3 has a Glu-Arg-Phe motif stabilising 
the receptor in an inactive conformation (Swaminath, et al. 2010). 
Furthermore, the discovery of 4-chloro-α-(1-methylethyl)-N-2-
thiazolylbenzeneacetamide, S-4-CMTB  (Lee, et al. 2008; Wang, et al. 2010), 
identified the first ago-allosteric modulator of FFAR2. It was found to function 
both as an agonist and a positive allosteric modulator binding to a distinct 
binding pocket to SCFA (Lee, et al. 2008). Further site directed mutation 
analysis identified important residues within these binding sites allowing 
positive allosteric interaction with endogenous ligands, rescuing inactive 
receptors by inducing conformation change to an active state (Swaminath, et 
al. 2010; 2011). This strategy demonstrated the importance of extracellular 
loop -2 for the positive allosteric modulation between orthosteric and 
family. Both receptors were found coupled to inositol 
1,4,5-trisphosphate formation, intracellular calcium release, ERK1/2 
activation and inhibition of cAMP accumulation (Le Poul, et al. 2003). The 
close structural properties of these two SCFA receptors have made 
understanding their pharmacology difficult (Stoddart, et al. 2008).  
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allosteric binding pockets in hFFAR2 (Smith, et al. 2011). A detailed overview 
of FFAR2 and FFAR3 pharmacology is provided in an excellent review 
(Milligan, et al. 2009). 
As our understanding of molecular pharmacology of FFAR2 and FFAR3 
advances there are greater opportunities to discover novel orthosteric 
agonists and allosteric modulators that provide useful tools to differentiate 
between the closely related SCFA receptors to elucidate their physiological 
roles (Schmidt, et al. 2011). Examples of recently identified agonists include: 
naturally occurring tiglic acid and angelic acid, propiolic acid and synthetic 
FFAR2 agonists; compound 1, compound 2, phenylacetamides 1 and 2. To 
give examples of FFAR3 agonists; 1-methylcyclopropanecarboxylic acid, 
cyclopropylacetic acid and the synthetic agonist compound 4 has been 
reported (Hudson, et al. 2013). Molecular pharmacological approaches have 
recently enabled development of a series of hexahydroquinolone-3-
carboxamides displaying selective FFAR3 activity and modest modulation 
(Hudson, et al. 2014). 
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Phylogenetic analysis of FFAR2 protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Phylogenetic tree showing relationship of FFAR2 amino 
acid coding sequences in 27 species. Amino acid sequences (Translated 
from corresponding nucleotide sequences available on the NCBI nucleotide 
database) were aligned on vector NTI software for phylogenetic assessment 
from a common 275 amino acid region across all aligned species sharing 
96.4% consensus positions and 56.5% identity position. The above 
phylogram is unrooted and the scale bar represents genetic distances in 
substitutions per nucleotide. 
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Phylogenetic analysis of FFAR3 protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Phylogenetic tree showing relationship of FFAR3 amino acid 
coding sequences in 27 species. Amino acid sequences (translated from 
corresponding nucleotide sequences available on the NCBI nucleotide 
database) were aligned on vector NTI software for phylogenetic assessment 
on a common 270 amino acid region across all aligned species. Sequences 
share 97.8% consensus positions and 49.5% identity positions. The above 
phylogram is unrooted and the scale bar represents genetic distances in 
substitutions per nucleotide. 
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Localisation of SCFA receptors 
Early tissue localisation studies found FFAR3 mRNA to be most abundant in 
adipose tissue while FFAR2 mRNA was found at highest levels in monocytes 
and neutrophils (Brown, et al. 2003). However, low levels of FFAR2 and 
FFAR3 was also found detectable in the intestine (Brown, et al. 2003). Use of 
immunohistochemistry first localised FFAR2 to intestinal enteroendocrine 
cells co-localised with peptide YY  (PYY) but not serotonin (5-HT) in the distal 
ileum and rat colonic epithelium (Karaki, et al. 2006), and then in human 
colonic mucosa (Karaki, et al. 2008). In a follow-up study, FFAR3 was found 
localised in human colonic mucosa within enteroendocrine cells co-localised 
with PYY but not 5-HT or FFAR2 (Tazoe, et al. 2009), an enteroendocrine 
cell subtype demonstrating co-localisation and secretion of PYY and GLP-1 
(Habib, et al. 2013). In another study, transgenic monomeric red fluorescent 
protein reporter mice were used to investigate expression of SCFA receptors 
in the gastrointestinal tract (Nohr, et al. 2013). Nohr and colleagues (2013) 
found FFAR3 expression to be strong in ghrelin and gastrin secreting cells of 
the stomach, CCK and GIP cells of the small intestine, and GLP-1, PYY and 
neurotensin cells of the distal small intestine and colon, while FFAR2 
expression was found to be weak. Strongest expression of FFAR2 was found 
in large populations of leukocytes while expression of FFAR3 was also found 
in neuronal cells of the submucosa and myenteric ganglia (Nohr, et al. 2013). 
In functional studies, FFAR2 and FFAR3 expression in enteroendocrine cells 
were shown to be involved in SCFA induced hormone secretion (Lin, et al. 
2012). The expression of FFAR2 in ghrelin secreting cells was shown to 
inhibit ghrelin secretion through a pertussis toxin-sensitive Gαi/o pathway 
(Engelstoft, et al. 2013). The expression of FFAR2 on enteric leukocytes was 
identified to be involved in SCFA-induced chemotaxis (Vinolo, et al. 2011), 
and in protecting against colitis by regulating the size and function of colonic 
regulatory T cells (Smith, et al. 2013). Furthermore, activation of FFAR3 on 
enteric neurons was shown to be involved in gut motility (Tazoe, et al. 2008), 
while FFAR3 activation of extrinsic neurons in the walls of the portal vein 
trigger a reflex arc to the brain inducing intestinal gluconeogenesis and 
satiety (Mithieux. 2014). Interestingly, SCFA receptors localised to pancreatic 
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β-cells have been shown to inhibit glucose stimulated insulin secretion (Tang, 
et al. 2015), with FFAR2 suppressing insulin-mediated accumulation of 
adipose tissue (Kimura, et al. 2013). 
Another intestinal SCFA receptor, GPR109A, has been identified and found 
to be localised to absorptive cells of the luminal epithelium, responsible for 
the tumour suppressive effects of butyrate (Thangaraju, et al. 2009), and 
short-term up-regulation of MCT1 in response to butyrate stimulation 
(Borthakur, et al. 2012). 
 
 
 
 
 
 
Figure 1.10: A representative image of the localisation of FFAR2 in 
human colonic tissue (Adapted from Karaki, et al. 2008) 
This implies that SCFA receptors serve several important functions; firstly, 
FFAR2 and FFAR3 are involved in energy homeostasis via hormone 
secretion from enteroendocrine cells (Lin, et al. 2012; Tolhurst, et al. 2012; 
Engelstoft, et al. 2013), and controlling intestinal gluconeogenesis (Mithieux. 
2014) and preventing fat accumulation (Kimura, et al. 2013). Secondly, 
FFAR2 and GPR109A are involved in mucosal defence against intestinal 
microbiota (Thangaraju, et al. 2009; Vinolo, et al. 2011; Smith, et al. 2013). 
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Energy imbalance has become a major global health and socioeconomic 
concern (Cannon and Kumar. 2009). In 2004, the world health organisation 
(WHO) declared an obesity epidemic but today it is now considered a 
pandemic (Burke and Wang. 2011). Global prevalence continues to rise at an 
alarming rate. In 2008, estimates suggested of the 1.46 billion adults who 
were overweight; 502 million were obese (Finucane, et al. 2011). Based on 
projections of two aging populations there will be a rise of 65 million obese 
individuals in USA and 11 million in the UK by 2030 (Wang, et al. 2011). 
Secondary complications associated with obesity include: diabetes mellitus 
type II, cardiovascular disease and cancer, and were reported as the leading 
causes of death in USA men and woman (CDC, 2007). Combined medical 
costs for these preventable diseases could reach $48-66 billion per annum in 
USA and £2 billion per year in the UK by 2030 (Wang, et al. 2011). 
Treatment and prevention has become a priority for societies and 
governments worldwide (Small and Bloom. 2004), with the WHO describing 
obesity as the greatest threat to human health (WHO. 2004). 
Obesity, a link to satiety peptides 
 
The aetiology of obesity has genetic and environmental factors causing 
susceptibility to weight gain. Genetic contributions involve interactions 
between many genes (Perusse, et al. 2005), to include mutations within the 
MC4R gene (Barsh, et al. 2000). However, overall progression to obesity is 
influenced by prolonged intake of caloric rich foods leading to an elevated 
body mass index, BMI (Rang. et al. 2007; Sanz, et al. 2010). Individuals with 
BMI <25kg/m2 are considered lean, while individuals BMI>30kg/m2 are 
considered overweight or obese with a BMI>35kg/m2 indicative of morbid 
obesity (Cannon and Kumar. 2009). Morbid obese patients display both 
upper and lower gastrointestinal symptoms such as gastro-oesophageal 
reflux and altered bowel habits (Huseini, et al. 2014). Rodent diet-induced 
obesity have shown the condition to be accompanied with lower levels of 
circulating gut hormones; such as ghrelin (Uchida, et al. 2014), and PYY 
(Rahardjo, et al. 2007).Such observations are shared among obese 
individuals (Zwirska-Korczala, et al. 2007) to include GLP-1 (De Luis, et al. 
2012).  
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In cases of morbid obesity treatment options include surgical gastric banding 
and bariatric surgeries or use of approved pharmaceutic drug, Orlistat™. 
Neither option is without complication or permanent benefit (Cannon and 
Kumar. 2009; Small and Bloom. 2004). The most long-term benefit is 
observed with gastric bypass surgery (Scholtz, et al. 2014; Yousseif, et al. 
2014). Patients display significant weight-loss and remission of secondary 
complications (Holst. 2013). In Roux-en Y surgery, gastric volume is reduced 
resulting in its rapid filling of the stomach but delayed gastric emptying. The 
bypass of the duodenum and the upper jejunum impairs nutrient absorption, 
delaying small intestinal transit but has no effect on colon transit (Dirksen, et 
al. 2013). Altered anatomy and physiology of the gastrointestinal tract results 
in different changes in circulating hormones dependent on the delivered 
surgical procedure; whether it be gastric banding, sleeve gastrectomy 
(Miyazaki, et al. 2013; Yousseif, et al. 2014), or gastric bypass (Scholtz, et al. 
2014).These invasive surgeries are only offered in extreme cases of obesity.  
Interestingly, the observed weight reduction is linked to lower fasting levels of 
ghrelin, enhanced secretion of satiety peptides, GLP-1 and PYY after a meal, 
and an improved insulin response (Chronaiou, et al. 2012). In addition to 
causing reduced appetite these surgeries cause the hedonic response to be 
suppressed thus improving dietary habit via the gut-brain axis (Scholtz, et al. 
2014; Ullrich, et al. 2013). This is attributed to subjective changes in patients 
perception of taste and smell (Graham, et al. 2014), resulting in reduced 
intake of high caloric foods and taste aversion in some patients (Ullrich, et al. 
2013).  
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A healthy balanced diet and regular exercise remains the first line of defence 
against obesity. Over forty years ago dietary fibre consumed in the form of 
wholegrain, vegetable, fruits and legumes were recognised as having health 
benefits that offer protection against diseases associated with obesity 
(Trowell. 1975), such as diabetes mellitus type 2 (Fujii, et al. 2013), 
cardiovascular disease (Threapleton, et al. 2013), and colonic cancer 
(Murphy, et al. 2012). In 1973, intake of dietary fibre was proposed to act as 
a physical obstacle limiting energy intake by: 1) displacing available calories 
and nutrients from diet, 2) promoting saliva and gastric juice production, to 
expand the stomach and increase satiety, and 3) reduce the absorption 
efficiency of the small intestine (Heaton. 1973). These fibres were 
traditionally consumed as solid food possessing less energy than high-fat 
diets, the bulk and viscosity of the fibre enhanced time spent chewing 
influencing satiety (Slavin. 1987). This relationship with fibre and its ability to 
suppress appetite and obesity were reported long ago (Rigaud, et al. 1987). 
Evidence has since emerged that intake of functional fibres offer protection 
against excess weight gain in multi-ethnic populations (Maskarinec et al. 
2006).  
Dietary fibre link to appetite control 
 
Studies now recognise functional fibres responsible for inducing satiety such 
as oligo-fructose (Cani, et al. 2006) poly-dextrose (Ranawana, et al. 2013), 
and resistant starches (Harrold, et al. 2014), while taking physico-chemical 
properties of fibre into account (Wanders, et al. 2013). The connection 
between fibre and secretion of satiety peptides is now recognised. For 
example, feeding rodents soluble fibres such as fructo-oligosaccharide, oat 
bran-glucan and apple pectin has been shown to increase production of 
SCFA, increase circulating levels of satiety peptides (GLP-1 and PYY), 
resulting in decreased food intake and body weight when compared to 
insoluble cellulose (Adam, et al. 2014), occurring in a dose-dependent 
manner in response to pectin (Adam, et al. 2015). Furthermore, it has been 
shown that an inulin-propionate ester significantly elevated secretion of PYY 
and GLP-1 from human colon cells (Chambers, et al. 2014). Taken together, 
this evidence provides strong indication that foods enriched in dietary fibres 
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offer a means of dietary intervention. The SCFA butyrate and propionate are 
able to regulate gut hormone secretion to protect against diet-induced obesity 
through a nutrient sensing mechanism (Tolhurst, et al. 2012; Lin, et al. 2012). 
In turn energy homeostasis is maintained in peripheral tissues (Kimura, et al. 
2011; 2013), and acetate regulates food intake by direct activation of central 
appetite centres (Frost, et al. 2014). 
SCFA receptors link to appetite control 
 
 
 
 
 
 
 
 
 
Figure 1.11: A diagrammatic illustration of the proposed mechanism of 
how SCFA derived from the colon may contribute to appetite control 
through the gut-brain axis. Luminal SCFA activates FFAR2 and/or FFAR3 
at the apical surface of colonic enteroendocrine L cells to stimulate secretion 
of satiety peptides, GLP-1 and/or PYY. These hormones are released into 
the circulatory system and activate GLP-1R and Y receptors on local afferent 
neurons relaying signals to appetite controlling centres in the brain via the 
vagus nerve. The nucleus of the solitary tract located in the brain stem is 
involved in short-term appetite control while the paraventricular nucleus 
(PVN) and arcuate nucleus (ARC) of the hypothalamus controls long-term 
energy homeostasis. In summary, ARC neurons give rise to products of pro-
opiomelanocortin/cocaine amphetamine regulated transcripts (POMC/CART) 
causing appetite inhibition whilst ARC neurons form products of agouti-
related peptide/neuropeptide Y (AgRP/NPY) causing appetite stimulation 
(Adapted from Sam, et al. 2012). 
Acetate 
Propionate 
Butyrate 
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Background: Dietary fibre and resistant starch are fermented by colonic 
microbiota to short chain fatty acids (SCFA); acetate, propionate and 
butyrate. The majority (90%) of SCFA produced are absorbed in the colon by 
a specific monocarboxylate transporter, MCT1. SCFA (butyrate) in addition to 
providing energy for colonic epithelial cells, play an important role in 
maintaining colonic tissue homeostasis. Furthermore, dietary fibre influences 
satiety through eliciting secretion of satiety hormones by the gut epithelium. 
Aims, objectives and hypothesis of the project  
 
Hypothesis: SCFA stimulate SCFA receptors, FFAR2 and/or FFAR3 leading 
to secretion of satiety hormones from colonic enteroendocrine L cells. 
 
Major aims of the work presented in chapters 3 and 4 were to determine 
mechanisms by which dietary fibre influences absorption and sensing of 
SCFA in the colon using ex-vivo colonic tissues. To this end: 
 
Work presented in Chapter 3 aimed to assess: 
1. The nucleotide sequence of pig FFAR3 allowing development of 
molecular probes 
2. The relative abundance of SCFA receptors, FFAR2 and FFAR3 
mRNA across the longitudinal axis of mouse, pig, and human colon. 
3. Cellular location of FFAR2 and FFAR3 proteins in mouse, pig and 
human colon 
 
Work presented in Chapter 4 aimed to determine the effects of dietary fibre 
consumption in pigs on: 
1. Expression of SCFA receptors 
2. Levels of luminal SCFA 
3. Expression of SCFA transporter, MCT1 
4. Expression of satiety peptide mRNA 
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Major aims of research presented in chapters five and six were to identify the 
potential involvement of FFAR2 in secretion of GLP-1 using in-vitro models. 
To this end: 
 
Work presented in chapter 5 addresses: 
1. Identification and characterisation of suitable L-type in-vitro cell lines 
2. Effect of SCFA on secretion of GLP-1 in selected cells 
3. Effect of specific FFAR2 ligands on GLP-1 secretion 
 
Work in chapter 6 assesses: 
1. SCFA receptor protein expression in NCI-H716 cells 
2. Effect of inhibition of FFAR2 expression on gut hormone release using 
RNA interference 
3. FFAR2 involvement in SCFA induced GLP-1 secretion  
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Thesis Structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: An illustration of thesis structure and summary of content 
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Collection of tissues samples; mice, pigs and humans 
 
Mice intestinal tissue  
Eight week old C57BL/6 mice were purchased from Charles River to be 
weaned onto a commercially available basal diet with moderate (40%) 
carbohydrate (Purina Mills, Richmond, IN, USA) for at least five days before 
sacrifice. Mice were euthanased by cervical dislocation (In line with the UK 
Home Office schedule 1 regulations). The abdominal cavity was opened with 
rat toothed forceps and sharp scissors. The entire gastrointestinal tract from 
the mouse was carefully removed with minimal amount of attached 
mesentery. Small intestine was divided into three equal length fractions; 
proximal (distal to the gastric-pylorus), mid (half way along the small 
intestine) and distal (proximal to the ileo-caecal junction). Nalgene®
 
 Scissor-
type Locking forceps were used to maintain orientation of each fraction while 
the mouse colon was removed. All tissue fragments were stored in chilled 
0.9% (w/v) saline before processing of tissue. 
Handling and processing of tissue from mice  
The 5cm length of colon and sections of small intestine were everted with a 
custom made glass rod and thoroughly washed in chilled 0.9% (w/v) saline. 
Three 30µg full thickness loops of mice intestine were cut for RNA extraction 
using a sharp scalpel. Tissue segments were placed into cryo-vials, frozen in 
liquid nitrogen (LN) for transport back to the laboratory to be stored at -80o
 
C 
until needed. Mucosal scrapings were acquired by scraping tissue with glass 
slides, scrapings were wrapped in tin-foil and flash frozen in LN. Everted 
tissue collected for immunohistochemistry was transferred into 4% (w/v) 
paraformaldehyde for four hour fixation. On return to the laboratory fixed 
tissue was processed to be gelatin-sucrose embedded (described in 
immunohistochemistry) for storage at -80°C. 
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Pig intestinal tissue 
A mix of male and female twenty-eight day year old Landrace X Large White 
piglets were used. Mixed gender pairs were kept in standard pens (1.5m2) 
with continuous heating 26.7o
 
C and a 12 hour light-dark cycle. They were 
weaned onto formulated diets (Target Feeds Limited, Whitchurch, UK) for 
fourteen days having free access to water and food. The amount of food 
consumed, intake of water, animal’s weight and stool consistency (graded 1 
to 5) were all recorded during this period. Animals were euthanased by 
intravenous injection using 20ml pentobarbital sodium (200mg/ml, Pentoject, 
Animal Care Ltd, York, UK) into the superior vena cava (In line with the UK 
Home Office schedule 1 regulations). Promptly following euthanasia the pig’s 
abdomen was carefully opened. A superficial laceration with a scalpel was 
created from the animal’s sternum to bottom of the abdomen. The bottom of 
the abdominal cavity was punctured with a scalpel then sharp scissors were 
used to fully open the abdomen. Collection of gastrointestinal tissue samples 
was then performed in a routine manner. Five intact loops of colonic tissue 
were collected, representing the anatomical regions of pig colon. After 
removal tissue was quickly placed into bowls of chilled 0.9% (w/v) saline (pH 
7.4) while processing the tissue. 
Tissue handling and processing 
Small intestinal lengths were cut into two segments to be everted using a 
brass rod. After removal of attached digesta the tissue was blotted with blue 
towel and placed onto an ice cold glass plate. Three 30μg whole thickness 
tissue fragments were excised using sharp scissors for RNA extraction, 
placed into cryo-vials and frozen in LN. Mucosal scrapings were collected 
using glass slides, wrapped in aluminium foil and flash frozen in LN. For 
immunohistochemistry intestinal loops were rinsed in 0.9% (w/v) saline to 
remove digesta. Intestinal loops were cut into 2cm2
 
 tissue sheets and fixed in 
4% (w/v) paraformaldehyde over four hours. On return to the laboratory 
tissue was processed for gelatin-embedded immunohistochemistry. Excess 
intestine and sampling from other tissues (adipose tissue) were packaged 
within aluminium foil and frozen in LN for our return trip to the laboratory. 
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Human intestinal biopsies 
Healthy human gastrointestinal biopsies were provided by Dr A. Ellis, a 
consultant gastroenterologist at Royal University Hospital, Liverpool, UK. 
Samples were collected on the day healthy patients were undergoing routine 
colonoscopy examination, following patient consent. Efforts were made to 
collect tissue biopsies from the ascending, transverse and descending colon 
of the same patient when possible. Attempts were made to acquire samples 
weekly for the duration of granted ethical approval but success was 
unpredictable. Acquired samples were placed directly into cryo-vials and 
snap frozen in LN and transferred into a LN storage tank at the laboratory. 
These samples were later used for real time PCR analysis. Alternatively, 
acquired colonic biopsies were promptly fixed in freshly prepared 4% (w/v) 
paraformaldehyde (Fisher Scientific) prepared in 1x phosphate buffered 
saline (PBS) from a 10xPBS stock (1.37M (w/v) sodium chloride, 26.8mM 
(w/v) potassium chloride, 81mM (w/v) sodium phosphate dibasic, 14.7mM 
(w/v) potassium dihydrogen phosphate, pH 7.4 (1M sodium hydroxide), 
filtered using Whatman paper 4. Tissues were returned to the laboratory 
within four hours of collection. After four hours tissues were considered 
adequately fixed and were processed for gelatin-sucrose embedded 
immunohistochemistry studies. 
All work carried out using acquired human biopsies were given ethical 
approval by The Royal University Hospital Trust, Liverpool, UK. (Medical 
Research Ethics Committee REF: 02/11/228/A and 2K/128. 
Ethical permissions 
Rodents were provided by the University of Liverpool Biomedical 
Sciences Unit, and were euthanised in accordance to the UK Home Office 
Regulation, schedule 1. Pigs were provided by the University of Liverpool 
Farm Animal Division; they were maintained on commercial diets and were 
euthanised by overdose of anaesthetics by University of Liverpool’s 
veterinary surgeons under schedule 1 of UK Home Office regulation. The use 
of animals and all procedures used were reviewed and approached by Mr 
Ewan Birnie, Animal Health Officer BVMS, FRCVS of the University of 
Liverpool acting on behalf of the Home Office. There were no requirements 
for a project licence, since the animals were sacrificed by schedule 1.   
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Nutritional Profile 
Mouse diet
basal diet with moderate (40%) carbohydrate, high in fat and protein. 
Amino Acids % Minerals % Vitamins IU/g Protein (%) 31.00 
Arginine (R) 1.22 Calcium 0.61 Vitamin A 22.10 Carbohydrate (%) 40.00 
Histidine (H) 0.90 Phosphorus 0.68 Vitamin D3 2.20  (Added) Fibre (%) 11.00 
Lysine (K) 3.03 Phosphorus (Available) 0.68 Vitamin E 50.10 Energy (kcal/g) 3.70 
2 
Leucine (L) 1.67 Potassium 0.40  Mcg/kg  kcal / (%) 
Methionine (M) 2.54 Magnesium 0.07 Vitamin B 26.00 12 Protein 1.24 / 33.30 
Cysteine (C) 1.05 Sodium 0.23   Fat 0.89 / 23.80 
Phenylalanine (F) 1.67 Chloride 0.29   Carbohydrate 1.60 / 42.90 
Tyrosine (Y) 1.77  ppm  ppm Ingredients (%) 
Threonine (T) 1.35 Fluorine 5.00 Vitamin K (as menadione) 10.40 Caesin – Vitamin free 35.00 
Tryptophan (W) 0.39 Iron 64.00 Thiamine Hydrochloride 20.70 Dextrin 23.06 
Valine (V) 2.00 Zinc 32.00 Riboflavin 21.20 Sucrose 15.00 
Alanine (A) 0.97 Manganese 65.00 Niacin 90.00 Powdered Cellulose 9.75 
Aspartic Acid (D) 2.25 Copper 15.00 Pantothenic Acid 57.00 RP Mineral Mix #10 (adds 1.29% fibre) 5.00 
Glutamic Acid (E) 7.15 Cobalt 3.20 Folic Acid 4.30 Corn Oil 5.00 
Glycine (G) 0.68 Iodine 0.57 Pyridoxine 16.50 Lard 4.84 
Proline (P) 4.12 Chromium 3.00 Biotin 0.40 RP Vitamin Mix (+ 1.94% sucrose) 2.00 
Serine (S) 1.93 Molybdenum 0.82 Choline Chloride 1400.00 Choline Chloride 0.20 
Taurine 0.00 Selenium 0.35 Absorbic Acid 0.00 DL-Methionine 0.15 
50 
C
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Composition of piglet diets 
Composition and analysis of piglet diets 
Composition g/kg (%) hCHO fCHO 1 fCHO2 
Porridge oats standard 170.0 170.0 170.0 
Micro ground wheat 372.5 372.5 372.5 
Micro ground maize 100.0 100.0 100.0 
Potato protein 25.0 25.0 25.0  
Full fat soy bean extruded 200.0 200.0 200.0 
Provimi white fish 75.0 75.0 75.0 
L-Lysine (HCl) 5.5 5.5 5.5 
DL-Methionine 2.5 2.5 2.5 
L-Threonine 2.0 2.0 2.0 
Soya oil 24.0 24.0 24.0 
Limestone Trucal 52 3.0 3.0 3.0 
Monocalcium phosphate 10.0 10.0 10.0 
Sodium chloride (Salt) 5.0 5.0 5.0 
Weaner trials supplement 5.0 5.0 5.0 
Piglet flavour (Vanilla) 0.5 0.5 0.5 
Microfos inulin 0.8 0.8 0.8 
Nutriose wheat dextrin 3.0 3.0 3.0 
Dairy crest whey 7.5 7.5 7.5 
Soya hulls ground - 5.0 - 
Unmolassed beet pulp - - 5.0 
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Analysis of piglet diets 
Analysis (%) hCHO 1 fCHO 1 fCHO 2 
Crude protein 21.8 22.1 22.1 
Oil 11.0 11.0 11.0 
Fibre 2.6 6.6 5.8 
Ash 5.4 5.4 5.4 
Starch 38.0 38.0 38.0 
Sugar 7.6 7.6 7.6 
Lactose 5.0 5.0 5.0 
Salt 0.6 0.6 0.6 
Essential fatty acids 6.3 6.3 6.3 
Lysine 1.6 1.6 1.6 
Methionine 0.6 0.6 0.6 
Threonine 1.0 1.0 1.0 
Calcium 0.7 1.0 1.0 
Phosphate 0.8 0.8 0.8 
Vitamin A 12.5 12.5 12.5 
Vitamin D 2.0 3 2.0 2.0 
Vitamin E 200.0 200.0 200.0 
Copper 165.0 165.0 165.0 
    
Digestible energy (KJ/g) 16.6 16.6 16.6 
 
Groups of eight piglets were weaned to and maintained on either of the 
defined fermentable carbohydrate (fCHO) diets or a comparable hydrolysable 
carbohydrate (hCHO) diet of an isoenergic value.    
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Measurements of SCFA concentrations from pig colonic content 
Methods 
Frozen luminal content (collected shortly following sacrifice) were removed 
from -80°C storage and promptly transferred into Eppendorf tubes to thaw. 
Samples were centrifuged at 13,000g (Eppendorf 5418) to pellet faecal 
material. The samples were homogenised and to every 1ml of supernatant 
collected 50µl 0.1M 2-ethyl butyric acid was added as an internal control. 
This was followed by concentrated hydrochloric acid and diethyl ether 
forming a diethyl ether layer containing tertiary butyldimethylsilyl derivatives 
of monocarboxylic acids. This layer was carefully collected and 
monocarboxylic acids separated using capillary gas chromatography 
(Richardson, et al. 1989) and detected by mass spectroscopy.  
 
Immunohistochemistry 
Tissue processing 
After four hours in 4% (v/v) paraformaldehyde tissue was considered 
adequately fixed for processing. Tissue samples were transferred into 20% 
(w/v) sucrose prepared in 1xPBS to be kept overnight in refrigerated (4°C) 
storage. The following day a gelatin-sucrose embedding matrix (7.5% (w/v) 
gelatin, 15% (w/v) sucrose and 0.05% (v/v) sodium azide) was prepared in 
1xPBS heated to 45°C to help dissolve gelatin. Chilled samples stored in 
20% (w/v) sucrose solution were warmed alongside prepared gelatin 
embedding matrix to allow temperature equilibration to occur in a 38°C 
incubator before transfer of samples. The tissue was then kept at 38°C within 
gelatin-sucrose embedding matrix for three hours before embedding the 
tissue in gelatin-sucrose embedding matrix within a weighing boat. The 
matrix was allowed to cool at room temperature for at least one hour before 
the weighing boats were wrapped in saram wrap for overnight 4°C storage.
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The following day gelatin-sucrose embedded tissue blocks; 2cm3
Immunohistochemistry studies 
 cubes were 
created with a sharp scalpel. Blocks were carefully adhered to cork discs with 
fresh OCT embedding matrix positioned to enable full thickness cryo-sections 
to be obtained from embedded tissue. To prepare blocks for cryo-sectioning 
tissue blocks were frozen by submersion into 3-methylbutane chilled by LN 
for approximately five seconds before being stored at -80°C until needed. 
Later 10µm cryo-sections were prepared using a cryostat (Leica, CM19000V-
1-1, Milton Keynes, Buckinghamshire, UK). Sections were placed onto poly-
L-Lysine coated immunohistochemistry slides (VWR International bvba, 
Leuven, Belgium). To confirm full thickness cryo-sections, tissue was cut and 
stained with toluidine blue for quick examination with a light microscope. 
Further sections were then prepared and returned to -80°C for future 
immunohistochemistry studies. 
Frozen colonic tissue sections were warmed to room temperature and 
encircled using an ImmEdge Hydrophobic Pen (Vector Laboratories INC, 
Burlingame, CA, USA). The tissue was incubated ten minutes in a 60°C 
incubator to remove excess mucous secreted by goblet cells. After washing 
tissue five times with 1xPBS sections were put into a humidified chamber to 
perform the following steps. Sections used to target SCFA receptors were 
blocked one hour at room temperature using Zaza’s blocking solution (2% 
(v/v) donkey serum, 5% (w/v) sucrose, 3% (w/v) bovine serum albumin with 
0.02% (v/v) sodium azide), heat-inactivated at 56°C for 30 minutes. A 10% 
(v/v) donkey serum blocking solution was used for all other targets. The 
intended target was probed by 4°C overnight incubation with a 1:100 dilution 
of primary antibody to antibody diluent (2.5% (v/v) donkey serum, 0.02% (v/v) 
sodium azide, 0.2% (v/v) triton-x100 prepared in 1xPBS). In each experiment 
a slide missing primary antibody was routinely included as a negative control. 
The following day slides were warmed to room temperature, washed five 
times with 1xPBS before sections were stained one hour at room 
temperature using a 1:500 dilution of secondary antibody conjugated to a 
fluorescent probe; Indocarbocyanine 3 (Cy3) or Fluorescein isothiocyanate 
(FITC). Stained tissue sections were coated with Vectashield® mounting 
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medium and covered with a cover slip for protection. Mounted slides were 
stored in complete darkness overnight before starting immunohistochemistry 
analysis. 
Two commonly used fluorophores FITC and Cy3 conjugated to donkey anti-
rabbit secondary antibodies were used as visual aids for detection of bound 
primary antibody on tissue sections using epifluorescence microscopy 
(Nikon, Kingston-Upon-Thames, Surrey, UK). A limitation of using these 
fluorophores was that they share overlapping fluorescent spectra. The 
fluorophore FITC with an excitation wavelength, 496nm, has an emission 
wavelength of 519nm (green). However, excitation of Cy3 occurs around 
512nm and peaks at 550nm causing emissions over a range of wavelengths 
(yellow - red) with optimal emission occurring at 570nm (red). Furthermore, 
the secondary antibodies employed in these studies were raised in the same 
host (rabbit). This makes it impossible to use a single section to investigate 
co-localisation using these secondary antibodies. Subsequently, a double 
immunohistochemistry strategy was employed. Two adjacent sections 
probed with primary antibody were incubated with secondary antibodies 
conjugated to Cy3 or FITC (discussed above). Photographs were captured 
using a Hamamatsu digital camera (C4742-96-12G04, Hamamatsu 
Photonics K.K, Hamamatsu City, Japan). To check for localisation in the 
same cell, images from adjacent sections were merged together using 
Imaging Products Laboratory software (BioVision Technologies, USA) as an 
indication co-localisation of the primary antibody target. 
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Immunohistochemistry antibodies 
 
Figure 2.1: Primary and secondary immunohistochemistry antibodies 
Abbreviations: Free Fatty Acid Receptor 2 (FFAR2), Free Fatty Acid 
Receptor 3 (FFAR3), Chromogranin A (ChA), Peptide YY (PYY) and 
Glucagon like peptide 1 (GLP-1), Serotonin (5-HT), Fluorescein 
isothiocyanate (FITC) and Indocarbocyanine 3 (Cy3). 
 
Primary Antibody Host Dilution Clonality and Source 
Anti – FFAR2 
C-terminal Region Rabbit 1:100 
Polyclonal, 
Custom Synthesis (aa291-315) 
LRNQGSSLLGRRGKDTAEGTNEDRG 
 
Anti – FFAR3 
C-terminal Region Rabbit 1:100 
Polyclonal, 
Custom Synthesis  (aa311-335) 
EQKGGEEQRADRPAERKTSEHSQGC 
Anti – ChA (E-20) 
Internal Region Goat 1: 100 
Polyclonal, 
sc-18232 (Santa cruz) 
Anti - GLP-1  (C–17) 
C-terminal Region Goat 1: 100 
Polyclonal, 
sc-7782 (Santa cruz) 
Anti – PYY (N-15) 
N-terminal Region Chicken 1: 100 
Polyclonal, 
Ab15879 (Abcam) aa29-40 
YPAKPEAPGEDA 
Anti – 5HT Mouse 1:100 Monoclonal Ab16007 (Abcam) 
Secondary 
Antibody Label Dilution Source 
Donkey 
Anti-Rabbit 
Conjugated IgG 
FITC 1:500  (711-095-152), Stratech Scientific Limited, Suffolk, UK. 
Donkey 
Anti-Rabbit 
Conjugated IgG 
CY3 1:500 (711-165-152), Stratech Scientific Limited, Suffolk, UK. 
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Molecular biological assays 
RNA isolation: intestinal tissue 
Tissue RNA extraction was performed using silica columns of the RNeasy® 
Mini kit (QIAGEN GmbH, Hilden, Germany) in accordance to the 
manufacturer’s instructions (centrifugation protocol). The optional DNase I 
On-Column digest was performed to maximise RNA yield. The process was 
performed quickly with all samples kept on ice between steps. In summary 
frozen tissue samples (-80°C) were weighed on an analytical balance. 
Frozen tissue pieces (≤30mg) were thawed in 600µl of lysis buffer containing 
1% (v/v) β-mercaptoethanol (Sigma-Aldrich) in a 2ml M/C sterile tube. In 
events of ≥30mg of tissue, an additional volume (400μl) of supplemented 
lysis buffer was used to assist homogenisation. Defrosted tissue was quickly 
homogenised using a Polytron X-10/25 rotor-stator device, fitted with a 6mm 
diameter Microshaft 6/T probe using setting 5 (approximately 1200rpm). 
Samples were briefly returned to ice at 60 second intervals to minimise heat 
until tissue was fully homogenised. Cellular debris was pelleted by 
centrifugation at 16,900g (Eppendorf 5418) for two minutes. Supernatants 
were transferred to fresh sterile tubes and mixed with an equal volume of 
70% (v/v) ethanol mixed with ten passes of a pipette. In 800μl transfers the 
RNA within the homogenised-ethanol samples were bound to sterile silica 
columns by thirty second centrifugation, 13,000g (Eppendorf 5418). Silica 
column were washed with supplied buffers according to manufacturer’s 
instructions, bound DNA was removed by an optional DNase I on-column 
digest for twenty minutes at room temperature. To increase the total RNA 
yield, columns were allowed to stand for one minute with 48µl RNase free 
ddH2
 
O. Elutes were collected in 1.5ml sterile tubes by centrifugation for a 
minute. Tubes were returned to ice for overnight storage at -80°C or until 
needed. 
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RNA isolation: adipose tissue 
Both subcutaneous and visceral adipose tissue was collected following pig 
sacrifice for RNA isolation. Several attempts were made to extract RNA using 
RNeasyTM Mini kit (Qiagen, UK) without success. The technical difficulty 
encountered was supported by availability of RNeasyTM
In summary, 100-150mg of frozen visceral adipose tissue was defrosted, 
added to a 2ml tube containing sodium dodecyl sulphate (SDS), phenol, 
citrate buffer and glass beads (0.1mm diameter) before being placed in a 
mini bead beater for two minutes.  Samples were incubated for ten minutes in 
a 60˚C water bath before being beaten again for another minute. The 
generated lipid layer was discarded and the underlying aqueous layer 
carefully removed. This aqueous layer was placed into a fresh 1.5ml tube 
containing glass beads and placed into a mini bead beater for two minutes. 
This was repeated twice to ensure the aqueous layer contained minimal lipid 
contaminant. 
 lipid tissue Midi Kit 
(QIAGEN), a specialised RNA extraction kit for extraction from fatty tissues. 
Due to the limited requirement to extract RNA from adipose tissue a 
traditional technique of phenol-chloroform extraction was identified within the 
literature (Daly, et al. 2012; Margolskee, et al. 2007). 
Following a third and final disruption with a mini bead beater the resultant 
aqueous layer was collected placed into a fresh tube. To extract nucleic acid 
a mini bead beater was used a further three times with phenol-chloroform-
isoamylalcohol at a ratio 25:24:1. Genomic DNA contaminant was removed 
from extracted nucleic acid using RNase-free DNase 1 digest before a final 
phenol-chloroform-isoamylalcohol extraction. To collect the resulting RNA, 
the product was precipitated into solution with 3M sodium acetate (0.1 
volumes) and isopropanol (0.7 volumes) before ten minute centrifugation at 
13,000g (Eppendorf 5418) to form a pellet. This was washed with 70% (v/v) 
ethanol and the pellet reformed by five minute centrifugation at 13,000g 
(Eppendorf 5418) to suspend the pellet in sterile RNase free water. The final 
purified product was generated using an equal volume of 13% polyethylene 
glycol (8000); samples were centrifuged five minutes at 13,000g (Eppendorf 
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5418) to form the final pellet which was re-suspended in sterile RNase free 
water and storage at -80˚C until needed. 
 
RNA isolation: in-vitro cell lines 
All RNA extraction from in-vitro cells was performed using peqGOLD Total 
RNA kit (PEQLAB, Erlangen, Germany). Cultured in-vitro cells were treated 
as follows; suspended NCI-H716 cells transferred to sterile universals were 
centrifuged at 300g (Mistral 1000, MSE) for three minutes. The pellet was re-
suspended in chilled Dulbecco’s Phosphate Buffered Saline (D-PBS) to wash 
the cells before being pelleted again by centrifugation. The D-PBS was 
aspirated and the washed NCI-H716 pellet stored at -80°C. Most in-vitro 
experiments with adherent cells were performed in a 24 well plate. In-vitro 
cells were harvested for RNA extraction by direct addition of 400μl of the 
supplied lysis buffer (PEQLAB) to cells by placing the 24 well plates on ice.  
To recover NCI-H716 cells grown on MatrigelTM 1ml of cell recovery 
solution was added to each well. After 30-40 minutes on ice the MatrigelTM 
As part of the RNA extraction process all samples from in-vitro cell lines were 
homogenised by passing samples through a 27G needle ten times with a 1ml 
syringe. RNA extraction was performed using silica columns from a PEQLAB 
RNA extraction kit in accordance to manufacturer’s instructions for using a 
centrifuge. In summary, cell lysis homogenates were passed through a DNA 
removing silica column into a 1.5ml sterile tube by centrifugation 13,000g 
(Eppendorf 5418). Filtrates were transferred to 2ml M/C tubes and an equal 
volume of 70% (v/v) ethanol mixed into the filtrate by ten passes with a 
P1000 pipette. The whole sample volume was transferred to Perfectbind MS 
RNA columns by several passes of ≤800μl homogenate-ethanol by one 
minute 13,000g centrifugation (Eppendorf 5418). RNA columns were washed 
using supplied wash buffers, remaining DNA was removed by applying 75µl 
of optional DNase I on-column digestion mix; 73.5µl DNase I digestion buffer 
with 1.5µl RNase-free DNase I (20Kunits/µl) for fifteen minutes at room 
was first digested to allow recovery of the cells. To maximise cell harvest the 
homogenate was passed through a P1000 ten times before being transferred 
to a sterile 1.5ml tube on ice. RNA extraction process was either started or 
the tubes were stored at -80°C until needed. 
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temperature. After washing the silica column as instructed, bound RNA was 
eluted with 26µl RNase free ddH2
 
O to enhance concentration. Samples were 
always stored at -80°C overnight prior to sample processing. 
Nucleic acid quantification 
To determine yield and purity of nucleic acids UV spectrophotometry was 
used to measure optical density (OD) of each sample. Absorbance was read 
at 260nm and 280nm wavelengths on a Spectrophotometer U-2000 (Hitachi). 
Absorbance at 260nm wavelength was used to determine nucleic acid yield 
using the beer-lambert law. One optical density unit equates to 40μg ml-1 
single stranded RNA, 33μg ml-1 single stranded cDNA and 50μg ml-1 
 
double 
stranded plasmid DNA. The absorbance ratio between 260nm: 280nm 
wavelengths were used as a measure of sample purity; a ratio between 1.8 
and 2.1 was an indication of samples without significant protein 
contamination. Quantification was routinely performed using a 1:100 RNA 
sample dilution, or a 1:20 cDNA sample dilution using the same milliQ water 
used to auto-zero the UV spectrophotometer before taken measurements. 
Assessment of RNA integrity 
To take into account the freeze-thaw anomaly associated with nucleic acid 
quantification. RNA samples were always frozen overnight in -80°C storage. 
The following day, RNA samples were quantified by UV spectrophotometer, 
using 1:100 dilution of sample. The RNA integrity was assessed by 1% (w/v) 
agarose gel electrophoresis. In preparation 0.04g agarose was added to a 
100ml conical flask suspended in 40ml 1xTTE buffer, prepared by a 1:10 
dilution of a 10xTTE stock (30mM Trizma Base, 30mM Taps, 0.1mM EDTA). 
The agarose suspension was dissolved by heating in a microwave and 
allowed to stand at room temperature to cool to approximately 50°C (hand 
warm). While still molten 3µl (5mg/ml) ethidium bromide was added into the 
solution to intercalate between planar nucleotide bases (present in samples), 
becoming luminescent under ultraviolet light. An agarose gel was cast with a 
small gel rig and left to solidify before transfer into a gel electrophoresis rig 
filled with 1xTTE buffer. A 10µl volume (2µl RNA sample, 3µl 5xGelPilotTM 
DNA loading dye and 5µl milliQ water prepared on parafilm to load into each 
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well. Electrophoresis at a constant voltage, 80 volts for 30-45 minutes 
allowed separation of three migration markers, xylene cyanol (2000-3000bp), 
bromophenol blue (250-400bp), and orange G (<100bp). RNA integrity was 
confirmed by the presence of 18S and 28S ribosomal bands visualised on a 
Bio-Doc-ItTM 
 
Imaging system UVP system. 
First strand cDNA synthesis 
First strand cDNA synthesis was performed in a thermocycler, GeneAmp® 
PCR system 2700 (Applied Biosciences, UK). Reactions were prepared in 
single 500µl PCR tubes by loading a calculated volume of milliQ water, 2.5μl 
of random hexamer primers (0.5µg µl-1) with 3μg to 5μg of sample RNA. A 
first strand synthesis programme was started after loading samples onto the 
instrument to be heated to 70°C for 10 minutes. When the instruments 
temperature reduced to approximately 30°C the instrument was paused and 
samples placed on ice for 10 seconds. Samples were returned to the 
instrument allowing the temperature to decrease to 25°C for five seconds 
allowing the random hexamer primers to anneal to RNA template before 
temperature increased to 50°C. One minute was given for the temperature to 
equilibrate before 8.1μl of master mix; 4μl 5X First Strand Reaction buffer 
(Invitrogen), 2μl 0.1mM DTT (Invitrogen), 1μ 40mM dNTP’s (10mM each 
dNTP), 0.6μl 40U µl-1 RNase OUTTM (Invitrogen) and 0.5μl 2000U µl-1 
Superscript IIITM
 
 was added to each reaction PCR tube. The reaction was 
then allowed to continue for sixty minutes at 50°C followed by a 20°C 
temperature increase (70°C) for 10 minutes. The reaction condition was then 
given a minute to equilibrate at 37°C before addition of 0.5μl RNase H into 
each reaction tube. This reaction was given 30 minutes to reach completion. 
Samples were cooled to 4°C for refrigerated storage. Generated first strand 
cDNA samples were always purified within 48 hours. 
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Purification of cDNA 
First strand cDNA (4°C) samples were cleaned on silica columns from a 
QIAquick®
Samples were diluted one in five with buffer PB and homogenised by ten 
passes through a pipette. The DNA within the sample was en-trapped within 
silica membrane of QIAquick columns following thirty second centrifugation. 
The flow through in the 2ml collection tube was discarded and the silica 
membrane washed with 750µl buffer PE. To remove residual ethanol the 
membrane was dried by a further one minute centrifugation. To retrieve 
bound cDNA the silica membrane was incubated one minute in elution buffer 
(10mM Tris/HCl pH 8.5); 36µl for animal studies and 26µl for in-vitro studies. 
These elution volumes take into account, 2μl sample being held within the 
silica column and the 1:20 (4µl) sample dilution needed to quantify cDNA 
concentration by spectrophotometry. Fresh sterile 1.5ml tubes were used to 
collect samples by centrifugation. Samples were quantified by UV 
spectrometry to prepare necessary dilutions and stored (-20°C) until needed.  
 Gel Extraction Kit (QIAGEN GmbH, Hilden, Germany), and 
performed in accordance to manufacturer’s instructions using a bench-top 
centrifuge at 13,000g (Eppendorf 5418). 
 
Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR reactions were set-up at room temperature by adding the following 
components to single 50µl domed PCR tubes in the order specified; 32µl 
milliQ water, 10µl MyTaq reaction buffer, 5µl template (neat cDNA), 1µl 
sense primer, 1µl antisense primer and 0.5µl MyTaq DNA Polymerase. 
Intron-spanning primers were designed to maximise amplification of target 
cDNA while minimising extension of genomic DNA. A minimum of three 
biological samples (N = 3) were used in reactions routinely performed on a 
GeneAmp®
 
 instrument programmed for 45 cycles and a 50°C annealing 
temperature, unless optimisation was needed. Analysis of RT-PCR products 
was performed by separating nucleotide sequence according to size using 
1% agarose gel electrophoresis as previously described. 
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Semi-quantitative real time polymerase chain reaction (QPCR) 
First strand cDNA generated using random hexamer primers (as previously 
described) was purified, then quantified by spectrophotometry and diluted to 
5ng μl-1, unless otherwise stated. 5μl sample volume was added to 50μl 
qPCR tubes containing 20μl of a master mix; each tube contained 12.5μl 
JumpstartTM Ready Mix with SYBR®
 
 green master mix 2X (Sigma, UK), 
1.25μl 20X primer mix (18μM Sense and Antisense primers) and also 6.25μl 
milliQ water. To maximise accuracy each reaction was performed as three 
technical replicates of the same sample. A non-template control was also 
included on each run by replacing cDNA for an equal volume of milliQ water.  
Relative abundance of mRNA from pig, mouse and human intestinal samples 
were compared to recognised reference genes; β-actin or RNA polymerase II 
(Nygard, et al. 2007; Radonic, et al. 2004). All QPCR reactions were 
performed on an automated real-time PCR machine, Rotor-Gene 3000 
(Corbett Research, Australia). The same cycling parameters were commonly 
used. Samples were held 2 minutes at 95°C, followed by 45 cycles: 15 
seconds denaturation (95°C), followed by 60 seconds to allow intron 
spanning primers to anneal to target cDNA minimising extension of genomic 
DNA. Melt curve measurements were performed between 60°C to 95°C. The 
first step was set to occur for forty five seconds allowing the temperature to 
equilibrate before being increased in an increment of 1°C every five seconds. 
Results were assessed by melt curve analysis to ensure only a single PCR 
product was formed, verified by included a non-template control. 
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PCR primers (Mouse) 
Primer name   Sequence (5’ – 3’)        Product Size 
FFAR2 1001  Sense  ‘GTGGGCACTGAGAACCAAATAAC’      
  1078 Antisense  ‘CAGTCGTACGGGCAGTACCA’  
FFAR2  658  Sense  ‘TGCCCCTGTGCACATCCTCCTG’ 
  1118 Antisense ‘TGACTGCCATGGGAACGAAA’ 
FFAR3 338  Sense  ‘ACCACTATTTACCTCACCTCCCTCTT’ 
405 Antisense  ‘TAGGCCACGCTCAGAAAACG’   
FFAR3  197 Sense  ‘GTGGACTTACTTTTGCTAAA’ 
426 Antisense ‘CGGGTTTTGTACCACAGTGG’ 
T1R1   2580 Sense  ‘ACTCTGAGTGGCGGCTTCA’ 
  2667 Antisense ‘GAAAGTGTTCTGTGTTGAGTTCTG’ 
T1R2  1890 Sense  ‘GGATGGTCCCCGTGTATGTG’ 
  1975 Antisense ‘GCAGACGGAGAAGCAAACG’ 
T1R3  1851 Sense  ‘AGTTCTGCTTTGGCCTGATCT 
  1963 Antisense ‘AGGGAGGTGAGCCATTGGT 
SGLT1 1874  Sense ‘CATTCCAGACGTGCACCTGTAC’ 
  1945 Antisense ‘TCCAGGTCGATTCGCTCTTC’ 
MCT1  1722 Sense  ‘CCTGCTGGCCTCTAGTCTACCA’ 
  1796 Antisense ‘GAACACCCGGTTTTCCA’ 
TRPA1 1532 Sense  ‘GCAGCCAGTTATGGGCGCAT’ 
  1647 Antisense ‘TTTGCTGCCAGGTGGAGAGG’           
GCG  312 Sense  ‘CCCAAGATTTTGTGCAGTGGTT’        
397 Antisense  ‘AGCATGCCTCTCAAATTCATCA’  
PYY  328 Sense  ‘CCTCCTGCGAGATGTGTTAACTAC’ 
423 Antisense ‘ACCGAGATATGAAGTGCCCTCTT’  
β-Actin 1035 Sense  ‘GCTCTGGCTCCTAGCACCAT’            
1109 Antisense  ’GCCACCGATCCACACACAGAGT’  
RPII  3399 Sense  ‘GCCAAAGACTCCTTCACTCACTGT’ 
  3485 Antisense  ‘TCCAAGCGGCAAAGAATGTC’   
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Figure 2.2: PCR Primers (Mouse) 
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PCR primers (Human) 
Primer name   Sequence (5’ – 3’)        Product Size 
FFAR2 1067 Sense   ‘GGCTCCCATCCAGATTCAGA’              
  1146 Antisense  ‘TACCAAGCTGGTGAAAGGCATT’ 
FFAR3  1231 Sense  ‘CCTAAGGGTATGCGCGCTAA’                                        
  1303 Antisense  ‘CAATCCATAGTGTGTGGGTGGAT’ 
FFAR1 718 Sense  ‘CGTAGGACCCTACAACGCCT’            
  836 Antisense ‘TCACCAGCGGATTAAGCACC’ 
T1R1  2407 Sense  ‘GGCTTCGGTGGGTATTTTCTG’ 
  2482 Antisense ‘GGAAGTGCTCTGTCTGTTGAG’ 
T1R2  2045 Sense  ‘TGGCATTTATCACGGTACTCAAA’        
  2124 Antisense ‘AGTACGGGTGGTGGGACTGA 
T1R3  1111 Sense  ‘CCGCAGTGTGACTGCATCAC’              
  1196 Antisense ‘CTATACACAGCTGCGTAGACAGAGAA’ 
TGR5  1593 Sense  ‘CACACTGCTCCTCTCAGT’                   
  1671 Antisense ‘AGGGAGAGGAGGGACAACAG’           
GPR93 678 Sense  ‘CTCCTACTACGCACTGCACC’            
  800 Antisense ‘TAGCGGTCCACGTTGATGAG’            
GPR119 719 Sense  ‘GAGGTTATCGATCCCCACGG’           
  836 Antisense ‘ACCTGCACAATGCCAGTGAT’           
TRPA1 1724 Sense  ‘GCAGCCAGTTATGGGCGTAT’ 
  1806 Antisense ‘TTTGCTGCCAGATGGAGAGG’ 
RPII  2770 Sense  ‘GCAAGCGGATTCCATTTGG’   
2841 Antisense  ‘TCTCAGGCCCGTAGTCATCCT  
β-Actin 291 Sense  ‘ACGGCATCGTCACCAACTG’                 
364 Antisense  ‘AGCCACACGCAGCTCATTG’ 
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Figure 2.3: PCR Primers (Human) 
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PCR primers (Human) 
Primer name   Sequence (5’ – 3’)        Product Size 
 
MCT1  1538 Sense  ‘GGATTGGTGACCATTGTGGAA’         
  1644 Antisense ‘CCACATGCCCAGTATGTGTATTTG’  
SGLT1 2022 Sense  ‘TAGATTTACCATGGCTGGACTCTTACT’
  2115 Antisense ‘CACCTGGGCAAAATTTACAACTG’  
PYY  700 Sense  ‘CCACTACCTCAACCTGGTCAC’ 
  783 Antisense ‘TCGGGGAAGAACGTTTTGGAA’   
GCG  588 Sense  ‘TGGAAGGCCAAGCTGCCAAGG’        
703 Antisense  ‘ACCATCAGCATGTCTGCGGC’           
 
 
PCR primers (Pig) 
Primer name   Sequence (5’ – 3’)        Product Size 
 
FFAR2 309  Sense  ‘GGCTTTCCCCGTGCAGTAC’             
  412  Antisense  ‘TGAACACGACGGTGCAGTGA’  
FFAR3 837  Sense  ‘CGAGTGGAGACCTTACGTGTTG        
  925  Antisense  ‘CTTGGAACCCCGAGGATGA’ 
MCT1  1300 Sense  ‘GCATGTGGCATAATCCTGATCAT’  
1374 Antisense  ‘TGCCAGAAGTCGGTAGTTGATG’ 
PYY  424 Sense  ‘CTCGCGATCCCAGAACCA’ 
  515 Antisense ‘CGAGGGCACCGAGAAATG’ 
GCG  420 Sense  ‘AGAACTCCGCCGCAGACA’ 
  502 Antisense ‘TAAAGTCTCGGGTGGCAAGATT’ 
β-Actin 502 Sense  ‘CGAGGCCCAGAGCAAGAG’   
582 Antisense  ‘TCCATGTCGTCCCAGTTGGT’ 
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Figure 2.3: PCR Primers (Human) 
Figure 2.4: PCR Primers (Pig) 
Chapter Two 
67 
 
 
Cloning of blunt ended PCR products 
Assessing the RT-PCR products 
The size of RT-PCR and QPCR products were visualised on a 1% (v/v) 
agarose gel following electrophoresis. Sample products were separated 
according to size determined by running 3µl GeneRulerTM 
 
100bp (Fermentas) 
alongside samples as a DNA ladder. When new primer sets were under 
evaluation, two adjacent wells were taped together and the remaining sample 
products separated on a 1% (v/v) agarose gel as described. In event of a 
single band of an expected size (visualisation under UV light), the band was 
excised with a sharp scalpel and placed into a sterile 1.5ml tube to be cloned 
and sequenced. 
Extraction and purification of DNA from agarose gel 
Bands removed from agarose gels were placed into sterile 1.5ml tubes. The 
weight of agarose was determined on an analytical balance, and DNA was 
retrieved using a QIAquick®
 In summary, weighed agarose was dissolved in x3 volume of buffer QG 
by incubation at 60°C for 10-15 minutes; tubes were inverted every five 
minutes to help dissolve the gel. DNA with the sample-buffer QG mix was 
adsorbed onto silica membranes of QIAquick columns by several one minute 
centrifugation steps at 13,000g (Eppendorf 5418) by filling columns to their 
maximal 800µl capacity. The columns were washed with 500µl buffer QG. 
After centrifugation the column stood for five minutes with 750µl buffer PE 
before centrifugation. To remove residue ethanol the column was given an 
additional centrifugation before purified DNA was collected using 36µl of 
elution buffer. Samples were stored at -20°C until needed. 
 Gel Extraction Kit (QIAGEN GmbH, Hilden, 
Germany), in accordance to manufacturer’s instructions for use of a bench 
top centrifuge. 
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Ligation of DNA into pGEM-T easy bacterial plasmids 
Ligation of DNA into pGEM-T easy bacterial plasmids was routinely 
performed by overnight incubation at 4°C. To perform overnight ligations the 
following was added to a sterile tube in the specified order. 
 
2X Rapid Ligation buffer, T4 DNA Ligase (Promega)  5µl 
PCR product        3µl 
pGEM-T easyTM 
T4 DNA Ligase
vector 50ng/µl (Promega)   1µl 
TM 3 Weiss units µl-1
 
 (Promega)  1µl   
Setting up for transformation 
To set up transformation into the competent Escherichia coli JM109 strain 
several solutions of Luria-Bertani (LB) culture medium were required so were 
freshly prepared; SOB Medium, SOC Medium, LB Broth, LB culture plates 
(composition and preparation are summarised below). 
 
  Medium   SOB   LB 
BactoTM
Bacto
 tryptone   2.0% (w/v)   1.0% (w/v) 
TM
Sodium chloride   10mM  (w/v)  1.0% (w/v) 
 Yeast Extract  0.5% (w/v)  0.5% (w/v) 
1M sodium hydroxide  pH7.0   pH 7.0 
 
The above was dissolved with 150ml RO water in a 400ml beaker using a 
medium sized flee positioned on a magnetic stirrer. Once dissolved, 1M 
sodium hydroxide was added drop-wise adjusting to pH 7.0. The solution was 
transferred to a measuring cylinder and made up to final working volume with 
RO water used to washout the beaker. Sealed with parafilm this was mixed 
by inverting several times before the solution was transferred to a 400ml 
DURAN®
 
 laboratory bottle to be autoclaved with a loose lid. Once cool they 
were stored at room temperature and only opened under aseptic conditions 
using a Bunsen burner.  
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SOC medium (prepared immediately before use) 
 SOB medium     980 µl 
 2M Magnesium (Mg2+
   1M Magnesium chloride 
)   10 µl 
   1M Magnesium Sulphate 
 2M D-Glucose , filter sterilised  10 µl 
 
Preparation of LB culture plates 
6g of BactoTM
Transformation into Escherichia coli 
 agar was added to 150ml of LB medium, pH 7.0 (1M sodium 
hydroxide), before being made up to 200ml with RO water to be autoclaved. 
At approximately 56°C 2ml of 10mg/ml ampicillin was added to give a final 
working concentration of 100µg/ml ampicillin. While the LB medium/agar was 
still molten approximately 30ml was poured into petri-dishes under aseptic 
conditions. Petri dishes were either used later the same day or stored (4°C) 
for no more than 14 days. 
The following was placed into a sterile 1.5 ml tube and placed on ice to allow 
plasmids to interact with the cell walls of Escherichia coli. 
 3µl Ligation mixture 
 25µl Competent JM109 E.coli cells (Stratagene) 
After 30 minutes the cells were subject to 1 minute heat shock at 42ºC in a 
water bath. Under aseptic conditions 450µl of freshly prepared SOC medium 
was added to the tube and placed in a 37ºC incubator and shaken for 90 
minutes at 200 shakes minute-1. During this time LB culture plates were 
prepared to allow identification of transformed colonies. Under a flame 20µl 
of 50mg/ml 5-bromo-4-chloro-indolyl-β-D-galactopyranoside, XGAL 
(Fermentas) and 100µl of 100mM Isopropyl β-D-1-thiogalactopyranoside, 
IPTG (Promega) was spread onto culture plates to allow blue/white selection. 
Three separate plates were generated for each gene of interest by spreading 
20µl, 50µl or 100µl of bacterial suspension onto plates before being 
incubated overnight (37ºC) to promote cell growth. 
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The next day these plates were used for blue/white selection.  The inducer 
IPTG causes production of β-galactosidase causing hydrolysis of X-GAL to 
form 5,5’-dibromo-4,4’-dichloro indigo (blue colonies). To intensify the colour 
of this insoluble material plates were placed at 4ºC to easily identify and 
dismiss the blue colonies. Only stand-alone white colonies in the centre of 
the plate were considered successfully transformed with plasmid insert. This 
successful insertion of DNA results in disruption of the β-galactosidase gene 
causing generation of a non-functional enzyme unable to hydrolyse X-GAL 
(white colonies). 
 
Setting up overnight culture for colony screening 
Freshly prepared LB Broth (1% (w/v) sodium chloride, 1% (w/v) BactoTM 
tryptone, 0.5% (w/v) BactoTM
 
 yeast extract, pH 7.0 (1M sodium hydroxide)) 
was autoclaved, once cooled, 5ml aliquots were dispensed into sterile 
universals under aseptic conditions and used within 48 hours. 
When an isolated white colony was identified it was carefully removed from a 
clone library and grown overnight in LB broth containing 50µl of 10mg/ml 
ampicillin in a shaking incubator, set at 200 shakes per minute (37°C). The 
following morning an opaque LB broth was evident of bacterial growth. To 
confirm the presence of an intended product a colony screen was performed 
by RT-PCR using GeneAmp PCR system (Applied Biosciences, UK): 
 
 37.5µl ddH2
 10µl MyTaq buffer  Program details 
O 
 1µl Forward (Sense) Primer  25 Cycles 
 1µl Reverse (Antisense) Primer 50ºC annealing 
 1µl MyTaq Polymerase            temperature 
 3µl LB Broth (overnight culture) 
Products were assessed by placing 10µl of neat RT-PCR product onto a 1% 
(w/v) agarose gel electrophoresis and visualised as previously described. 
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Extraction and quantification of plasmid DNA 
A pellet of transformed cells was prepared in universals by centrifugation of 
LB broths at 1860g (3000rpm) for 4 minutes using a SH-3000 rotor in a 
Sorvall RC 5C Plus centrifuge. Universals were decanted into Lysol and the 
remaining pellet used for plasmid preparation, performed in accordance to 
the manufacturer’s instructions of a QIAprep®
 
 Spin Miniprep kit (QIAGEN 
GmbH, Hilden, Germany). Yield and purity of plasmid DNA was estimated by 
spectrophotometry as previously outlined. 2μg of plasmid was prepared and 
lyophilised using a speedvac DNA100 (savant) for sequence analysis 
(Eurofins MWG Operon, UK). 
Cell culture: Origin of in-vitro cell lines 
The in-vitro cell lines used in these studies were human or mouse derived.  
 
Murine cell line 
GLUTag: A colonic enteroendocrine carcinoma (Drucker, et al. 1992) 
 
Human derived cell lines 
HT-29: A colonic adenocarcinoma (Fogh, et al. 1977) 
HUTU-80: A duodenum adenocarcinoma (Le Neve, et al. 2010) 
NCI-H716: An adenocarcinoma of the caecum (de Bruine, et al. 1992) 
AAC1: A human colonic adenoma (Williams et al. 1990) 
 
HEK293 Flp-InTM TRExTM
Cells were generated using HEK293 Flp-In
 FFAR2 or FFAR3 cell lines 
TM TRExTM cells (Invitrogen), by 
first making a stable cell line expressing the universal G-protein Gα15 
(Internal Report: VD04 0211). Plasmids containing either FFAR2 or FFAR3 
(OriGene), were sub-cloned into an inducible expression vector pcDNA5-
FRT-TO (Invitrogen). Transfections in generation of the two separate 
inducible HEK293 Flp-InTM TRExTM cell lines expressing FFAR2 or FFAR3 
were performed according to manufacturer’s instructions. 
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Culture requirements of in-vitro cell lines 
All cell lines were maintained under standard cell culture conditions in a 
humidified cell culture cabinet set at 37°C, supplemented with an air intake 
containing 5% CO2
 
. 
HT-29 
This cell line was maintained in complete Dulbecco’s Modified Eagle’s 
Medium, DMEM 6546 (Sigma). New incomplete medium was warmed and 
supplemented by first discarded 60ml incomplete medium and replacing this 
volume with the following additives (final working concentrations shown). 
 
50ml  heat-inactivated foetal bovine serum (HI-FBS)*  (10%) 
5ml  L-glutamine        (2mM) 
5ml  Penicillin and streptomycin  (100U ml-1 and 100µg ml-1
 
) 
*FBS (Sera Laboratories International) was heat-inactivated by incubation in 
a 56°C water bath for 30 minutes before use. 
A 15ml cell suspension was used to seed 2-3.0 x104 cells / cm2 into a 75 cm2 
 
flask (T75). Medium was replenished three times each week with cells 
routinely passaged on a weekly basis using passage numbers 15-21. 
AAC1 
This adherent cell line was maintained in supplemented Dulbecco’s Modified 
Eagle’s Medium (Sigma, D6546) with the following supplements: 
 
100ml  Heat-inactivated foetal bovine serum (HI-FBS)*   (20%) 
5ml  Penicillin and streptomycin  (100U ml-1 and 100µg ml-1
1ml  Hydrocortisone sodium succinate         (1µg ml
) 
-1
1ml  Human actrapid insulin         (0.2U ml
) 
-1
5ml  Glutamine        (2mM) 
) 
 
A 15ml cell suspension was used to seed 6-8 x 104 cells / cm2 into a T75 and 
grown to a near confluent monolayer over one week (Note: this is a slow 
growing cell line). Growth medium was replenished three times each week 
and passaged at the beginning of each week. Passage numbers 83 to 90 
were used in studies presented in this thesis. 
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GLUTag 
This adherent cell line was grown in supplemented Dulbecco’s Modified 
Eagle’s Medium (Sigma, D6546), see HT29 cells for details.  
 
A 15ml cell suspension was used to seed 6-8 x 104 cells / cm2
 
 into a T75 
flask and grown to a confluent monolayer over seven days. Growth medium 
was replenished three times each week and passaged early each week. 
Passage numbers 35 through to 45 were used. 
NCI – H716 
This cell line was grown in suspension using a modified version of RPMI 
1640 as recommended by the American Type Culture Collection (ATCC), 
Cat. No: 30-2001 (Life technologies). New incomplete culture medium was 
warmed in a 37°C water bath; 55ml was discarded and replaced with the 
following supplements (final working concentrations are shown below). 
 
50ml  Heat-inactivated foetal bovine serum (HI-FBS)*, (10%) 
5ml  Penicillin and streptomycin        (100U ml-1/ 100µg ml-1
 
) 
A 15ml cell suspension was prepared and seeded at 4.0 x 105
 
 cells / ml into 
a T75, cultured in a horizontal orientation under standard cell culture 
conditions. The cell density was adjusted three times each week using a 1:3 
sub-cultivation ratio to maintain the cell density within the recommendation 
range (ATCC) for cell growth. Cells were passaged weekly and commonly 
replaced every ten to twelve weeks. 
HUTU – 80 
The adherent HUTU-80 cell line was maintained in supplemented Dulbecco’s 
Modified Eagle’s Medium, DMEM 6546 (sigma), see HT29 cells. 
 
As described above a 4.0 x 104 cells / cm2 cell suspension were seeded into 
a T75 and grown to a confluent monolayer over one week. The medium was 
replenished twice each week and passaged at the beginning of a new week. 
Passage numbers 22 to 30 were used. 
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HEK293 Flp-InTM TRExTM
Cells were maintained under standard conditions at 37°C, 5% CO
 FFAR2 or FFAR3 cell lines 
2 in 15ml 
Dulbecco’s Modified Eagle Medium (DMEM) with Ultra L-glutamine, without 
Sodium Pyruvate supplemented with 10% (v/v) tetracycline negative foetal 
bovine serum and the additional antibiotics, 4ml Geneticin (400μg/ml), 1ml 
Hygromycin B (100μg/ml) and 250μl Blasticidin S (5μg/ml). The functional 
roles of these antibiotics were to maintain the expression of Gα15
 
 protein, the 
FFAR receptors and the tetracycline repressor, respectively. Cells were fed 
on Wednesday and Friday by replenishing growth medium with 15ml 
supplemented DMEM. The cells were routinely passaged on Monday to 
control cell density. 
Passaging of cell lines 
HEK293-Flp-in Trex FFAR2 and FFAR3 cells lines 
Cells were passaged once a week to avoid the cells reaching full confluence, 
routinely on a Monday. Old growth medium was removed and the cells were 
washed with 2ml trypLE™ Express to detach adherent cells from the flask 
following 10 minute incubation at 37°C, 5% CO2. The trypLE™ Express was 
neutralised using 8ml complete growth medium. A cell pellet was generated 
by centrifugation at 300g for 3 minutes (Mistral 1000, MSE). The supernatant 
was removed and the pellet re-suspended in 10ml fresh complete growth 
medium using a 10ml pasture pipette. The cells were then passed through a 
19G needle to breakup clumped cells to form a homogenous single cell 
suspension. The cells were counted by transferring 20μl of cell suspension 
into a counting chamber (Nexcelom Biosciences). A cell count was routinely 
performed on a Cellometer® Auto T4 (Nexcelom Bioscience). To continue the 
HEK293-Flp-InTM TRExTM FFAR2/3 cell lines and to allow a weekly passage 
the cells were seeded at 0.5x106
 
 cells into a fresh T75. On average this was 
14.5ml DMEM with 0.5ml cell suspension. Upon restoring a low cell density 
to continue the cell lines all remaining cells were available for setting up 
desired assays. 
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Passaging of all other adherent cell lines 
All other adherent cell lines were passaged weekly at a confluence 70-80%. 
After washing cells twice with 1x phosphate buffered saline (PBS). Adherent 
cells were detached from T75 flasks using 1:10 dilution of trypsin to versene 
(1xD-PBS supplemented with 0.1% (v/v) EDTA). Cells became detached 
after five to fifteen minutes incubation at 37ºC. The trypsin was neutralised 
with complete growth medium before the suspension was centrifuged at 300g 
for three minutes (Mistral 1000, MSE) forming a cell pellet. To re-suspend the 
pellet the medium was replenished with 10ml complete medium and passed 
through a 19G needle to breakup clumps into a single cell suspension. After 
several gentle inversions, 6.5µl of cell suspension was used to perform a cell 
count with a haemocytometer to estimate cell density. Cells were either 
seeded for cell culture continuation or experiments setup in 24 well plates. 
 
Passage of NCI-H716 cells (a suspended cell line) 
Cells were passaged weekly or once cells formed excessive clumps. Cells 
were pelleted by centrifugation at 300g (2500rpm) for 3 minutes (Mistral 
1000, MSE) and medium replenished with 10ml to re-suspend the pellet. The 
suspension was passed through a 19G needle to breakup clumps into single 
cell suspension. The universal was gently inverted several times to ensure a 
homogenised cell suspension. Both cell density and viability were determined 
simultaneously during a routine cell count. Cell viability was routinely 
assessed using the trypan blue exclusion test*. An equal volume (100µl) of 
cell suspension was added to 100µl of 0.4% (w/v) Trypan Blue, mixed and 
incubated 5 minutes at room temperature. Viable cells are unable to take-up 
trypan blue, therefore non-viable cells stain blue allowing easy identification. 
Cells were counted, seeded and maintained as previously described.  
 
*The Trypan Blue exclusion test was performed as a precautionary measure 
during routine cell passage, and also when plating cells for experiments to 
ensure an accurate and viable cell count was obtained. Viability was always 
96-100% viable. 
Cell Viability = (Number of viable cells / Total number of cells) x 100 
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Preparations of homogenate and membrane fractions 
Preparation of post nuclear membrane fractions 
To prepare post nuclear membrane fractions (PNMFs), samples were 
homogenised followed by two-step centrifugation to remove nuclear material. 
Integrity was preserved by keeping samples on ice or refrigerated (4°C) 
during processing of samples. PNMF preparation required a working solution 
of ice cold hypotonic buffer 1 (100mM mannitol, 2mM HEPES/tris pH 7.1 
(4°C)) which was supplemented with 0.2mM benzamidine, 0.2mM 
phenylmethanesulfonylfluoride (PMSF) and 0.2mM dithiothreitol
Preparation of PNMF from in-vitro cells 
 (DTT) final 
working concentrations (1:1000 dilution from stocks).  
A cell pellet within a universal was taken from -80°C storage, briefly warmed 
to room temperature before being re-suspended in 5ml ice cold hypotonic 
buffer 1 (HB1). This was transferred to a 25ml beaker on ice containing 
another 5ml HB1. Remaining cells were retrieved by washing the universal 
twice with 2ml ice cold HB1. This osmotic gradient causes cells to swell 
making them more fragile. These cells were homogenised for forty-five 
seconds with a Polytron, setting 5, The probe was washed with 1ml ice cold 
HB1 into the 25ml beaker before returning it to ice. The homogenised cell 
suspension was transferred to a measuring cylinder, the beaker washed with 
HB1 and added to the measuring cylinder up to 20ml. This suspension was 
transferred to a centrifugation tube (with lip) and remaining cells retrieving by 
washing the measuring cylinder with a further 5ml ice cold HB1. Balanced 
centrifugation tubes were centrifuged (4°C) at 500g (2050rpm) using a SS-34 
rotor on a Sorvall RC 5C Plus (Kendro Laboratory Products, USA) for twenty 
minutes to pellet nuclear components. The resulting supernatant 1 (S1) was 
decanted over the pellet into a second centrifugation tube (without lip). The 
remaining pellet was discarded. 
To pellet PNMF S1 was centrifuged (4°C) thirty minutes at 40,000g 
(18,300rpm) in a SS-34 rotor on a Sorvall RC 5C Plus (Kendro Laboratory 
Products, USA), the resultant supernatant (S2) was discarded over the pellet. 
Centrifugation tubes were positioned upside down to drain away remaining 
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supernatant, further removed with tissue and a cotton bud. The PNMF pellet 
was re-suspended in 20-100µl buffer 3 (300mM mannitol, 20mM HEPES/tris 
pH = 7.4, 0.1mM magnesium sulphate, 0.02% (v/v) sodium azide) dependent 
on pellet size. The pellet was homogenised by ten passes through a 100µl 
Hamilton syringe in preparation of a BioRad micro-protein assay. Sample 
dilutions were prepared with 5x sample buffer and maintained at -20°C.   
Preparation of PNMF from human colon biopsies 
Human colonic biopsies taken from LN were placed on an ice cold glass 
plate. A sharp scalpel was used to cut biopsies into small pieces to be placed 
into a 2ml M/C collection tube containing 120µl of hypotonic buffer 1 with 
added inhibitors. Human tissue was homogenised twice for 60 seconds on a 
handheld custom glass homogeniser. After use the homogeniser was 
washed twice with 40µl buffer 1. Remaining epithelial cells were removed 
using a vibro-mixer for two minutes at its highest setting. The vibromixer was 
rinsed with 1ml buffer 1 collected and added to the 2ml collection tube. The 
sample tube was whirly mixed and large pieces of connective tissue 
removed. Nuclear material was pelleted by placing balanced 2ml collection 
tubes into adaptors to allow 20 minute centrifugation (4°C) 500g (2050rpm) 
with a SS-34 rotor on a Sorvall RC 5C Plus (Kendro Laboratory Products, 
USA). Discarding the nuclear pellet the resulting supernatant S1 was 
transferred to a fresh sterile 2ml M/C collection tube. PNMFs from S1 were 
pelleted by thirty minute centrifugation (4°C) at 30,000g (18,200rpm) using a 
SS-34 rotor on a Sorvall RC 5C Plus (Kendro Laboratory Products, USA). 
Discarding the supernatant (S2), the remaining PNMF pellet was re-
suspended in 10µl buffer 3 (300mM mannitol, 20mM HEPES/tris pH 7.4, 
0.1mM MgSO4
 
, 0.02% (v/v) sodium azide), and homogenised by ten passes 
through a 10µl Hamilton syringe. A BioRad micro-protein assay was 
performed and 20µg and 40µg samples prepared in 5x sample buffer diluent. 
All samples were stored at -20°C until needed. 
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BioRad micro-protein assay 
The Bio-Rad protein assay is a method based on dye-binding to protein 
(Bradford. 1976). Various protein concentrations lead to a differential colour 
change. The dye Coomassie® 
A relative measurement of protein concentration was achieved by 
interpolation of a sample’s mean absorbance at 595nm on a benchtop 
spectrophotometer. A whirly mixed stock of bovine γ-globulin (1.5mg/ml) was 
used to create a standard curve of known amounts of protein in buffer 3. Test 
samples were fully homogenised before measurement by passing through a 
27G needle attached to a 1ml syringe or through a 100µl Hamilton syringe 
ten times as appropriate. Samples were prepared in duplicate for 
measurement mixing 1µl sample with 799µl buffer 3. All tubes were slowly 
but swiftly topped up with 200µl of BioRad Protein Assay dye reagent. The 
tubes were inverted several times to mix samples with the dye reagent and 
promptly whirly-mixed for a short-time. Tubes were incubated at room 
temperature for 10 minutes before contents of tubes were decanted into 
micro-assay cuvettes to measure absorbance readings at 595nm with a 
spectrophotometer.  
Brilliant Blue G-250 was shown to mainly bind 
to basic and aromatic amino acid residues, especially arginine (Compton and 
Jones. 1985). When binding to protein it was shown that the maximum 
absorbance of an acidic solution of dye shifts from 465nm to 595nm (Sedmak 
and Grossberg. 1977). The extinction co-efficient of a dye-albumin complex 
solution remains constant over a 10 fold concentration range, allowing for the 
application of the Beer-Lambert law to accurately quantify unknown protein 
concentrations from a standard curve, using an appropriate ratio of dye 
volume to sample concentration (Spector. 1978). Hence, a micro (1-20µg) 
protein assay or macro (20-200µg) assay can be performed to determine 
unknown protein concentrations. 
A linear standard curve intended for use for interpolation of unknown values 
was constructed using software GraphPad prism version 5. Corresponding r2 
value was assessed to ensure a goodness of fit. Values ≥ 0.97 provided 
confidence that the samples interpolated protein content were reliable. 
Samples for SCFA receptor blotting were prepared with 15µl (40µg protein) 
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loading volume. Samples were diluted in a 5x sample buffer (5% (w/v) SDS, 
25% (v/v) glycerol, 0.125% (v/v) β-mercaptoethanol, 156.25mM trizma base; 
pH 6.8 (hydrochloric acid) and 0.025% (v/v) bromophenol blue). SDS used in 
sample buffer gives all protein a negative charge. Once current is applied 
samples migrate towards the positive electrode (anode) separating proteins 
on a SDS PAGE gel according to size. 
Setting up a standard curve for a BioRad micro-protein assay 
 
 
 
 
 
 
 
 
Figure 2.5: Graph to illustrate all standard curves generated performing 
protein micro-assays to highlight consistency. 
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SDS-polyacrylamide gel electrophoresis 
 
Preparation of SDS PAGE gels 
All sodium dodecyl sulphate (SDS) polyacrylamide gels for electrophoresis 
were prepared using ethanol cleaned glassware. Routinely, a 1mm BioRad 
spacer plate with a thin glass plate was used to cast gels and a 100ml 
Buchner flask was used to prepare solutions. Before starting, the gel casting 
system was set up by warming a 20% stock solution of SDS at 60°C to 
ensure crashed out SDS was fully re-dissolved. At this time a vial of 20% 
(w/v) ammonium persulphate was freshly prepared in a 1.5ml tube by 
dissolving 0.02 grams in 100µl milliQ water. 
Preparation of an SDS-PAGE gel is a two-step process routinely performed 
in duplicate to have a back-up gel available. 
First, a running gel was cast with running gel buffer (1.5M (w/v) Trizma base, 
pH 8.8 (1M HCl) prepared to a desired percentage acrylamide, components 
were added in the order specified (see next page). Polymerisation of SDS 
PAGE gels were initiated following addition of ammonium persulphate and 
tetramethylethylenediamine. The running gel was cast to 1cm below the 1mm 
sample comb later used to cast wells into the stacking gel. 50µl butan-2-ol 
saturated water was added drop-wise on top of the running gel to generate a 
thin layer to protect free radicals reacting with air and to remove remaining 
bubbles. The running gel was given an hour to set before butan-2-ol 
saturated water was removed with filter paper in preparation to cast a 
stacking gel (stage 2). 
Stacking gels were prepared using stacking gel buffer (0.5M (w/v) Trizma 
base, pH 6.8 (1M HCl) containing 8% (v/v) acrylamide, adding components in 
the specified order (see next page). The stacking gel buffer was added on 
top of the cast running gel to 0.5cm below the maximum capacity of the rig. A 
1mm comb was then introduced with care avoiding formation of bubbles 
while excess buffer was removed with a P1000.  
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One hour was generally given for the stacking gel to solidify; SDS PAGE gels 
were then ready for use. However, SDS-PAGE gels were routinely prepared 
in advance and wrapped in saram wrap, encased in moist blue roll and 
wrapped again in saram wrap for storage at 4°C for up to three days. 
 
 
Preparation of a SDS PAGE gel running and stacking buffers 
Buffer 
(% Acrylamide) 
Running 
(8%) 
Running 
(12%) 
Stacking 
(8%) 
 Stage 1 Stage 2 
milliQ ddH2 4.75 O (ml) 3.40 6.00 
Working Buffer (ml) 2.50 2.50 2.50 
Acrylamide (ml) 2.66 3.99 1.33 
20% Sodium dodecyl sulphate (µl) 50 50 50 
    
20% Ammonium persulphate (µl) 50 50 50 
Tetramethylethylenediamine (µl) 5 5 10 
    
Total volume per gel ≈ 4.00 ≈ 4.00 ≈ 1.50 
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Separation of proteins on a SDS-PAGE gel 
A discontinuous reducing gel SDS-PAGE was used to separate proteins 
according to their size using Bio-Rad Mini-Protean II dual slab cell apparatus 
to prepare 1mm thick gels.  
Prepared SDS-PAGE reducing gels were removed from 4°C storage, 
unwrapped and warmed to room temperature. The gel sandwich was placed 
onto the electrode assembly to position the notch above the short plate. In 
the event of running just one gel, a buffer dam was used in replacement. The 
electrode assembly was placed into the clamping frame and cams pushed 
forward to enforce pressure on the plate to form a tight seal with the inner 
chamber. Placed into a mini-tank, filled to a third of the total volume, the 
electrode assembly was filled completely with 1x tank buffer. In quick 
succession, 10-15µl samples were quickly added using a sample loading 
guide. The sample loading guide was removed and the lid closed, ensuring 
the red (anode) banana plug and black (cathode) banana plug were matching 
the corresponding colours of the power pack. While being quick enough as 
not to allow time for samples to diffuse into the gel the power pack was set at 
a constant 12mA per gel. 
Once samples were loaded, the 4% (acrylamide) stacking gel brings all 
proteins in a sample together at the stacking/running gel interface. The 
presence of SDS in sample buffer and both gels coats ensures all proteins 
are coated with a negative charge to cause migration towards a positive 
electrode (Anode). Since larger proteins become more negatively charged all 
proteins are solely separated according to size in the 8% or 12% 
(acrylamide) running gel. 
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Transfer of proteins to PVDF membrane 
Immediately following separation of proteins by SDS-PAGE, the proteins 
were transferred onto a polyvinyldifluoride (PVDF) membrane (BioRad, UK). 
The gel rigs used to run out the SDS-PAGE gels were removed from 1x tank 
buffer and placed on absorbent blue roll. The gels were removed from their 
cast using a wedge to break surface tension of the glass plates. A spacer 
was used to tease the gel from the outer glass plate onto the rear 1mm 
spacer plate, and then into transfer buffer onto a sheet of 3mm filter paper. 
Having cut an identically sized piece of PVDF membrane, it was removed 
from its packaging with Millipore forceps and soaked in methanol. This was 
transferred into transfer buffer and weighed down using a sheet of 3mm filter 
paper. The PVDF membrane was promptly positioned on top of the SDS-
PAGE gel and covered with a second piece of wet filter paper. Remaining air 
was removed by gently spreading the spacer from the centre in both 
directions. A transfer sandwich was carefully created within a transfer 
cassette in the following order: sponge pad, 3mm filter paper, running gel, 
PVDF membrane, 3mm filter paper, sponge pad. 
The gel was always positioned towards the black side of the cassette with the 
membrane on top towards the colourless side of the transfer cassette. Two 
transfer cassettes were placed into the transfer rig with the colourless side 
facing the user. The transfer cassettes were quickly submerged in the 
transfer buffer previously used to prepare the transfer cassettes. An ice pack 
was positioned behind the black side of the transfer rig (nearest the 
membrane) and a medium sized flee positioned under the ice pack. Further 
transfer buffer was added if needed to cover the transfer cassettes. A 
magnetic stirrer set at mark 3 was used for the duration of protein transfer 
(gel to membrane) to help reduce the heat generated during a one hour 
transfer at a constant 100 volts, replacing the ice pack after 30 minutes if 
necessary. 
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Detection of proteins using Ponceau Red 
To determine successful transfer of proteins from gel to membrane the PVDF 
membranes were stained with Ponceau Red (1% (w/v) Ponceau Red in 3% 
(w/v) trichloroacetic acid). Membranes were removed from the transfer rig 
sandwiched between the two pieces of thin filter paper. Excess membrane 
was cut away and the membrane quickly placed onto saram wrap. Each 
membrane was promptly soaked in methanol and transferred to a container 
to be submerged in milliQ water. Membranes were stained by replacement of 
water with Ponceau Red and manually rocked for 30-40 seconds until 
bands/lanes become visible. To remove excess stain, membranes were 
washed several times with milliQ water. Membranes were placed on tissue to 
dry at room temperature before being labelled and cut at the top right corner 
to provide orientation. Protected by tissue paper, each membrane was 
wrapped in tin-foil and stored at -20°C until required for immuno-blotting. 
 
Western blot analysis of SCFA receptors 
 
Primary 
Antibody Host Dilution Clonality and source 
Anti-FFAR2 
C-terminus Rabbit 1:500 
Polyclonal, 
Custom Synthesis (aa291-315) 
LRNQGSSLLGRRGKDTAEGTNEDRG 
Anti-FFAR3 
C-terminus Rabbit 1:500 
Polyclonal, 
Custom Synthesis  (aa311-335) 
EQKGGEEQRADRPAERKTSEHSQGC 
 
Secondary  
Antibody 
 
Host Dilution Source 
Anti-rabbit 
Ig-HRP Swine 1:2000 
Polyclonal, 
P 0217 (Dako, UK) 
 
 
 
Figure 2.6: Primary and secondary western blot antibodies 
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Immuno-detection of human FFAR2 
To immuno-detect FFAR2 from post nuclear membrane fractions (PNMF) of 
in-vitro cells, a room temperature membrane was soaked in methanol and 
quickly transferred to an ethanol cleaned container (Millipore) filled with milliQ 
water. The membrane was washed with tris-buffered saline, TBS (50mM 
Trizma base, 100mM sodium chloride). It was treated three hours at room 
temperature on a rocker with 15ml freshly prepared blocking solution; TBS 
supplemented with 5% (w/v) bovine serum albumin (BSA) and 0.1% (v/v) 
tween-20. After blocking the membrane it was stained over-night at 4°C on a 
rocker using an in-house FFAR2 primary antibody at a 1:500 dilution, in 
freshly prepared probe buffer containing 1% (w/v) BSA with 0.1% tween-20. 
The next day excess antibody was removed with three ten minute washes 
(10ml) using probe solution. Then the membrane was probed for one hour at 
room temperature using 1:2000 dilution of swine anti-rabbit IgG secondary 
antibody conjugated to horse radish peroxidase (HRP) for detection of bound 
FFAR2 primary antibody. After three ten minute washes in 10ml wash buffer 
the membrane was transferred to TBS in preparation for immuno-blotting. 
Immuno-detection of human FFAR3 
To detect FFAR3 in PNMF from in-vitro cells, the PVDF membrane were 
prepared as described above. The membrane was blocked for three hours on 
a rocker with 15ml freshly prepared blocking solution (50mM Trizma base, 
100mM sodium chloride, 0.1% (v/v) tween-20, 0.5% (w/v) casein, pH 7.4 (1M 
hydrochloric acid). To probe for FFAR3 the membrane was treated overnight 
at 4°C on a rocker with a 1:500 dilution of in-house FFAR3 primary antibody 
within probe/wash solution (identical to blocking solution). The next day the 
membrane was washed three times for 10 minutes in 10ml wash buffer on a 
rocker to remove excess primary antibody. To detect bound primary 
antibody, the membrane was incubated one hour at room temperature on a 
rocker submerged in 10ml probe solution which contained a 1:2000 dilution 
of a swine anti-rabbit IgG secondary antibody conjugated to HRP. Excess 
secondary antibody was removed with three ten minute washes and then 
submerged in 15ml TBS for immuno-blotting.  
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Development of immuno-blots 
During incubation of secondary antibody WESToneTM
 
 was removed from 4°C 
storage and warmed to room temperature and approximately 1cm x 1cm 
pieces of tracker tape were exposed to bright light for fifteen minutes while 
setting up a dark room for development of immuno-blots. 
In a dark room, the probed membrane was correctly orientated by a clipped 
upper right corner. Millipore forceps were used to position the membrane 
vertically on blue roll to drain buffer before being positioned on saram wrap 
with exposed proteins. WESToneTM
 
 was applied to the probed membrane in 
six even sprays and incubated for 60 seconds. Excess was quickly removed 
by draining the membrane before the probed membrane was sandwiched 
between crease free saram wrap. Tracker tape was attached to excess 
saram wrap at the upper right and bottom left corners. The membrane was 
then ready for developing immuno-blots. 
Immuno-blotted PVDF membranes (seram wrapped) were exposed to half a 
sheet of 18cm x 24cm Carestream Kodak BioMax light film in a Kodak 
exposure cassette (13cm x 18cm). In principle this is a chemiluminescent 
reaction involving hydrogen peroxide and luminol in WESToneTM
    
 spray. 
These substrates are used in an enzymatic reaction involving horse radish 
peroxidase (HRP) found conjugated to secondary antibody. This catalysed 
oxidation of luminol forms the excited intermediate (3-aminophthalate) 
emitting light as it decays, detected by development of immuno-blots on film.  
Once film was exposed to the membrane it was removed and correctly 
orientated to be developed. The top right corner of the exposed film was 
folded to provide a handle while developing the exposed film. Rat toothed 
forceps were used to submerge the exposed film into a working solution of 
developer (replaced when in it turned black). When appropriate bands were 
detected from the immuno-blot, exposure conditions were optimised to gain 
the best signal to noise ratio.  
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At this point the developing reaction was terminated by submerging the 
developed film into an intermediate stopping solution (2% (v/v) acetic acid 
prepared in milliQ water containing a small unmeasured amount of acridine 
orange). The film was transferred to a bath of working fixing solution 
(Carestream Kodak Autoradiography GBX Fixer / Replenisher, Sigma) to 
protect the film from exposure to light. The film was then submerged in RO 
water to remove residue fixing solution and dried in a 60°C oven. The tracker 
tape allowed positioning of dried film on top of immuno-blots in order to mark 
the protein ladder onto the film, assisted by a light box. This revealed the size 
of the detected bands to allow interpretation of results. 
 
Stripping and re-probing of PVDF membranes 
PVDF membranes were re-probed to detect proteins of a different size to the 
existing probe by first stripping the PVDF membrane in the following manner. 
A probed membrane stored at -20°C was brought to room temperature still in 
saram wrap. At room temperature the saram wrap was removed with milliQ 
forceps and placed on top of fresh saram wrap. The membrane was then 
covered in methanol and quickly submerged in 20ml milliQ water within an 
ethanol cleaned container (MF mixed cellulose ester filters, Millipore). The 
membrane was incubated on a rocker three times for 10 minutes with 10ml 
stripping buffer (137mM Sodium Chloride, 20mM Glycine, pH 2.5 (1M 
hydrochloric acid). The membrane was rinsed in TBS and then re-probed.  
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Calcium Assays: HEK293 Flp-InTM TRExTM 
Preparation of poly-L-lysine coated plates 
FFAR2 and FFAR3 
A number of poly-L-lysine pre-coated 96 well plates, black/clear bottom 
(Greiner, CS40 655096) were prepared and stored at -20°C. To prepare 
these plates 200μl poly-L-lysine was added to each well of 96 well plates. 
Plates were incubated inside a cell culture incubator (37°C, 5% CO2) 
Inducing receptor expression 
for at 
least 30 minutes and then decanted. Wells were washed in 200μl RO water. 
The poly-L-lysine coated 96 well plates were incubated (37°C) for 30 minutes 
before use. 
The required volume of cell suspension was prepared in DMEM (11ml per 
plate) at a cell density of 4 x104 cells ml-1. 100μl of this cell suspension was 
seeded into wells of a 96 well black/clear bottom plate coated with poly-L-
lysine (see above). These cells were incubated overnight under standard cell 
culture conditions. The following morning receptor expression was induced 
by the addition of 100μl DMEM supplemented with 0.5μg ml-1 doxycyclin to 
give a working concentration of 0.25μg ml-1
Loading cells with FLUO-4 AM 
. To setup control cells (without 
induced receptor expression), 100µl complete DMEM without doxycycline 
was added to a selection of cells. 
Between 24-30 hours after inducing receptor expression the cells were 
primed to detect changes in intracellular calcium.  This was achieved by 
loading the cells with a fluorescent calcium indicator, FLUO-4 AM. Growth 
medium was decanted and replaced with 50µl of delivery buffer; comprised 
of Tyrode’s buffer containing 5mg ml-1 fatty acid free bovine serum albumin, 
0.5mM Pluronic F-127, 0.5mM probenecid, 5% tetracycline free foetal bovine 
serum and 4µM FLUO-4 AM. The cells were then incubated 60 minutes 
under standard cell culture conditions before the loading buffer was 
decanted. During this time the non-fluorescent acetoxymethyl ester (FLUO-4 
AM) was taken up by the cells and cleaved forming the fluorescent label, 
FLUO-4. This was replaced with 150μl Tyrode’s buffer supplemented with 
0.5mM probenecid to prevent leakage of FLUO-4 from the cells. The test 
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plate containing cells and the compound plate were given 30 minutes to 
equilibrate at 37°C before starting to take intracellular calcium 
measurements. 
Measurement of intracellular calcium changes 
Calcium measurements were performed using a FLEX STATION III 
(Molecular Devices).  The instrument was programmed to transfer 50μl of 
sample from a 96 well compound plate (containing test stimulants) into a test 
plate (containing cells with induced receptor expression) after 18 seconds of 
calcium measurements. All measurements were used by converting raw data 
acquired from SoftMax Pro Version 5.1 software (Molecular Devices) into 
relative fluorescence units (RFU). The detected change in fluorescence 
(Maximal fluorescence – Base line fluorescence) was divided by the base 
line fluorescence taking into account background noise, and potential 
variation between wells due to cell density and loading of FLUO-4 AM.  
Calcium Assays: NCI-H716 cells 
SCFA induced changes in intracellular calcium concentration in the 
NCI-H716 cell line 
SCFA induced activation of NCI-H716 cells was assessed by detection of 
intracellular calcium changes using FLEX STATION III (Molecular Devices). 
NCI-H716 cells were seeded at 4x104 cells ml-1 into 96 well black/clear 
bottom plate (100µl per well) pre-coated with Matrigel in DMEM (high 
glucose). After 48 hours cells were pre-conditioned 4 hours in DMEM (low 
glucose). To detect intracellular calcium changes NCI-H716 cells were first 
loaded with FLUO-4 dye (molecular devices). Cells were incubated 30 
minutes in 100µl loading buffer (glucose free Tyrode’s buffer supplemented 
with 5mg ml-1 fatty acid free BSA, 0.5mM Pluronic F127, 0.5mM Probenecid 
and 4µM FLUO-4 AM. The loading buffer was replaced after 30 minutes with 
150µl glucose free Tyrode’s buffer supplemented with 0.5mM Probenecid 
and incubated for 30 minutes to equilibrate test conditions. Calcium 
measurements were taken for 18 seconds to determine a baseline before 
NCI-H716 cells were exposed to stimulants. Relative fluorescent units (RFU) 
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were calculated from the detected intracellular calcium changes as previously 
described. Each effector was tested in triplicate in each experiment. 
 
SCFA induced GLP-1 secretion from in-vitro cell lines 
SCFA induced GLP-1 secretion from the GLUTag cell line 
To setup experiments GLUTag cells were seeded into 24 well plates at a 
density of 2x105 cells ml-1
SCFA induced GLP-1 secretion from the NCI-H716 cell line 
 in DMEM 6546 two days in advance. The night 
before the experiment, growth medium was replenished using low glucose 
DMEM supplemented with 10% FBS and maintained under standard growth 
conditions. On the day, cells were washed with warm Hanks Balanced Salt 
Solution (HBSS) and then incubated (37°C) for 2 hours with 500µl HBSS 
supplemented with 20µl/ml dipeptidyl peptidase-4 inhibitor in the presence 
and absence of stimulants. To minimise further secretion from GLUTag cells 
the 24 well plates were placed on ice. Supernatants were collected in 1.5ml 
tubes and centrifuged at 13,000g (Eppendorf 5418) for one minute to remove 
cell debris. Three 150µl aliquots were prepared in 0.5ml tubes, snap frozen in 
liquid nitrogen and stored at -80°C until needed. The content of GLP-1 in 
neat samples was determined by GLP-1 ELISA (Millipore) performed in 
accordance to manufacturer’s instructions. 
Preparation of Matrigel coated 24 well plates 
The required number of 24 well plates was pre-coated with ice-cold 150µl 
Matrigel diluted in freshly prepared glucose free Tyrode’s buffer giving a thin 
coat to all wells in accordance to manufacturer’s instructions. Plates were 
allowed to stand open at room temperature inside a biosafety class II cell 
culture cabinet for thirty minutes. Plates were then gently shaken for one 
minute intervals to ensure an even coat of Matrigel. The Matrigel was then 
given an hour to set inside a humidified cell culture cabinet under standard 
culture conditions. Wells were washed three times using 1ml glucose free 
Tyrode’s buffer and aspirated to remove unbound material (taken care not to 
disrupt set Matrigel). 
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Setting up NCI-H716 cells 
Once set, NCI-H716 cells in suspension (RPMI-1640 ATCC® 30-2001) were 
placed into a universal and pelleted at 300g (2500rpm) for 3 minutes (Mistral 
1000, MSE). Spent RPMI-1640 medium was aspirated and exchanged for 
10ml DMEM 6546 containing 4.5g ml-1 glucose with added supplements; 
10% (v/v) HI-FBS and pen/strep. A cell suspension was generated and 
cellular integrity assessed using trypan blue exclusion test. 1ml of a viable 
cell suspension containing 5.0 x 105 cells ml-1
Pre-conditioning of NCI-H716 cells for GLP-1 secretion  
 was seeded into required wells 
of a 24 well plate pre-coated with Matrigel as described. NCI-H716 cells were 
incubated 40 hours within a humidified cell culture cabinet under standard 
conditions in preparation for experiments. 
After incubated NCI-H716 cells for 40 hours on Matrigel, spent DMEM 6546 
(4.5g/l glucose) was aspirated and cells washed three times with 1ml warm 
glucose free Tyrode’s buffer. Cells were pre-conditioned with 1ml low glucose 
DMEM supplemented with pen/strep, L-glutamine and 10% FBS for 4 hours 
under standard cell culture conditions. 
SCFA induced GLP-1 secretion from NCI-H716 cells 
During treatment of cells with low glucose DMEM, intended stimulants were 
prepared in fresh glucose free Tyrode’s buffer and working stimulant 
concentrations prepared in 24 well compound plates. After four hours pre-
conditioning, cells were washed three times with 1ml glucose free Tyrode’s. 
On the last wash step care was taken to ensure no residue volume remained 
as not to alter the working stimulant concentration. Cells were exposed to 
500µl of stimulant for 2 hours under standard cell culture conditions.  
Test plates were placed onto ice in an attempt to prevent further secretion 
and to minimise enzymatic activity. Entire supernatants were collected into 
1.5ml tubes, and centrifuged for one minute at 13,000g (Eppendorf 5418) to 
pellet cellular debris. The debris-free supernatant was transferred to fresh 
1.5ml tubes and placed onto ice. A 96 well dilution plate was immediately 
setup; one part (50µl) supernatant to three parts (150µl) GLP-1 ELISA assay 
buffer. Remaining stock solutions were stored at -80°C for future analysis. 
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GLP-1 Antibody
GLP-1 binds at the N terminus of the 
immobilised GLP-1 antibody
Anti-GLP-1 alkaline phosphatase
detection conjugate 
Alkaline Phosphatase
methyl umbelliferyl phosphate (MUP)
Umbelliferone (fluorescent product)
The 96 well dilution plate was given a gentle mix and 100µl of each sample 
transferred to wells of a Glucagon like peptide-1 (Active) ELISA kit EGLP-
35K (Millipore, UK). Measurements were performed in accordance to 
manufacturer’s instructions. 
 
 
 
 
 
 
 
Figure 2.7: An overview of GLP-1 ELISA (Millipore) chemistry 
Assessment of in-vitro cell viability  
ViaLightTM
The Vialight
 Plus: Cell proliferation and cytotoxicity bioassay 
TM
 
 plus kit was used to safely determine adenosine triphosphate 
(ATP) levels of cultured NCI-H716 cells following exposure to SCFA. Since 
cellular injury leads to a rapid decrease of intracellular ATP, ability to retain 
cellular integrity can easily be demonstrated. This bioluminescent method of 
detection offers the advantages of being very rapid, giving greater 
reproducibility with high sensitivity over the conventional radioisotope method 
making it much safer. Detection uses the luciferase enzyme catalysing the 
formation of light in the reaction below. In this assay emitted light intensity 
and ATP share a linear relationship. ATP levels in supernatants from NCI-
H716 cells were assessed after exposure of SCFA, in accordance to protocol 
1 of the manufacturer’s instructions (Lonza), as an indicator of cell health. 
      Luciferase 
ATP + Luciferin + O2                           Oxyluciferin + AMP + PPi + CO2
   Magnesium (Mg
 + 
Light 
2+) 
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Lactate dehydrogenase cytotoxicity assay 
Lactate dehydrogenase (LDH) is a classical marker of cell cytoplasm used to 
determine cell membrane integrity. It is rapidly released from all cell types 
upon damage to the plasma membrane. A LDH cytotoxicity assay kit II 
(ab65393) was purchased from Abcam. This calorimetric assay utilises an 
enzymatic coupled reaction. LDH released from damaged cells oxidises 
lactate to form nicotinamide adenine dinucleotide (NADH). When NADH 
reacts with the kits advanced WST reagent it generates a yellow colour. The 
colour intensity directly correlates to the cells lysed. LDH activity was 
quantified on a plate reader set at OD450nm
RNA interference 
 and performed in accordance to 
manufacturer’s instructions. In this thesis it was used to assess impact of 
SCFA on membrane integrity of cell lines after two hour stimulation (see 
SCFA induced GLP-1 secretion). 
Assessment of FFAR2 involvement in butyrate induced GLP-1 release 
NCI-H716 cells were plated onto Matrigel coated 24 well plates as previously 
described for measuring GLP-1 secretion. Following overnight incubation, 
Silencer Select predesigned FFAR2 siRNA duplex; 1) s223805, 2) s223804, 
or 3) s6082 (Ambion, Life technologies) were transfected into cells using the 
cationic lipid reagent Lipofectamine®
A volume (1.5µl per well) of Lipofectamine
 3000 (Life Technologies, Paisley, UK) 
according to manufacturer’s instructions. In short, a volume of 25µl per well 
of high glucose DMEM (without supplements) was added to two 1.5ml tubes. 
® 3000 was added to one 
tube and FFAR2 siRNA duplex (final concentration) to the second tube. Both 
were giving a brief vortex before equal volumes were mixed together. The 
mix was given 20 minutes at room temperature to allow formation of 
complexes. Then a working volume of 250µl per well was prepared by adding 
supplement free DMEM (high glucose). After four hour transfection, 750µl of 
complete DMEM (high glucose) was added to each well to replenish 
available nutrients. 72 hours later, the involvement of FFAR2 in butyrate 
induced GLP-1 secretion was evaluated using GLP-1 ELISA (Millipore). 
Furthermore, NCI-H716 cells were harvested for RNA extraction to confirm 
Chapter Two 
94 
 
FFAR2 mRNA knockdown compared against a scrambled siRNA duplex; 
4390843 (Ambion, Life technologies) as a control. 
Statistical analysis 
GraphPad prism 5 software was used to create all graphs and perform 
statistical analysis. To assess normality of data, D’Agostino-Pearson tests 
were performed to test the null hypothesis that all values were sampled from 
a population with Gaussian distribution. Possible outliers within data sets 
were identified using the extreme studentised deviate method (Grubb’s test). 
Furthermore, the Levene’s method was used to test the null hypothesis that 
two groups share equal variance to differentiate between the need for 
nonparametric analysis or parametric analysis (equal variance). 
In events two unpaired group’s shared equal variance the non-parametric 
Mann-Whitney test was used. Similarly, when two unpaired group’s 
demonstrated equal variance and their populations followed a normal 
distribution, unpaired student t tests were used to evaluate the same null 
hypothesis that both groups share the same distribution. In cases a time-
matched control was used data analysis was performed by using the paired 
student t test. To compare two or more data sets following a normal 
distribution one-way ANOVA with Bonferroni’s multiple comparison post-test 
correction was employed. Two-way ANOVA with Bonferroni post-test 
correction was used to analyse data affected by two factors. To analyse three 
or more data sets not following Gaussian distribution, the nonparametric 
Kruskal-Wallis test was performed using Dunn’s multiple comparison post-
test correction. 
To measure ligand-receptor potency and maximal efficacy, dose-
response curves were generated from transformed data (-log X; X = 
concentration). Non-linear regression dose-response curves were plotted 
with least squares ordinary fit to represent the concentration and response 
relationship using an equation with the standard slope factor (Hill Slope = 1). 
In all bar charts data are presented as sample mean ± standard error of the 
mean (error bars). Results of statistical analysis denoted as statistically 
significant *P<0.05, very significant **P<0.01, highly significant ***P<0.001 or 
not statistical significant nsP>0.05. 
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of mammals; 
Mice, pigs and humans 
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Introduction 
Since 2003, it has been recognised that FFAR2 and FFAR3 are GPCR for 
SCFA (Brown, et al. 2003; Le Poul, et al. 2003). Tissue localisation studies 
identified FFAR3 mRNA to be most abundant in adipose tissue (Brown, et al. 
2003) while FFAR2 mRNA was found at highest levels in monocytes and 
neutrophils (Brown, et al. 2003). However, both were detectable at low levels 
in the intestine (Brown, et al. 2005). This general expression pattern of free 
fatty acid receptor family led to their proposed involvement in energy 
homeostasis functioning through a nutrient sensing mechanism (Covington, 
et al. 2006). 
FFAR2 was found to be present in the whole wall and mucosal preparations 
of rat distal ileum and colon (Karaki, et al. 2006). Immunohistochemistry 
demonstrated localisation in mast cells of the lamina propria containing 
serotonin (5-HT) and enteroendocrine cells of the mucosal epithelium 
possessing peptide YY (PYY) but not 5-HT (Karaki, et al. 2006; 2008), with 
expression also observed in absorptive epithelial cells of human colonic 
tissue (Karaki, et al. 2008). FFAR3 was also found to be localised to the 
human colonic mucosa within enteroendocrine cells expressing PYY but not 
5-HT or FFAR2 (Tazoe, et al. 2009), with cellular population of FFAR2 cells 
being higher in the human colonic crypts than FFAR3 containing cells 
(Tazoe, et al. 2009). These studies suggested that luminal SCFA may induce 
enhancement of colonic motility though release of 5-HT (Fukumoto, et al. 
2003), and regulation of smooth muscle contractions (Mitsui, et al. 2005). 
Furthermore, co-expression of SCFA receptors with PYY implicates 
involvement in gut motility, such as mediating SCFA induced colonic break 
(Ropert, et al. 1996), and in appetite control to co-ordinate energy 
homeostasis. 
In work presented by Karaki and colleagues (2008) and Tazoe et al (2009) 
the SCFA receptors were found localised with PYY but no evidence was 
presented for SCFA receptor localisation with satiety peptide, glucagon like 
peptide 1 (GLP-1). Therefore, to expand knowledge it was essential to carry 
out careful examination of tissue localisation for SCFA receptors and gut 
hormones by well-controlled immunohistochemistry. 
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The work presented in this thesis focuses on intestinal expression of short 
chain fatty acid (SCFA) receptors, FFAR2 and FFAR3. Furthermore, the aim 
was to assess the potential role of SCFA receptors in secretion of gut 
hormones implicated in controlling satiety and gut motility. In work by Karaki, 
et al. (2008) and Tazoe, et al. (2009) SCFA receptors expression had been 
shown in the human ascending colon at mRNA and protein levels. However, 
at the time of these studies no information was available on the expression of 
SCFA receptors across the longitudinal axis of mouse, pig or human colon. 
Therefore, the work presented in this chapter aimed to determine the 
expression profile of these two SCFA receptors across the longitudinal axis 
of the human colon at mRNA and protein levels.  
To these ends, it was aimed to determine: 
1) The unknown nucleotide sequence of pig FFAR3. 
2) FFAR2 and FFAR3 mRNA expression profiles across the 
longitudinal axis of mouse, pig and human colon. 
3) Cellular location(s) of FFAR2 and FFAR3 proteins within 
colonic tissue. 
 
Pig intestine 
Colonic 2cm2 tissue segments were fixed in 4% (w/v) paraformaldehyde as 
well as 20-25mg of adjacent tissue being collected and, flash frozen in liquid 
nitrogen. Frozen tissue samples were used to acquire PCR based laboratory 
techniques including: RNA extraction, cDNA synthesis, traditional reverse 
transcription polymerase chain reaction (RT-PCR), semi quantitative 
polymerase chain reaction (QPCR), agarose gel electrophoresis and the 
steps needed to clone PCR products for nucleotide sequence analysis. The 
treated 2cm2 tissue segments were used to learn immunohistochemistry. 
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Designing primers targeting the unknown pig FFAR3 mRNA 
In recent years, the pig alimentary canal has been considered an in-vivo 
model to the human gut (Zhang, et al. 2013). Through a research programme 
carried out in our laboratory on pig digestive physiology, tissues were 
available to be used for this research. The coding nucleotide sequences 
(CDS) for mouse (NM_001033316) and human (NM_005304) were aligned 
to design consensus and degenerate primers for RT-PCR. Target specificity 
was confirmed by NCBI nucleotide blast search before being manufactured. 
 
Using colonic tissue in a number of RT-PCR procedures such as i) 25-40 
cycles, annealing temperatures of 45-55°C and ii) use of degenerate primers 
in association with nested RT-PCR were all unsuccessful.  However, the 
knowledge that adipose tissue possesses the highest level of FFAR3 
provided a good opportunity to clone pig FFAR3. To this end RNA isolated 
from pig visceral adipose tissue using the phenol-chloroform extraction was 
used in nested RT-PCR reactions to successfully amplify and sequence 
segments of pig FFAR3 mRNA. Each time new primers or reaction conditions 
were tested a reaction in the absence of starting template was used as a 
negative control to recognise none-specific primer artefacts.  
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Cloning pig FFAR3 from pig adipose tissue 
 
 
 
 
 
 
 
 
Figure 3.1: Nested RT-PCR using RNA extracted from adipose tissue  
Images showing products of two round nested RT-PCR using consensus-
degenerate primers used to isolate fragments of pig FFAR3 mRNA from 
adipose tissue. RT-PCR of 40 cycles (50°C annealing) was performed using 
samples of cDNA from adipose tissue (lanes) and products separated 
according to size by agarose gel electrophoresis (described in methods). 
Using DNA ladder Plus 100 (Lane 1, 5 and 8) segments of agarose gel 
expected to contain products of predicted size were excised, purified and 
used as a template for second round RT-PCR. Products (shown above) of 
expected sizes 199bp (A) and 183bp (Image B) were excised (shown as blue 
boxes), purified and separated on a 2% (w/v) agarose gel for higher 
resolution. Reactions absent of starting template are shown above as a 
representative negative control (image C). Lastly, products of 183bp and 
199bp were carefully excised for cloning and sequence analysis.  
 
Results 
Two of the bands removed were successfully cloned and sequenced. 
Sequence results were analysed using Vector NTI alignment software and 
validated by a NCBI nucleotide database search. Results revealed two 
positive clones for FFAR3 with high similarity to goat and cattle FFAR3 (and 
pig FFAR3 mRNA once it became available).  
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Alignment of the two cloned sequences with this predicted pig FFAR3 mRNA 
sequence demonstrated a mere 30 base pair gap between these two <200 
base pair fragments. Collectively, the fragments cover approximately 
400/1200 base pairs of the predicted pig FFAR3 mRNA. Sequence 
information was confirmed using high-fidelity PCR to clone the two pig 
FFAR3 fragments. To accurately uncover the mRNA sequence, fragments 
were sequenced both in the forward (T7) and reverse (SP6) directions. 
Results revealed that the 199 base pair fragment was 100% and the smaller 
183 base pair fragment to be 99% identical to a predicted pig FFAR3 mRNA.  
 
The availability of a pig FFAR3 mRNA provided sufficient information to allow 
progression. Molecular probes were successfully designed to target mouse, 
pig and human SCFA receptors, FFAR2 and FFAR3 mRNA. 
Round Sequence (5’ – 3’) Product Size (Confirmation) 
1 109 - ‘TAGGCCACGCTCAGAAAACG’ 939 – ‘ATGAAAGTCGGCTTGGAACC’ 
830 
(Product A) 
1 329 ‘TCATCCTCTGCCCACTCTCTG’ 
822 ‘ATAGCCCACGACATGGGACA’ 
493 
(Product B) 
   
2 604 ‘CAGCTRGCCATCCTCCTGCC 
822 ‘ATAGCCCACSACATGGGACA’ 
199 
(Product A) 
100% Identity  
2 436 ‘CTGTGGTACAARACCCGGCC’ 
619 ‘GGAGGATGGCSAGCTGGTCCT’ 
183 
(Product B) 
98% Identity   
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Alignment of FFAR2 mRNA sequences in six species 
The nucleotide coding regions of FFAR2 mRNA from six species obtained 
from the NCBI nucleotide database, Human (NM_005306.2), Mouse 
(NM_146187.4), Rat (NM_001005877.1), Cow (NM_001163784.1), Goat 
(NM_001285655.1) and Pig (NM_001278758.1) were aligned using 
commercially available alignment software, Vector NTI. Their alignment 
revealed sequence consensus of 99% with 66.6% identity positions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Alignment of FFAR2 mRNA coding sequence in six species 
 
1 14510 20 30 40 50 60 70 80 90 100 110 120 130(1)
ATGCTGCCGGACTGGAAGAGCTCCTTGATCCTCATGGCTTACATCATCATCTTCCTCACTGGCCTCCCTGCCAACCTCCTGGCCCTGCGGGCCTTTGTGGGGCGGATCCGCCAGCCCCAGCCTGCACCTGTGCACATCCTCCTGCHuman (1)
ATGACCCCAGACTGGCACAGTTCCTTGATCCTCACGGCCTACATCCTCATCTTTCTTACTGGGCTCCCTGCCAACCTGCTGGCCCTGCGGGCCTTCATGGGCCGGGTTCGCCAGCCTCAGCCTGCCCCTGTGCACATCCTCCTGCMouse (1)
ATGACCCCAGACTGGCACAGTTCCTTGATCCTCACGGCCTACATCCTCATCTTTCTTACTGGGCTCCCTGCCAACCTGCTGGCCCTGCGGGCCTTCGTGAGCCGGGTTCGCCAGCCCCAGCCTGCACCCGTGCACATCCTCCTGCRat (1)
---ATGCCAGACTGGGATAGCTCCTTGATCCTCACGGCTTACATTATTATCTTGCTCACCGGTCTCCCTGCCAACCTCCTGGCGCTGCGGGCCTTCCTGGGACGCGTGCGTCAGCCCCACCCTGCACCTGTCCACATCCTCCTGCCow (1)
---ATGCCAGACTGGGATAGCTCCTTGATCCTCGCGGCCTACATTATTATCTTGCTCACCGGTCTCCCTGCCAACCTCCTGGCGCTGCGAGCCTTCCTGGGACGGGTGCGCCAGCCCCACCCCGCACCCGTCCACATCCTCCTGCGoat (1)
---ATGCTGGACTTGCACAGCTCCGTGATCCTCACGGCCTACATCCTCATCTTCCTCACTGGTCTCCCAGCCAACCTCCTGGCCCTGCGGGCCTTCGTGGGGCGCGTCCGCCAGCCCCACCCTGCACCCATCCACATCCTCCTGCPig (1)
50 19460 70 80 90 100 110 120 130 140 150 160 170 180(50)
TCTTCCTCACTGGCCTCCCTGCCAACCTCCTGGCCCTGCGGGCCTTTGTGGGGCGGATCCGCCAGCCCCAGCCTGCACCTGTGCACATCCTCCTGCTGAGCCTGACGCTGGCCGACCTCCTCCTGCTGCTGCTGCTGCCCTTCAAHuman (50)
TCTTTCTTACTGGGCTCCCTGCCAACCTGCTGGCCCTGCGGGCCTTCATGGGCCGGGTTCGCCAGCCTCAGCCTGCCCCTGTGCACATCCTCCTGCTTAATCTGACCCTGGCGGACTTGCTCCTGTTGCTGCTGCTGCCCTTCCGMouse (50)
TCTTTCTTACTGGGCTCCCTGCCAACCTGCTGGCCCTGCGGGCCTTCGTGAGCCGGGTTCGCCAGCCCCAGCCTGCACCCGTGCACATCCTCCTGCTTAATCTGACCCTGGCGGACTTGCTGTTGTTGCTGCTGCTGCCCTTCCGRat (50)
TCTTGCTCACCGGTCTCCCTGCCAACCTCCTGGCGCTGCGGGCCTTCCTGGGACGCGTGCGTCAGCCCCACCCTGCACCTGTCCACATCCTCCTGCTCAGCCTGACGCTGGCCGACGTCCTGCTGCTGCTGCTGCTGCCCTTCAACow (47)
TCTTGCTCACCGGTCTCCCTGCCAACCTCCTGGCGCTGCGAGCCTTCCTGGGACGGGTGCGCCAGCCCCACCCCGCACCCGTCCACATCCTCCTGCTCAACCTGACACTGGCCGACCTCCTGCTGCTGCTGCTGCTGCCCTTCAAGoat (47)
TCTTCCTCACTGGTCTCCCAGCCAACCTCCTGGCCCTGCGGGCCTTCGTGGGGCGCGTCCGCCAGCCCCACCCTGCACCCATCCACATCCTCCTGCTCAGCCTGACGCTGGCAGACCTGCTGCTGCTGCTGCTGCTGCCCTTGAAPig (47)
100 244110 120 130 140 150 160 170 180 190 200 210 220 230(100)
GGGCGGATCCGCCAGCCCCAGCCTGCACCTGTGCACATCCTCCTGCTGAGCCTGACGCTGGCCGACCTCCTCCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAGGCTGCGTCGAACTTCCGCTGGTACCTGCCCAAGGTCGTCTHuman(100)
GGCCGGGTTCGCCAGCCTCAGCCTGCCCCTGTGCACATCCTCCTGCTTAATCTGACCCTGGCGGACTTGCTCCTGTTGCTGCTGCTGCCCTTCCGGATCGTGGAAGCAGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTMouse(100)
AGCCGGGTTCGCCAGCCCCAGCCTGCACCCGTGCACATCCTCCTGCTTAATCTGACCCTGGCGGACTTGCTGTTGTTGCTGCTGCTGCCCTTCCGGATCGTGGAAGCTGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTRat(100)
GGACGCGTGCGTCAGCCCCACCCTGCACCTGTCCACATCCTCCTGCTCAGCCTGACGCTGGCCGACGTCCTGCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTAATCTAGCCTCow (97)
GGACGGGTGCGCCAGCCCCACCCCGCACCCGTCCACATCCTCCTGCTCAACCTGACACTGGCCGACCTCCTGCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTGATCTAGCCTGoat (97)
GGGCGCGTCCGCCAGCCCCACCCTGCACCCATCCACATCCTCCTGCTCAGCCTGACGCTGGCAGACCTGCTGCTGCTGCTGCTGCTGCCCTTGAAGATCACTGAGGCCGCGTCTAACTTCCGCTGGTACCTGCCTGGGATCGTCTPig (97)
150 294160 170 180 190 200 210 220 230 240 250 260 270 280(150)
CCTGACGCTGGCCGACCTCCTCCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAGGCTGCGTCGAACTTCCGCTGGTACCTGCCCAAGGTCGTCTGCGCCCTCACGAGTTTTGGCTTCTACAGCAGCATCTACTGCAGCACGTGGHuman(150)
TCTGACCCTGGCGGACTTGCTCCTGTTGCTGCTGCTGCCCTTCCGGATCGTGGAAGCAGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTGCGCGCTGACAGGCTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGMouse(150)
TCTGACCCTGGCGGACTTGCTGTTGTTGCTGCTGCTGCCCTTCCGGATCGTGGAAGCTGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTGCGCGCTCACGGGCTTCGGCTTCTACAGCAGTATCTACTGCAGCACGTGGRat(150)
CCTGACGCTGGCCGACGTCCTGCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTAATCTAGCCTGTGCCCTCATGGGTTTCGGCTTCTACGGCAGCATCTACTGCAGCACGTTGCow(147)
CCTGACACTGGCCGACCTCCTGCTGCTGCTGCTGCTGCCCTTCAAGATCATCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTGATCTAGCCTGCGCCCTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGGoat(147)
CCTGACGCTGGCAGACCTGCTGCTGCTGCTGCTGCTGCCCTTGAAGATCACTGAGGCCGCGTCTAACTTCCGCTGGTACCTGCCTGGGATCGTCTGTGCCCTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGPig(147)
200 344210 220 230 240 250 260 270 280 290 300 310 320 330(200)
TCGAGGCTGCGTCGAACTTCCGCTGGTACCTGCCCAAGGTCGTCTGCGCCCTCACGAGTTTTGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTCCTGGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTHuman(200)
TGGAAGCAGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTGCGCGCTGACAGGCTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTGCTGGCGGGCATCAGCATGGAACGCTACCTGGGAGTGGCCTTCCCGGTMouse(200)
TGGAAGCTGCATCCAACTTCCGCTGGTACCTACCAAAGATCGTGTGCGCGCTCACGGGCTTCGGCTTCTACAGCAGTATCTACTGCAGCACGTGGCTGCTGGCGGGCATCAGCATAGAACGCTACCTGGGAGTGGCTTTCCCGGTRat(200)
TCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTAATCTAGCCTGTGCCCTCATGGGTTTCGGCTTCTACGGCAGCATCTACTGCAGCACGTTGCTACTGGCGGGCATCAGCGTCGAGCGCTACCTGGGAGTGGCTTTCCCCGTCow(197)
TCGAAGCCGCGTCTGACTTCCGCTGGGAGCTGTCTGATCTAGCCTGCGCCCTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTACTGGCGGGCATCAGCATCGAGCGCTACCTAGGAGTGGCTTTCCCCGTGoat(197)
CTGAGGCCGCGTCTAACTTCCGCTGGTACCTGCCTGGGATCGTCTGTGCCCTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTCCTGGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTPig(197)
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Figure 3.2: Alignment of FFAR2 mRNA coding sequence in six species 
250 394260 270 280 290 300 310 320 330 340 350 360 370 380(250)
CTCACGAGTTTTGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTCCTGGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTCTCCCGCCGGCCTCTGTATGGAGTGATTGCAGCTCTGGHuman(250)
CTGACAGGCTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTGCTGGCGGGCATCAGCATGGAACGCTACCTGGGAGTGGCCTTCCCGGTGCAGTACAAGTTATCCCGCCGGCCACTGTATGGAGTGATCGCTGCTCTGGMouse(250)
CTCACGGGCTTCGGCTTCTACAGCAGTATCTACTGCAGCACGTGGCTGCTGGCGGGCATCAGCATAGAACGCTACCTGGGAGTGGCTTTCCCGGTGCAGTACAAGCTATCCCGCCGGCCACTGTACGGAGTGATCGCTGCTCTGGRat(250)
CTCATGGGTTTCGGCTTCTACGGCAGCATCTACTGCAGCACGTTGCTACTGGCGGGCATCAGCGTCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCGTGTATGGAGTGATCGCTGCTCTGACow(247)
CTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTACTGGCGGGCATCAGCATCGAGCGCTACCTAGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCTGTGTACGGAGTGATCGCTGCTCTGAGoat(247)
CTCATGGGTTTCGGCTTCTACAGCAGCATCTACTGCAGCACGTGGCTCCTGGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCTTGTACGGAGTGATTGCTGCTCTGGPig(247)
300 444310 320 330 340 350 360 370 380 390 400 410 420 430(300)
GGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTCTCCCGCCGGCCTCTGTATGGAGTGATTGCAGCTCTGGTGGCCTGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAAHuman(300)
GGCGGGCATCAGCATGGAACGCTACCTGGGAGTGGCCTTCCCGGTGCAGTACAAGTTATCCCGCCGGCCACTGTATGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGMouse(300)
GGCGGGCATCAGCATAGAACGCTACCTGGGAGTGGCTTTCCCGGTGCAGTACAAGCTATCCCGCCGGCCACTGTACGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCATTGCACCATCGTCATCATCGTTCAGRat(300)
GGCGGGCATCAGCGTCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCGTGTATGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCTTTTGGTCACGGCACTGTGGTGATCATTGTTCAGCow(297)
GGCGGGCATCAGCATCGAGCGCTACCTAGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCTGTGTACGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCCTTTGGTCACGGCACCGTGGTGATCATTGTTCAGGoat(297)
GGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCTTGTACGGAGTGATTGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGTCACTGCACTGTCGTGTTCATCGTTCAGPig(297)
350 494360 370 380 390 400 410 420 430 440 450 460 470 480(350)
ACAAGCTCTCCCGCCGGCCTCTGTATGGAGTGATTGCAGCTCTGGTGGCCTGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAATACTTGAACACGACTGAGCAGGTCAGAAGTGGCAATGAAATTACCTGCTAHuman(350)
ACAAGTTATCCCGCCGGCCACTGTATGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACTGAGCAGGTGGGCACTGAGAACCAAATAACCTGCTAMouse(350)
ACAAGCTATCCCGCCGGCCACTGTACGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCATTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACCGAGCAGGTGGGCACCGAGAACCAAATCACCTGCTARat(350)
ACAAGCTGTCCCGCCGGCCCGTGTATGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCTTTTGGTCACGGCACTGTGGTGATCATTGTTCAGTACCTGAATTCAACCCAGAGGGCCCCAAAGGAGAATGAGACCACCTGCTACow(347)
ACAAGCTGTCCCGCCGGCCTGTGTACGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCCTTTGGTCACGGCACCGTGGTGATCATTGTTCAGTACCTGAATTCCACCCAGAGGGTCCCAAAGGAGAATGAGACCTCCTGCTAGoat(347)
ACAAGCTGTCCCGCCGGCCCTTGTACGGAGTGATTGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGTCACTGCACTGTCGTGTTCATCGTTCAGTACTTGAACTCAACCCAGAAGGCCGAGGGTATGAACGTCAGTACCTGCTAPig(347)
400 544410 420 430 440 450 460 470 480 490 500 510 520 530(400)
TGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAATACTTGAACACGACTGAGCAGGTCAGAAGTGGCAATGAAATTACCTGCTACGAGAACTTCACCGATAACCAGTTGGACGTGGTGCTGCCCGTGCGGCTGGHuman(400)
TGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACTGAGCAGGTGGGCACTGAGAACCAAATAACCTGCTACGAGAACTTCACCCAAGAGCAGCTGGATGTGGTACTGCCCGTACGACTGGMouse(400)
TGGATCATGTCCTTTGGCCATTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACCGAGCAGGTGGGCACCGAGAACCAAATCACCTGCTATGAGAACTTCACCCAAGCGCAGCTGGATGTGGTGCTGCCCGTGCGACTGGRat(400)
TGGGTCATGTCTTTTGGTCACGGCACTGTGGTGATCATTGTTCAGTACCTGAATTCAACCCAGAGGGCCCCAAAGGAGAATGAGACCACCTGCTACGAGAACTTCACCCAAGAGCAGCTGAGGCTATTGCTACCCATTCGGCTGGCow(397)
TGGGTCATGTCCTTTGGTCACGGCACCGTGGTGATCATTGTTCAGTACCTGAATTCCACCCAGAGGGTCCCAAAGGAGAATGAGACCTCCTGCTACGAGAACTTCAGCCAAGAGCAGCTGAGGATATTGCTGCCCATTCGGCTGGGoat(397)
TGGATCATGTCCTTTGGTCACTGCACTGTCGTGTTCATCGTTCAGTACTTGAACTCAACCCAGAAGGCCGAGGGTATGAACGTCAGTACCTGCTATGAGAACTTCACCAAAGAGCAGCTGGACGTGGTGCTTCCCGTGCGGCTGGPig(397)
450 594460 470 480 490 500 510 520 530 540 550 560 570 580(450)
GAACACGACTGAGCAGGTCAGAAGTGGCAATGAAATTACCTGCTACGAGAACTTCACCGATAACCAGTTGGACGTGGTGCTGCCCGTGCGGCTGGAGCTGTGCCTGGTGCTCTTCTTCATCCCCATGGCAGTCACCATCTTCTGCHuman(450)
GAACTCAACTGAGCAGGTGGGCACTGAGAACCAAATAACCTGCTACGAGAACTTCACCCAAGAGCAGCTGGATGTGGTACTGCCCGTACGACTGGAGCTGTGCCTGGTCCTGTTTTTCGTTCCCATGGCAGTCACCATCTTCTGTMouse(450)
GAACTCAACCGAGCAGGTGGGCACCGAGAACCAAATCACCTGCTATGAGAACTTCACCCAAGCGCAGCTGGATGTGGTGCTGCCCGTGCGACTGGAGCTGTGCCTGGTCCTCTTTTTCGTCCCCATGACAGTCACCATCTTCTGCRat(450)
GAATTCAACCCAGAGGGCCCCAAAGGAGAATGAGACCACCTGCTACGAGAACTTCACCCAAGAGCAGCTGAGGCTATTGCTACCCATTCGGCTGGAGCTGTGCCTCCTCCTCTTCTTCTTCCCCATGGTGGTCACCACCTTCTGCCow(447)
GAATTCCACCCAGAGGGTCCCAAAGGAGAATGAGACCTCCTGCTACGAGAACTTCAGCCAAGAGCAGCTGAGGATATTGCTGCCCATTCGGCTGGAGCTGTGCCTCCTCCTCTTCTTTTTCCCCATGGTGGTCACCACCTTTTGCGoat(447)
GAACTCAACCCAGAAGGCCGAGGGTATGAACGTCAGTACCTGCTATGAGAACTTCACCAAAGAGCAGCTGGACGTGGTGCTTCCCGTGCGGCTGGAGCTGTGCCTCGTCCTCTTCTTCATCCCCATGGTGGTCACCATCTTCTGCPig(447)
300 444310 320 330 340 350 360 370 380 390 400 410 420 430(300)
GGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTCTCCCGCCGGCCTCTGTATGGAGTGATTGCAGCTCTGGTGGCCTGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAAHuman(300)
GGCGGGCATCAGCATGGAACGCTACCTGGGAGTGGCCTTCCCGGTGCAGTACAAGTTATCCCGCCGGCCACTGTATGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGMouse(300)
GGCGGGCATCAGCATAGAACGCTACCTGGGAGTGGCTTTCCCGGTGCAGTACAAGCTATCCCGCCGGCCACTGTACGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCATTGCACCATCGTCATCATCGTTCAGRat(300)
GGCGGGCATCAGCGTCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCGTGTATGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCTTTTGGTCACGGCACTGTGGTGATCATTGTTCAGCow(297)
GGCGGGCATCAGCATCGAGCGCTACCTAGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCTGTGTACGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCCTTTGGTCACGGCACCGTGGTGATCATTGTTCAGGoat(297)
GGCGGGCATCAGCATCGAGCGCTACCTGGGAGTGGCTTTCCCCGTGCAGTACAAGCTGTCCCGCCGGCCCTTGTACGGAGTGATTGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGTCACTGCACTGTCGTGTTCATCGTTCAGPig(297)
350 494360 370 380 390 400 410 420 430 440 450 460 470 480(350)
ACAAGCTCTCCCGCCGGCCTCTGTATGGAGTGATTGCAGCTCTGGTGGCCTGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAATACTTGAACACGACTGAGCAGGTCAGAAGTGGCAATGAAATTACCTGCTAHu an(350)
ACAAGTTATCCCGCCGGCCACTGTATGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACTGAGCAGGTGGGCACTGAGAACCAAATAACCTGCTAMouse(350)
ACAAGCTATCCCGCCGGCCACTGTACGGAGTGATCGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGCCATTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACCGAGCAGGTGGGCACCGAGAACCAAATCACCTGCTARat(350)
ACAAGCTGTCCCGCCGGCCCGTGTATGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCTTTTGGTCACGGCACTGTGGTGATCATTGTTCAGTACCTGAATTCAACCCAGAGGGCCCCAAAGGAGAATGAGACCACCTGCTACow(347)
ACAAGCTGTCCCGCCGGCCTGTGTACGGAGTGATCGCTGCTCTGATCGCCTGGGTCATGTCCTTTGGTCACGGCACCGTGGTGATCATTGTTCAGTACCTGAATTCCACCCAGAGGGTCCCAAAGGAGAATGAGACCTCCTGCTAGoat(347)
ACAAGCTGTCCCGCCGGCCCTTGTACGGAGTGATTGCTGCTCTGGTGGCCTGGATCATGTCCTTTGGTCACTGCACTGTCGTGTTCATCGTTCAGTACTTGAACTCAACCCAGAAGGCCGAGGGTATGAACGTCAGTACCTGCTAPig(347)
400 544410 420 430 440 450 460 470 480 490 500 510 520 530(400)
TGGGTTATGTCCTTTGGTCACTGCACCATCGTGATCATCGTTCAATACTTGAACACGACTGAGCAGGTCAGAAGTGGCAATGAAATTACCTGCTACGAGAACTTCACCGATAACCAGTTGGACGTGGTGCTGCCCGTGCGGCTGGu an(400)
TGGATCATGTCCTTTGGCCACTGCACCATCGTCATCATCGTTCAGTACCTGAACTCAACTGAGCAGGTGGGCACTGAGAACCAAATAACCTGCTACGAGAACTTCACCCAAGAGCAGCTGGATGTGGTACTGCCCGTACGACTGGouse(400)
ATCATGTCCTTT G CA TGCA CATCGTCATCATCGTTCAGTACCTGAA TCAACC AGCAG T GG ACCGAGAACCAAAT AC GCT TG GAA TT ACCCAAGCGCAGCTGGATGTGGTG T CC TGC ACTGGRat(400)
GTCATGTCTTTT GTCAC GCACTGT GTGATCA TGTTCAGTACCTGAATTCAA CC A GG CC AAGGAGAATGAGA AC G T CG GAA TT ACCCAAGAGCAGCTGAGGCTA TG T CC ATTC CTGGCo (397)
GTCATGTCCTTT GTCAC GCA CGT GTGATCA TGTTCAGTACCTGAATTC A CC A GGT CC AAGGAGAATGAGA C G T CG GAA TT AGCCAAGAGCAGCTGAGGATA TG TGCC ATTC CTGGoat(397)
ATCATGTCCTTT GTCACTGCACTGTCGTG TCATCGTTCAGTACTTGAA TCAA CC GAAGGCC A GGTATGAACGTCAGTAC GCT TG GAA TT CCAAAGAGCAGCTGGACGTGG G TTCC TGC CTGGPig(397)
0 594460 470 480 490 500 510 520 530 540 550 560 570 580(450)
CACGACTGAGCA GTCAG AGT GC ATG A TACCTGCTACGAGAACTT ACCG TAACCAGTTGGACGTGGTGCTGCCCGT G CT GA CTGTGCC G GCTCTTCTTCATCCCCAT G GTCA CATCTTCTGCa ( )
CTCAACTGAGCA GT GCACTGAG A C AT ACCTGCTACGAGAACTT A CCA AGCAGCTGGA GTGGTACTGCCCGT GACT GA CTGTGCC GG CCTGTTTTTCGTTCCCAT G GTCA CATCT CTGTs ( )
CTCAACCGAGCA GT GCA CGAG A C ATCACCTGCTATGAGAACTT A CCAA GCAGCTGGA GTGGTGCTGCCCGTG GACT GA CTGTGCC GG CTCTTTTTCGTCCCCAT A GTCA CATCTTCTGCt( )
TTCAACCCAGA G C A GAG ATGAGA CACCTGCTACGAGAACTT A CCA AGCAGCT AGGCTATTGCTACCCATT G CT GA CTGTG CTCTTCTTCTTCCCCAT GTGGTCA CA CTTCTGC( )
TTCCACCCAGA GT C A GAG ATGAGA CTCCTGCTACGAGAACTTCAGCCA AGCAGCT AGGATATTGCTGCCCATT G CT GA CTGTG CTCTTCTTTTTCCCCAT GTGGTCA CACCTTTTGCt( )
CTCAACCCAGAA G CGA GTATG ACGTCAGTACCTGCTATGAGAACTT ACC A AGCAGCTGGACGTGGTGCTTCCCGT G CT GA CTGTG C G CTCTTCTTCATCCCCAT GTGGTCA CATCTTCTGCi ( )
500 644510 520 530 540 550 560 570 580 590 600 610 620 630(500)
ACTTCACCGATAACCAGTTGGACGTGGTGCTGCCCGTGCGGCTGGAGCTGTGCCTGGTGCTCTTCTTCATCCCCATGGCAGTCACCATCTTCTGCTACTGGCGTTTTGTGTGGATCATGCTCTCCCAGCCCCTTGTGGGGGCCCAHuman(500)
ACTTCACCCAAGAGCAGCTGGATGTGGTACTGCCCGTACGACTGGAGCTGTGCCTGGTCCTGTTTTTCGTTCCCATGGCAGTCACCATCTTCTGTTATTGGCGCTTCGTGTGGATCATGCTCACGCAGCCCCACGTTGGGGCTCAMouse(500)
ACTTCACCCAAGCGCAGCTGGATGTGGTGCTGCCCGTGCGACTGGAGCTGTGCCTGGTCCTCTTTTTCGTCCCCATGACAGTCACCATCTTCTGCTATTGGCGCTTTGTATGGATCATGCTCACACAGCCCCATGTTGGGGCTCARat(500)
ACTTCACCCAAGAGCAGCTGAGGCTATTGCTACCCATTCGGCTGGAGCTGTGCCTCCTCCTCTTCTTCTTCCCCATGGTGGTCACCACCTTCTGCTACTCGCGCTTTGTGTGGATTATGCTCACCCAGCCCCATATGGGGGCTCACow(497)
ACTTCAGCCAAGAGCAGCTGAGGATATTGCTGCCCATTCGGCTGGAGCTGTGCCTCCTCCTCTTCTTTTTCCCCATGGTGGTCACCACCTTTTGCTACTGGCGCTTTGTGTGGATCATGCTCACCCAGCCCCATATGGGGGCTCAGoat(497)
ACTTCACCAAAGAGCAGCTGGACGTGGTGCTTCCCGTGCGGCTGGAGCTGTGCCTCGTCCTCTTCTTCATCCCCATGGTGGTCACCATCTTCTGCTACTCGCGCTTTGTGTGGATCATGCTCGCCCAGCCCCACGTGGGGGCCCAPig(497)
550 694560 570 580 590 600 610 620 630 640 650 660 670 680(550)
TGCCTGGTGCTCTTCTTCATCCCCATGGCAGTCACCATCTTCTGCTACTGGCGTTTTGTGTGGATCATGCTCTCCCAGCCCCTTGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACGCTGCTCAATTTCCHuman(550)
TGCCTGGTCCTGTTTTTCGTTCCCATGGCAGTCACCATCTTCTGTTATTGGCGCTTCGTGTGGATCATGCTCACGCAGCCCCACGTTGGGGCTCAGAGGCGACGCCGGGCAGTGGGCCTGGCTGTTGTGACGCTTCTTAATTTCCMouse(550)
TGCCTGGTCCTCTTTTTCGTCCCCATGACAGTCACCATCTTCTGCTATTGGCGCTTTGTATGGATCATGCTCACACAGCCCCATGTTGGGGCTCAGAGGCGACGCCGGGCGGTGGGCCTGGCTGTGGTGACGCTTCTTAATTTCCRat(550)
TGCCTCCTCCTCTTCTTCTTCCCCATGGTGGTCACCACCTTCTGCTACTCGCGCTTTGTGTGGATTATGCTCACCCAGCCCCATATGGGGGCTCAGAAGCAGCGCCGAGCCATGGGGCTGGCCATCGTGTCGCTCCTTAATTTCCCow(547)
TGCCTCCTCCTCTTCTTTTTCCCCATGGTGGTCACCACCTTTTGCTACTGGCGCTTTGTGTGGATCATGCTCACCCAGCCCCATATGGGGGCTCAGAAGAGGCGCCGAGCCATGGGGCTGGCCATCGTGTCACTCCTTAATTTCCGoat(547)
TGCCTCGTCCTCTTCTTCATCCCCATGGTGGTCACCATCTTCTGCTACTCGCGCTTTGTGTGGATCATGCTCGCCCAGCCCCACGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACACTCCTTAACTTCCPig(547)
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600 744610 620 630 640 650 660 670 680 690 700 710 720 730(600)
GCGTTTTGTGTGGATCATGCTCTCCCAGCCCCTTGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACGCTGCTCAATTTCCTGGTGTGCTTCGGACCTTACAACGTGTCCCACCTGGTGGGGTATCACCAGHuman(600)
GCGCTTCGTGTGGATCATGCTCACGCAGCCCCACGTTGGGGCTCAGAGGCGACGCCGGGCAGTGGGCCTGGCTGTTGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCCTACAACATGTCCCACCTGGTGGGGTTCTACCTGMouse(600)
GCGCTTTGTATGGATCATGCTCACACAGCCCCATGTTGGGGCTCAGAGGCGACGCCGGGCGGTGGGCCTGGCTGTGGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCTTACAACATGTCCCACCTGGTGGGGTTCCACTTGRat(600)
GCGCTTTGTGTGGATTATGCTCACCCAGCCCCATATGGGGGCTCAGAAGCAGCGCCGAGCCATGGGGCTGGCCATCGTGTCGCTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCTACATGCow(597)
GCGCTTTGTGTGGATCATGCTCACCCAGCCCCATATGGGGGCTCAGAAGAGGCGCCGAGCCATGGGGCTGGCCATCGTGTCACTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCCACATGGoat(597)
GCGCTTTGTGTGGATCATGCTCGCCCAGCCCCACGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACACTCCTTAACTTCCTGGTGTGCTTCGGGCCCTATAACATATCCCACCTGGTGGGCTTCCACACGPig(597)
650 794660 670 680 690 700 710 720 730 740 750 760 770 780(650)
GGCGCCGAGCCGTGGGGCTGGCTGTGGTGACGCTGCTCAATTTCCTGGTGTGCTTCGGACCTTACAACGTGTCCCACCTGGTGGGGTATCACCAGAGAAAAAGCCCCTGGTGGCGGTCAATAGCCGTGGTGTTCAGTTCACTCAAHuman(650)
GACGCCGGGCAGTGGGCCTGGCTGTTGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCCTACAACATGTCCCACCTGGTGGGGTTCTACCTGAGGCAGAGCCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAAMouse(650)
GACGCCGGGCGGTGGGCCTGGCTGTGGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCTTACAACATGTCCCACCTGGTGGGGTTCCACTTGAGGCAGAGTCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAARat(650)
AGCGCCGAGCCATGGGGCTGGCCATCGTGTCGCTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCTACATGAAAGCAAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAACow(647)
GGCGCCGAGCCATGGGGCTGGCCATCGTGTCACTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCCACATGAAAGCAAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAAGoat(647)
GGCGCCGAGCCGTGGGGCTGGCTGTGGTGACACTCCTTAACTTCCTGGTGTGCTTCGGGCCCTATAACATATCCCACCTGGTGGGCTTCCACACGAAGGAGAGCCCCAAATGGCGCGCGGAGGCTGTGGTATTCAGCTCCCTCAAPig(647)
700 844710 720 730 740 750 760 770 780 790 800 810 820 830(700)
TGCTTCGGACCTTACAACGTGTCCCACCTGGTGGGGTATCACCAGAGAAAAAGCCCCTGGTGGCGGTCAATAGCCGTGGTGTTCAGTTCACTCAACGCCAGTCTGGACCCCCTGCTCTTCTATTTCTCTTCTTCAGTGGTGCGCAHuman(700)
TGCTTTGGACCCTACAACATGTCCCACCTGGTGGGGTTCTACCTGAGGCAGAGCCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAATGCCAGCCTGGATCCATTATTGTTCTACTTCTCCTCCTCCGTGGTGCGCAMouse(700)
TGCTTTGGACCTTACAACATGTCCCACCTGGTGGGGTTCCACTTGAGGCAGAGTCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAATGCCAGCCTGGACCCTCTGCTATTCTACTTCTCCTCCTCCGTGGTACGCARat(700)
TGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCTACATGAAAGCAAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAATGCCAGTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTCGTACGCACow(697)
TGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCCACATGAAAGCAAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAATGCCAGTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTTGTACGCAGoat(697)
TGCTTCGGGCCCTATAACATATCCCACCTGGTGGGCTTCCACACGAAGGAGAGCCCCAAATGGCGCGCGGAGGCTGTGGTATTCAGCTCCCTCAACGCCAGTCTGGACCCCCTGCTTTTCTATTTCTCGTCTTCAGTGGTGCGCAPig(697)
750 894760 770 780 790 800 810 820 830 840 850 860 870 880(750)
AAGCCCCTGGTGGCGGTCAATAGCCGTGGTGTTCAGTTCACTCAACGCCAGTCTGGACCCCCTGCTCTTCTATTTCTCTTCTTCAGTGGTGCGCAGGGCATTTGGGAGAGGGCTGCAGGTGCTGCGGAATCAGGGCTCCTCCCTGHuman(750)
GAGCCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAATGCCAGCCTGGATCCATTATTGTTCTACTTCTCCTCCTCCGTGGTGCGCAGAGCTTTTGGGAAAGGTTTGCTACTGATCCGCAATCCTGCCTCCTCTATGMouse(750)
GAGTCCCTCGTGGCGGGTGGAGGCTGTGGTGTTCAGTTCCCTCAATGCCAGCCTGGACCCTCTGCTATTCTACTTCTCCTCCTCCGTGGTACGCAGGGCCTTCGGGAAAGGTTTGCTACTACTCCGCAATCCCGGCTCCTCTATGRat(750)
AAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAATGCCAGTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTCGTACGCAGGTCCTTTGGGAAAGGGCTGCAGGCACTGTACCATTGGGGCTCCTCCCTGCow(747)
AAGCCCCAAGTGGCGGAGGGAAGCTGTCGTATTTGGTAGCCTCAATGCCAGTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTTGTACGCAGGTCCTTTGGGAAAGGGCTGCAGGCGCTGCACCATCGGGGCTCCTCTCTTGoat(747)
GAGCCCCAAATGGCGCGCGGAGGCTGTGGTATTCAGCTCCCTCAACGCCAGTCTGGACCCCCTGCTTTTCTATTTCTCGTCTTCAGTGGTGCGCAGGACCTTTGGCAAAGGGCTGCAGGCGCTGCGGAATCAGGGCTCCTTGCTGPig(747)
800 944810 820 830 840 850 860 870 880 890 900 910 920 930(800)
GTCTGGACCCCCTGCTCTTCTATTTCTCTTCTTCAGTGGTGCGCAGGGCATTTGGGAGAGGGCTGCAGGTGCTGCGGAATCAGGGCTCCTCCCTGTTGGGACGCAGAGGCAAAGACACAGCAGAGGGGACAAATGAGGACAGGGGHuman(800)
GCCTGGATCCATTATTGTTCTACTTCTCCTCCTCCGTGGTGCGCAGAGCTTTTGGGAAAGGTTTGCTACTGATCCGCAATCCTGCCTCCTCTATGCTGGGCAGGGGAGCCAAAGAGACAGTGGAGGGGACCAAGATGGACAGGGGMouse(800)
GCCTGGACCCTCTGCTATTCTACTTCTCCTCCTCCGTGGTACGCAGGGCCTTCGGGAAAGGTTTGCTACTACTCCGCAATCCCGGCTCCTCTATGCTGGGCAGGGGAGCCGAAGAGACAGTGGAGGGGACCAAGACAGACAGGGGRat(800)
GTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTCGTACGCAGGTCCTTTGGGAAAGGGCTGCAGGCACTGTACCATTGGGGCTCCTCCCTGCTGGGACGCAGATGCAAAGAAACAGCGGAGGCCGCGAATGAGGACCCGGGCow(797)
GTCTGGACCCCTTGCTTTTCTATTTCTCTTCCTCAGTTGTACGCAGGTCCTTTGGGAAAGGGCTGCAGGCGCTGCACCATCGGGGCTCCTCTCTTTTGGGACGCAGATGCAAAGAAACAGCGGAGGCCACGAATGAGGACCCAGGGoat(797)
GTCTGGACCCCCTGCTTTTCTATTTCTCGTCTTCAGTGGTGCGCAGGACCTTTGGCAAAGGGCTGCAGGCGCTGCGGAATCAGGGCTCCTTGCTGCTGGGCCGCAGAGGCAAAGAGACCGAGGAGGCGGCGAACGGGGACAGGGGPig(797)
849 993860 870 880 890 900 910 920 930 940 950 960 970 980(849)
ATTTGGGAGAGGGCTGCAGGTGCTGCGGAATCAGGGCTCCTCCCTGTTGGGACGCAGAGGCAAAGACACAGCAGAGGGGACAAATGAGGACAGGGGTGTGGGTCAAGGAGAAGGGATGCCAAGTTCGGACTTCACTACAGAGTAGHuman(849)
TTTTGGGAAAGGTTTGCTACTGATCCGCAATCCTGCCTCCTCTATGCTGGGCAGGGGAGCCAAAGAGACAGTGGAGGGGACCAAGATGGACAGGGGTGGAAGTCAAGCAGAAGGGGTACAGAGTTCTGAATTTGTCACCGAGTAGMouse(849)
CTTCGGGAAAGGTTTGCTACTACTCCGCAATCCCGGCTCCTCTATGCTGGGCAGGGGAGCCGAAGAGACAGTGGAGGGGACCAAGACAGACAGGGGTGGGAGTCAAACAGAAGGGGCACAGAGCTCTGACTTTGTCACCGAGTGARat(849)
CTTTGGGAAAGGGCTGCAGGCACTGTACCATTGGGGCTCCTCCCTGCTGGGACGCAGATGCAAAGAAACAGCGGAGGCCGCGAATGAGGACCCGGGCGTGAGTCAAGCAGAGGGAGCCCCGAGTTCGGACTTCACCCTGGACTAGCow(846)
CTTTGGGAAAGGGCTGCAGGCGCTGCACCATCGGGGCTCCTCTCTTTTGGGACGCAGATGCAAAGAAACAGCGGAGGCCACGAATGAGGACCCAGGCGTGAGTCAAGCAGAGGGAGCGCCGAGTTCGGACTTCACCCTGGACTAGGoat(846)
CTTTGGCAAAGGGCTGCAGGCGCTGCGGAATCAGGGCTCCTTGCTGCTGGGCCGCAGAGGCAAAGAGACCGAGGAGGCGGCGAACGGGGACAGGGGTGTGAGTCAAACCGAGGGAGCGCCGAGTTCTGACTTCACCACCGACTAGPig(846)
600 744610 620 630 640 650 660 670 680 690 700 710 720 730(600)
GCGTTTTGTGTGGATCATGCTCTCCCAGCCCCTTGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACGCTGCTCAATTTCCTGGTGTGCTTCGGACCTTACAACGTGTCCCACCTGGTGGGGTATCACCAGHu an(600)
GCGCTTCGTGTGGATCATGCTCACGCAGCCCCACGTTGGGGCTCAGAGGCGACGCCGGGCAGTGGGCCTGGCTGTTGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCCTACAACATGTCCCACCTGGTGGGGTTCTACCTGMouse(600)
GCGCTTTGTATGGATCATGCTCACACAGCCCCATGTTGGGGCTCAGAGGCGACGCCGGGCGGTGGGCCTGGCTGTGGTGACGCTTCTTAATTTCCTGGTGTGCTTTGGACCTTACAACATGTCCCACCTGGTGGGGTTCCACTTGRat(600)
GCGCTTTGTGTGGATTATGCTCACCCAGCCCCATATGGGGGCTCAGAAGCAGCGCCGAGCCATGGGGCTGGCCATCGTGTCGCTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCTACATGCow(597)
GCGCTTTGTGTGGATCATGCTCACCCAGCCCCATATGGGGGCTCAGAAGAGGCGCCGAGCCATGGGGCTGGCCATCGTGTCACTCCTTAATTTCCTGCTGTGCTTTGGGCCCTATAACATATCCCACCTGGTGGGGTTCCACATGGoat(597)
GCGCTTTGTGTGGATCATGCTCGCCCAGCCCCACGTGGGGGCCCAGAGGCGGCGCCGAGCCGTGGGGCTGGCTGTGGTGACACTCCTTAACTTCCTGGTGTGCTTCGGGCCCTATAACATATCCCACCTGGTGGGCTTCCACACGPig(597)
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Figure 3.2: Alignment of FFAR2 coding sequences in six species. 
 
 Human Mouse Rat Cow Goat Pig 
Human 100 81.9 82.1 81.2 81.5 85.3 
Mouse  100 93.9 77.0 77.2 80.8 
Rat   100 77.6 78.2 82.1 
Cow    100 95.6 84.8 
Goat     100 84.4 
Pig      100 
 
Figure 3.3: FFAR2 nucleotide sequence homology (%) between six 
species 
 
 
849 993860 870 880 890 900 910 920 930 940 950 960 970 980(849)
ATTTGGGAGAGGGCTGCAGGTGCTGCGGAATCAGGGCTCCTCCCTGTTGGGACGCAGAGGCAAAGACACAGCAGAGGGGACAAATGAGGACAGGGGTGTGGGTCAAGGAGAAGGGATGCCAAGTTCGGACTTCACTACAGAGTAGHuman(849)
TTTTGGGAAAGGTTTGCTACTGATCCGCAATCCTGCCTCCTCTATGCTGGGCAGGGGAGCCAAAGAGACAGTGGAGGGGACCAAGATGGACAGGGGTGGAAGTCAAGCAGAAGGGGTACAGAGTTCTGAATTTGTCACCGAGTAGMouse(849)
CTTCGGGAAAGGTTTGCTACTACTCCGCAATCCCGGCTCCTCTATGCTGGGCAGGGGAGCCGAAGAGACAGTGGAGGGGACCAAGACAGACAGGGGTGGGAGTCAAACAGAAGGGGCACAGAGCTCTGACTTTGTCACCGAGTGARat(849)
CTTTGGGAAAGGGCTGCAGGCACTGTACCATTGGGGCTCCTCCCTGCTGGGACGCAGATGCAAAGAAACAGCGGAGGCCGCGAATGAGGACCCGGGCGTGAGTCAAGCAGAGGGAGCCCCGAGTTCGGACTTCACCCTGGACTAGCow(846)
CTTTGGGAAAGGGCTGCAGGCGCTGCACCATCGGGGCTCCTCTCTTTTGGGACGCAGATGCAAAGAAACAGCGGAGGCCACGAATGAGGACCCAGGCGTGAGTCAAGCAGAGGGAGCGCCGAGTTCGGACTTCACCCTGGACTAGGoat(846)
CTTTGGCAAAGGGCTGCAGGCGCTGCGGAATCAGGGCTCCTTGCTGCTGGGCCGCAGAGGCAAAGAGACCGAGGAGGCGGCGAACGGGGACAGGGGTGTGAGTCAAACCGAGGGAGCGCCGAGTTCTGACTTCACCACCGACTAGPig(846)
849 993860 870 880 890 900 910 920 930 940 950 960 970 980(849)
ATTTGGGAGAGGGCTGCAGGTGCTGCGGAATCAGGGCTCCTCCCTGTTGGGACGCAGAGGCAAAGACACAGCAGAGGGGACAAATGAGGACAGGGGTGTGGGTCAAGGAGAAGGGATGCCAAGTTCGGACTTCACTACAGAGTAGHuman(849)
TTTTGGGAAAGGTTTGCTACTGATCCGCAATCCTGCCTCCTCTATGCTGGGCAGGGGAGCCAAAGAGACAGTGGAGGGGACCAAGATGGACAGGGGTGGAAGTCAAGCAGAAGGGGTACAGAGTTCTGAATTTGTCACCGAGTAGMouse(849)
CTTCGGGAAAGGTTTGCTACTACTCCGCAATCCCGGCTCCTCTATGCTGGGCAGGGGAGCCGAAGAGACAGTGGAGGGGACCAAGACAGACAGGGGTGGGAGTCAAACAGAAGGGGCACAGAGCTCTGACTTTGTCACCGAGTGARat(849)
CTTTGGGAAAGGGCTGCAGGCACTGTACCATTGGGGCTCCTCCCTGCTGGGACGCAGATGCAAAGAAACAGCGGAGGCCGCGAATGAGGACCCGGGCGTGAGTCAAGCAGAGGGAGCCCCGAGTTCGGACTTCACCCTGGACTAGCow(846)
CTTTGGGAAAGGGCTGCAGGCGCTGCACCATCGGGGCTCCTCTCTTTTGGGACGCAGATGCAAAGAAACAGCGGAGGCCACGAATGAGGACCCAGGCGTGAGTCAAGCAGAGGGAGCGCCGAGTTCGGACTTCACCCTGGACTAGGoat(846)
CTTTGGCAAAGGGCTGCAGGCGCTGCGGAATCAGGGCTCCTTGCTGCTGGGCCGCAGAGGCAAAGAGACCGAGGAGGCGGCGAACGGGGACAGGGGTGTGAGTCAAACCGAGGGAGCGCCGAGTTCTGACTTCACCACCGACTAGPig(846)
Chapter Three 
105 
 
Alignment of FFAR3 mRNA sequences in six species 
Six known nucleotide sequences for FFAR3 taken from the NCBI nucleotide 
database; Human (NM_005304.3), Mouse (NM_001033316.2), Rat 
(NM_001108912.1), Cow (NM_001145233.1), Goat (NM_001285653.1) and 
the predicted pig sequence (XM_005664489.1) were aligned using Vector 
NTI software. Sequence alignment revealed a sequences consensus of 
90.2% with 55.3% identity positions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Alignment of FFAR3 mRNA coding sequences in six species 
1 14410 20 30 40 50 60 70 80 90 100 110 120 130(1)
------------------------------ATGGATACAGGCCCCGACCAGTCCTACTTCTCCGGCAATCACTGGTTCGTCTTCTCGGTGTACCTTCTCACTTTCCTGGTGGGGCTCCCCCTCAACCTGCTGGCCCTGGTGGTCHuman (1)
------------------------------------------ATGGGGACAAGCTTCTTTCTTGGCAATTACTGGCTTTTCTTTTCCGTCTACCTGTTGGTGTTCCTCGTGGGACTCCCCCTCAACGTGATGGCCCTGGTGGTCMouse (1)
------------------------------------------ATGGACACAAGCTTCTTTCCCGGCAACCACTGGCTTTTCTTTTCAGTGGATCTGTTGGTGTTCCTCGTGGGACTACCCCTCAACGTGATGGCCCTGGTGGTCRat (1)
------------------------------ATG---ACCAACCCAGACCACTCCTTCTTCCTCGGCAATCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCCow (1)
------------------------------ATG---ACCAGCCCAGACCGCTCCTTCTTCCTCGGCAACCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCGoat (1)
ATGGAGGCCTGGAGCTGGGTCACAGGGGAAGTGGCCACGGCCATGGGCACAAGCTTCTTCCCCGGCCATTACTGGCTCTACTTCTCCGTGTACCTCTTGACGTTCCTCGTGGGGCTGCCCCTCAACCTGGGAGCCCTGGTGATCPig (1)
50 19360 70 80 90 100 110 120 130 140 150 160 170 180(50)
AGTCCTACTTCTCCGGCAATCACTGGTTCGTCTTCTCGGTGTACCTTCTCACTTTCCTGGTGGGGCTCCCCCTCAACCTGCTGGCCCTGGTGGTCTTCGTGGGCAAGCTGCAGCGCCGCCCGGTGGCCGTGGACGTGCTCCTGCHuman (20)
CAAGCTTCTTTCTTGGCAATTACTGGCTTTTCTTTTCCGTCTACCTGTTGGTGTTCCTCGTGGGACTCCCCCTCAACGTGATGGCCCTGGTGGTCTTCGTGGGCAAGCTGCGCCGACGCCCAGTGGCTGTGGACTTACTTTTGCMouse (8)
CAAGCTTCTTTCCCGGCAACCACTGGCTTTTCTTTTCAGTGGATCTGTTGGTGTTCCTCGTGGGACTACCCCTCAACGTGATGGCCCTGGTGGTCTTCGTGAACAAGCTGCGTCGCCGCCCGGTGGCCGTGGACTTACTTTTGCRat (8)
ACTCCTTCTTCCTCGGCAATCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCTTCGTGGGCAAGCTGCGGCGCCGCCCGCTGGCTGTGGACGTGCTCTTGCCow (17)
GCTCCTTCTTCCTCGGCAACCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCTTCGTGGGCAAGCTGCGGCGCCGCCCGGTGGCCGTGGACGTGCTCTTGCGoat (17)
CAAGCTTCTTCCCCGGCCATTACTGGCTCTACTTCTCCGTGTACCTCTTGACGTTCCTCGTGGGGCTGCCCCTCAACCTGGGAGCCCTGGTGATCTTCGTGGGCAAGCTGCGCCGCCGCCCGGTGGCCGTGGATGTGCTCCTGCPig (50)
100 243110 120 130 140 150 160 170 180 190 200 210 220 230(100)
ACTTTCCTGGTGGGGCTCCCCCTCAACCTGCTGGCCCTGGTGGTCTTCGTGGGCAAGCTGCAGCGCCGCCCGGTGGCCGTGGACGTGCTCCTGCTCAACCTGACCGCCTCGGACCTGCTCCTGCTGCTGTTCCTGCCTTTCCGCHuman (70)
GTGTTCCTCGTGGGACTCCCCCTCAACGTGATGGCCCTGGTGGTCTTCGTGGGCAAGCTGCGCCGACGCCCAGTGGCTGTGGACTTACTTTTGCTAAACCTGACCATTTCGGACCTGCTCCTGCTCCTCTTCCTGCCGTTTCGCMouse (58)
GTGTTCCTCGTGGGACTACCCCTCAACGTGATGGCCCTGGTGGTCTTCGTGAACAAGCTGCGTCGCCGCCCGGTGGCCGTGGACTTACTTTTGCTTAACCTGACCATTTCGGACCTGCTTCTGCTCCTCTTCCTGCCATTCCGTRat (58)
ACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCTTCGTGGGCAAGCTGCGGCGCCGCCCGCTGGCTGTGGACGTGCTCTTGCTAAACCTCACCCTCTCGGATCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCCow (67)
ACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCTTCGTGGGCAAGCTGCGGCGCCGCCCGGTGGCCGTGGACGTGCTCTTGCTAAATCTCACCCTCTCGGACCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCGoat (67)
ACGTTCCTCGTGGGGCTGCCCCTCAACCTGGGAGCCCTGGTGATCTTCGTGGGCAAGCTGCGCCGCCGCCCGGTGGCCGTGGATGTGCTCCTGCTGAACCTGACCCTGTCAGACCTGCTCCTGTTGCTCTTCCTGCCCTTCCGCPig (100)
150 293160 170 180 190 200 210 220 230 240 250 260 270 280(150)
GGGCAAGCTGCAGCGCCGCCCGGTGGCCGTGGACGTGCTCCTGCTCAACCTGACCGCCTCGGACCTGCTCCTGCTGCTGTTCCTGCCTTTCCGCATGGTGGAGGCAGCCAATGGCATGCACTGGCCCCTGCCCTTCATCCTCTGHuman (120)
GGGCAAGCTGCGCCGACGCCCAGTGGCTGTGGACTTACTTTTGCTAAACCTGACCATTTCGGACCTGCTCCTGCTCCTCTTCCTGCCGTTTCGCATGGTGGAGGCAGCATGTGGCATGAGATGGCTTCTGCCCTTCATCTTCTGMouse (108)
GAACAAGCTGCGTCGCCGCCCGGTGGCCGTGGACTTACTTTTGCTTAACCTGACCATTTCGGACCTGCTTCTGCTCCTCTTCCTGCCATTCCGTATAGTGGAGGCGGCCTGTGGCATGAAATGGATTCTGCCCTTCATCTTCTGRat (108)
GGGCAAGCTGCGGCGCCGCCCGCTGGCTGTGGACGTGCTCTTGCTAAACCTCACCCTCTCGGATCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCATGGTGGAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGCow (117)
GGGCAAGCTGCGGCGCCGCCCGGTGGCCGTGGACGTGCTCTTGCTAAATCTCACCCTCTCGGACCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCATGGTGGAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGGoat (117)
GGGCAAGCTGCGCCGCCGCCCGGTGGCCGTGGATGTGCTCCTGCTGAACCTGACCCTGTCAGACCTGCTCCTGTTGCTCTTCCTGCCCTTCCGCATGGCGGAGGCGGCCAGTGGCATGCACTGGCCCTTGCCCTTCATCTTCTGPig (150)
200 343210 220 230 240 250 260 270 280 290 300 310 320 330(200)
TGACCGCCTCGGACCTGCTCCTGCTGCTGTTCCTGCCTTTCCGCATGGTGGAGGCAGCCAATGGCATGCACTGGCCCCTGCCCTTCATCCTCTGCCCACTCTCTGGATTCATCTTCTTCACCACCATCTATCTCACCGCCCTCTHuman (170)
TGACCATTTCGGACCTGCTCCTGCTCCTCTTCCTGCCGTTTCGCATGGTGGAGGCAGCATGTGGCATGAGATGGCTTCTGCCCTTCATCTTCTGCCCCCTTTCTGGGTTCCTTTTCTTCACCACTATTTACCTCACCTCCCTCTMouse (158)
TGACCATTTCGGACCTGCTTCTGCTCCTCTTCCTGCCATTCCGTATAGTGGAGGCGGCCTGTGGCATGAAATGGATTCTGCCCTTCATCTTCTGCCCCCTTTCTGGCTTCCTTTTCTTCACCACCATCTACCTCACCTCCCTCTRat (158)
TCACCCTCTCGGATCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCATGGTGGAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGCCCCTTCTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTCow (167)
TCACCCTCTCGGACCTGGTCCTGTTGCTCTTCCTGCCGTTCCGCATGGTGGAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGCCCCTTCTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTGoat (167)
TGACCCTGTCAGACCTGCTCCTGTTGCTCTTCCTGCCCTTCCGCATGGCGGAGGCGGCCAGTGGCATGCACTGGCCCTTGCCCTTCATCTTCTGCCCCGTCTCCGGATTCCTCTTCTTCACCACCGTCTATCTCACGTCCCTCTPig (200)
1 14410 20 30 40 50 60 70 80 90 100 110 120 130(1)
------------------------------ATGGATACAGGCCCCGACCAGTCCTACTTCTCCGGCAATCACTGGTTCGTCTTCTCGGTGTACCTTCTCACTTTCCTGGTGGGGCTCCCCCTCAACCTGCTGGCCCTGGTGGTCHuman (1)
------------------------------------------ATGGGGACAAGCTTCTTTCTTGGCAATTACTGGCTTTTCTTTTCCGTCTACCTGTTGGTGTTCCTCGTGGGACTCCCCCTCAACGTGATGGCCCTGGTGGTCMouse (1)
------------------------------------------ATGGACACAAGCTTCTTTCCCGGCAACCACTGGCTTTTCTTTTCAGTGGATCTGTTGGTGTTCCTCGTGGGACTACCCCTCAACGTGATGGCCCTGGTGGTCRat (1)
------------------------------ATG---ACCAACCCAGACCACTCCTTCTTCCTCGGCAATCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCCow (1)
------------------------------ATG---ACCAGCCCAGACCGCTCCTTCTTCCTCGGCAACCACTGGCTCTTCTTCTCCGTGTACCTCTTCACCTTCCTCGTGGGGCTCCCCCTCAACCTGATGGCCCTGGTGATCGoat (1)
ATGGAGGCCTGGAGCTGGGTCACAGGGGAAGTGGCCACGGCCATGGGCACAAGCTTCTTCCCCGGCCATTACTGGCTCTACTTCTCCGTGTACCTCTTGACGTTCCTCGTGGGGCTGCCCCTCAACCTGGGAGCCCTGGTGATCPig (1)
250 393260 270 280 290 300 310 320 330 340 350 360 370 380(250)
GAGGCAGCCAATGGCATGCACTGGCCCCTGCCCTTCATCCTCTGCCCACTCTCTGGATTCATCTTCTTCACCACCATCTATCTCACCGCCCTCTTCCTGGCAGCTGTGAGCATTGAACGCTTCCTGAGTGTGGCCCACCCACTGHuman (220)
GAGGCAGCATGTGGCATGAGATGGCTTCTGCCCTTCATCTTCTGCCCCCTTTCTGGGTTCCTTTTCTTCACCACTATTTACCTCACCTCCCTCTTCCTGACGGCGGTGAGCATCGAACGTTTTCTGAGCGTGGCCTATCCACTGMouse (208)
GAGGCGGCCTGTGGCATGAAATGGATTCTGCCCTTCATCTTCTGCCCCCTTTCTGGCTTCCTTTTCTTCACCACCATCTACCTCACCTCCCTCTTCCTGATGACGGTGAGCATAGAACGTTTTCTGAGCGTAGCCTACCCACTGRat (208)
GAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGCCCCTTCTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCCGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCGCTTCow (217)
GAGGCGGCCAGTGCCATGCACTGGTCCCTGCCCTTCGTCTTCTGCCCCTTCTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCTGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCACTTGoat (217)
GAGGCGGCCAGTGGCATGCACTGGCCCTTGCCCTTCATCTTCTGCCCCGTCTCCGGATTCCTCTTCTTCACCACCGTCTATCTCACGTCCCTCTTCCTGACAGCTGTGAGCATTGAGCGCTTCCTAAGCGTGGCCTACCCACTCPig (250)
300 443310 320 330 340 350 360 370 380 390 400 410 420 430(300)
CTCTGGATTCATCTTCTTCACCACCATCTATCTCACCGCCCTCTTCCTGGCAGCTGTGAGCATTGAACGCTTCCTGAGTGTGGCCCACCCACTGTGGTACAAGACCCGGCCGAGGCTGGGGCAGGCAGGTCTGGTGAGTGTGGCHuman (270)
TTCTGGGTTCCTTTTCTTCACCACTATTTACCTCACCTCCCTCTTCCTGACGGCGGTGAGCATCGAACGTTTTCTGAGCGTGGCCTATCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGTAGTMouse (258)
TTCTGGCTTCCTTTTCTTCACCACCATCTACCTCACCTCCCTCTTCCTGATGACGGTGAGCATAGAACGTTTTCTGAGCGTAGCCTACCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGGCATRat (258)
CTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCCGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCGCTTTGGTACAAGACTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCow (267)
CTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCTGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCACTTTGGTACAAGGCTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCGoat (267)
CTCCGGATTCCTCTTCTTCACCACCGTCTATCTCACGTCCCTCTTCCTGACAGCTGTGAGCATTGAGCGCTTCCTAAGCGTGGCCTACCCACTCTGGGTACAGACCCGGCCGAGGCCAGGACAGGCTGGCCTGGTCAGCGTGGTPig (300)
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Figure 3.4: Alignment of FFAR3 mRNA coding sequences in six species 
300 443310 320 330 340 350 360 370 380 390 400 410 420 430(300)
CTCTGGATTCATCTTCTTCACCACCATCTATCTCACCGCCCTCTTCCTGGCAGCTGTGAGCATTGAACGCTTCCTGAGTGTGGCCCACCCACTGTGGTACAAGACCCGGCCGAGGCTGGGGCAGGCAGGTCTGGTGAGTGTGGCHuman (270)
TTCTGGGTTCCTTTTCTTCACCACTATTTACCTCACCTCCCTCTTCCTGACGGCGGTGAGCATCGAACGTTTTCTGAGCGTGGCCTATCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGTAGTMouse (258)
TTCTGGCTTCCTTTTCTTCACCACCATCTACCTCACCTCCCTCTTCCTGATGACGGTGAGCATAGAACGTTTTCTGAGCGTAGCCTACCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGGCATRat (258)
CTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCCGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCGCTTTGGTACAAGACTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCow (267)
CTCCAGGTTCCTCTTCTTCACCACCATCTATCTCACGTCCCTCTTCCTGGCAGCTGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCACTTTGGTACAAGGCTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCGoat (267)
CTCCGGATTCCTCTTCTTCACCACCGTCTATCTCACGTCCCTCTTCCTGACAGCTGTGAGCATTGAGCGCTTCCTAAGCGTGGCCTACCCACTCTGGGTACAGACCCGGCCGAGGCCAGGACAGGCTGGCCTGGTCAGCGTGGTPig (300)
350 493360 370 380 390 400 410 420 430 440 450 460 470 480(350)
CAGCTGTGAGCATTGAACGCTTCCTGAGTGTGGCCCACCCACTGTGGTACAAGACCCGGCCGAGGCTGGGGCAGGCAGGTCTGGTGAGTGTGGCCTGCTGGCTGTTGGCCTCTGCTCACTGCAGCGTGGTCTACGTCATAGAATHuman (320)
CGGCGGTGAGCATCGAACGTTTTCTGAGCGTGGCCTATCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGTAGTCTGTTGGTTCCTGGCATCGGCTCACTGTAGTGTGGTTTACATCACTGAATMouse (308)
TGACGGTGAGCATAGAACGTTTTCTGAGCGTAGCCTACCCACTGTGGTACAAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGGCATCTGTTGGTTCTTGGCATCAGCTCACTGTAGTGTGATTTATGTCACTGAATRat (308)
CAGCCGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCGCTTTGGTACAAGACTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCTGCTGGCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTACGTGATCGAATCow (317)
CAGCTGTGAGCACAGAGCGCTTCCTGAGCGTGGCCTACCCACTTTGGTACAAGGCTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCTGCTGGCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTATGTCATCGAATGoat (317)
CAGCTGTGAGCATTGAGCGCTTCCTAAGCGTGGCCTACCCACTCTGGGTACAGACCCGGCCGAGGCCAGGACAGGCTGGCCTGGTCAGCGTGGTCTGCTGGCTCCTGGCTGCCGCTCACTGCAGCGTGGTCTACATCATCGAGTPig (350)
400 543410 420 430 440 450 460 470 480 490 500 510 520 530(400)
AAGACCCGGCCGAGGCTGGGGCAGGCAGGTCTGGTGAGTGTGGCCTGCTGGCTGTTGGCCTCTGCTCACTGCAGCGTGGTCTACGTCATAGAATTCTCAGGGGACATCTCCCACAGCCAGGGCACCAATGGGACCTGCTACCTGHuman (370)
AAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGTAGTCTGTTGGTTCCTGGCATCGGCTCACTGTAGTGTGGTTTACATCACTGAATACTGGGGAAATGCAACCTACAGCCAGGGGACCAATGGAACCTGCTACCTGMouse (358)
AAAACCCGGCCCCGGCTGGCCCAGGCTGGTCTGGTCAGTGGCATCTGTTGGTTCTTGGCATCAGCTCACTGTAGTGTGATTTATGTCACTGAATACTGGGGAAATGCAACCTACAGCCAGGGGACCAACGGAACCTGCTACCTGRat (358)
AAGACTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCTGCTGGCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTACGTGATCGAATTCTCGGGGAACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGCow (367)
AAGGCTCGGCCGAGGCCAGGGCAGGCTGGCCTGGTCAGTGGGGCCTGCTGGCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTATGTCATCGAATTCTCAGGGGACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGGoat (367)
CAGACCCGGCCGAGGCCAGGACAGGCTGGCCTGGTCAGCGTGGTCTGCTGGCTCCTGGCTGCCGCTCACTGCAGCGTGGTCTACATCATCGAGTTCTCGGGGGACTCCTCCAACAGCCAGGATGCCAACGGGACCTGCTACCTGPig (400)
450 593460 470 480 490 500 510 520 530 540 550 560 570 580(450)
GCTGTTGGCCTCTGCTCACTGCAGCGTGGTCTACGTCATAGAATTCTCAGGGGACATCTCCCACAGCCAGGGCACCAATGGGACCTGCTACCTGGAGTTCCGGAAGGACCAGCTAGCCATCCTCCTGCCCGTGCGGCTGGAGATHuman (420)
GTTCCTGGCATCGGCTCACTGTAGTGTGGTTTACATCACTGAATACTGGGGAAATGCAACCTACAGCCAGGGGACCAATGGAACCTGCTACCTGGAATTCCGGGAGGACCAGCTGGCCATCCTCCTGCCTGTACGACTAGAGATMouse (408)
GTTCTTGGCATCAGCTCACTGTAGTGTGATTTATGTCACTGAATACTGGGGAAATGCAACCTACAGCCAGGGGACCAACGGAACCTGCTACCTGGAATTCCGGGAGGACCAGCTGGCCATCCTCCTCCCCGTGCGACTGGAAATRat (408)
GCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTACGTGATCGAATTCTCGGGGAACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCCCTTCTCCTGCCCGTCCGGCTAGAGATCow (417)
GCTCCTGGCCGCTGCTCACTGCAGCGTGGTCTATGTCATCGAATTCTCAGGGGACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCCCTTCTCCTGCCTGTCCGGCTAGAGATGoat (417)
GCTCCTGGCTGCCGCTCACTGCAGCGTGGTCTACATCATCGAGTTCTCGGGGGACTCCTCCAACAGCCAGGATGCCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCTCTTCTCCTGCCCGTCCGGCTGGAGATPig (450)
500 643510 520 530 540 550 560 570 580 590 600 610 620 630(500)
GGGACATCTCCCACAGCCAGGGCACCAATGGGACCTGCTACCTGGAGTTCCGGAAGGACCAGCTAGCCATCCTCCTGCCCGTGCGGCTGGAGATGGCTGTGGTCCTCTTTGTGGTCCCGCTGATCATCACCAGCTACTGCTACAHuman (470)
GAAATGCAACCTACAGCCAGGGGACCAATGGAACCTGCTACCTGGAATTCCGGGAGGACCAGCTGGCCATCCTCCTGCCTGTACGACTAGAGATGGCTGTGGTCCTTTTCATGGTGCCCCTGTGTATCACGAGTTACTGCTACAMouse (458)
GAAATGCAACCTACAGCCAGGGGACCAACGGAACCTGCTACCTGGAATTCCGGGAGGACCAGCTGGCCATCCTCCTCCCCGTGCGACTGGAAATGGCTGTGGTCCTTTTCATGGTGCCCCTGTGTATTACCAGTTACTGCTACARat (458)
GGAACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCCCTTCTCCTGCCCGTCCGGCTAGAGATGGCAGTGGTCCTCTTTGGGGTGCCCCTGTTCATCAGCAGCTACTGCTACACow (467)
GGGACTCCTCCCCCAGCCAGGGTATCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCCCTTCTCCTGCCTGTCCGGCTAGAGATGGCAGTGGTCCTCTTTGGGGTGCCCCTGTTTATCAGCAGCTACTGCTACAGoat (467)
GGGACTCCTCCAACAGCCAGGATGCCAACGGGACCTGCTACCTGGAGTTCCGGGAGGATCAGCTGGCTCTTCTCCTGCCCGTCCGGCTGGAGATGGCTGTGGTCCTTTTCGGGGTGCCCCTGCTCATCACCAGCTACTGCTACAPig (500)
550 693560 570 580 590 600 610 620 630 640 650 660 670 680(550)
CGGAAGGACCAGCTAGCCATCCTCCTGCCCGTGCGGCTGGAGATGGCTGTGGTCCTCTTTGTGGTCCCGCTGATCATCACCAGCTACTGCTACAGCCGCCTGGTGTGGATCCTCGGCAGAGGGGGCAGCCACCGCCGGCAGAGGHuman (520)
CGGGAGGACCAGCTGGCCATCCTCCTGCCTGTACGACTAGAGATGGCTGTGGTCCTTTTCATGGTGCCCCTGTGTATCACGAGTTACTGCTACAGTCGCCTGGTGTGGATACTGAGCCGGGGGGCCAGCCGGCGCCGGCGCAAGMouse (508)
CGGGAGGACCAGCTGGCCATCCTCCTCCCCGTGCGACTGGAAATGGCTGTGGTCCTTTTCATGGTGCCCCTGTGTATTACCAGTTACTGCTACAGTCGCCTGGTGTGGATTCTGAGCCAGGGAGCCAGCCGGCGCAGGCGCAAGRat (508)
CGGGAGGATCAGCTGGCCCTTCTCCTGCCCGTCCGGCTAGAGATGGCAGTGGTCCTCTTTGGGGTGCCCCTGTTCATCAGCAGCTACTGCTACAGCCGCCTGGTCTGCATACTCGGGAGGGGAGCTAGCCATCGCCGTCGGAAGCow (517)
CGGGAGGATCAGCTGGCCCTTCTCCTGCCTGTCCGGCTAGAGATGGCAGTGGTCCTCTTTGGGGTGCCCCTGTTTATCAGCAGCTACTGCTACAGCCGCCTGGTCTGCATACTCGGGAGGGGAGCAAGCCATCGCCGTCGGAAGGoat (517)
CGGGAGGATCAGCTGGCTCTTCTCCTGCCCGTCCGGCTGGAGATGGCTGTGGTCCTTTTCGGGGTGCCCCTGCTCATCACCAGCTACTGCTACAGCCGCCTGGTGTGCATACTCAGCAGGGGAGCCAGCTACCACCGGCGGAAGPig (550)
600 743610 620 630 640 650 660 670 680 690 700 710 720 730(600)
GGTCCTCTTTGTGGTCCCGCTGATCATCACCAGCTACTGCTACAGCCGCCTGGTGTGGATCCTCGGCAGAGGGGGCAGCCACCGCCGGCAGAGGAGGGTGGCGGGGCTGTTGGCGGCCACGCTGCTCAACTTCCTTGTCTGCTTHuman (570)
GGTCCTTTTCATGGTGCCCCTGTGTATCACGAGTTACTGCTACAGTCGCCTGGTGTGGATACTGAGCCGGGGGGCCAGCCGGCGCCGGCGCAAGAGGATAATGGGGCTTCTTGCAGCCACACTGCTCATCTTCTTCGTCTGCTTMouse (558)
GGTCCTTTTCATGGTGCCCCTGTGTATTACCAGTTACTGCTACAGTCGCCTGGTGTGGATTCTGAGCCAGGGAGCCAGCCGGCGCAGGCGCAAGAGAGTGATGGGGCTTCTTGTAGCCACGTTGCTCATCTTCTTTGTCTGCTTRat (558)
GGTCCTCTTTGGGGTGCCCCTGTTCATCAGCAGCTACTGCTACAGCCGCCTGGTCTGCATACTCGGGAGGGGAGCTAGCCATCGCCGTCGGAAGAGGGTGGCAGGGCTAGCGGCTGCCACATTGCTCAACTTCCTTGTCTGCTTCow (567)
GGTCCTCTTTGGGGTGCCCCTGTTTATCAGCAGCTACTGCTACAGCCGCCTGGTCTGCATACTCGGGAGGGGAGCAAGCCATCGCCGTCGGAAGAGAGTGGCAGGGCTGGCGGCCGCCACGTTGCTCAACTTCCTCGTCTGCTTGoat (567)
GGTCCTTTTCGGGGTGCCCCTGCTCATCACCAGCTACTGCTACAGCCGCCTGGTGTGCATACTCAGCAGGGGAGCCAGCTACCACCGGCGGAAGAGGGTGGCAGGACTTGTGGCAGCCACGCTGCTCAACTTCCTCGTCTGCTTPig (600)
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Figure 3.4: Alignment of FFAR3 mRNA coding sequence in six species 
 
650 793660 670 680 690 700 710 720 730 740 750 760 770 780(650)
TGGTGTGGATCCTCGGCAGAGGGGGCAGCCACCGCCGGCAGAGGAGGGTGGCGGGGCTGTTGGCGGCCACGCTGCTCAACTTCCTTGTCTGCTTTGGGCCCTACAACGTGTCCCATGTCGTGGGCTATATCTGCGGTGAAAGCCHuman (620)
TGGTGTGGATACTGAGCCGGGGGGCCAGCCGGCGCCGGCGCAAGAGGATAATGGGGCTTCTTGCAGCCACACTGCTCATCTTCTTCGTCTGCTTCGGCCCCTATAATATGTCCCATGTGGTGGGCTATGTCAGCCGTGAGAGTCMouse (608)
TGGTGTGGATTCTGAGCCAGGGAGCCAGCCGGCGCAGGCGCAAGAGAGTGATGGGGCTTCTTGTAGCCACGTTGCTCATCTTCTTTGTCTGCTTCGGCCCCTACAATATGTCCCACGTGGTGGGCTACGTGCGCGGTGAGAGTCRat (608)
TGGTCTGCATACTCGGGAGGGGAGCTAGCCATCGCCGTCGGAAGAGGGTGGCAGGGCTAGCGGCTGCCACATTGCTCAACTTCCTTGTCTGCTTTGGGCCCTACAACATGTCCCACATCGTGGGCTACATCCAGGGTAAAAGCCCow (617)
TGGTCTGCATACTCGGGAGGGGAGCAAGCCATCGCCGTCGGAAGAGAGTGGCAGGGCTGGCGGCCGCCACGTTGCTCAACTTCCTCGTCTGCTTTGGGCCCTACAACGTGTCCCACATCGTGGGCTACATCCAGGGTGAAAGCCGoat (617)
TGGTGTGCATACTCAGCAGGGGAGCCAGCTACCACCGGCGGAAGAGGGTGGCAGGACTTGTGGCAGCCACGCTGCTCAACTTCCTCGTCTGCTTTGGGCCCTACAACGTGTCCCACGTCGTGGGCTACATCCAGGGCAAAAGCCPig (650)
700 843710 720 730 740 750 760 770 780 790 800 810 820 830(700)
GCGGGGCTGTTGGCGGCCACGCTGCTCAACTTCCTTGTCTGCTTTGGGCCCTACAACGTGTCCCATGTCGTGGGCTATATCTGCGGTGAAAGCCCGGCGTGGAGGATCTACGTGACGCTTCTCAGCACCCTGAACTCCTGTGTCHuman (670)
ATGGGGCTTCTTGCAGCCACACTGCTCATCTTCTTCGTCTGCTTCGGCCCCTATAATATGTCCCATGTGGTGGGCTATGTCAGCCGTGAGAGTCCGTCCTGGCGGAGCTACGTGCTCCTCCTCAGCACCCTCAACTCTTGTATCMouse (658)
ATGGGGCTTCTTGTAGCCACGTTGCTCATCTTCTTTGTCTGCTTCGGCCCCTACAATATGTCCCACGTGGTGGGCTACGTGCGCGGTGAGAGTCCGACCTGGCGGAGCTACGTGCTTCTCCTCAGCACCCTCAACTCTTGTATTRat (658)
GCAGGGCTAGCGGCTGCCACATTGCTCAACTTCCTTGTCTGCTTTGGGCCCTACAACATGTCCCACATCGTGGGCTACATCCAGGGTAAAAGCCCCACGTGGAGAAGTTATGTGCTGCTCCTCAGCACCCTGAATTCCTGCGTCCow (667)
GCAGGGCTGGCGGCCGCCACGTTGCTCAACTTCCTCGTCTGCTTTGGGCCCTACAACGTGTCCCACATCGTGGGCTACATCCAGGGTGAAAGCCCCACGTGGAGAAGTTACGTGCTGCTCCTCAGCACCCTGAATTCCTGCTTTGoat (667)
GCAGGACTTGTGGCAGCCACGCTGCTCAACTTCCTCGTCTGCTTTGGGCCCTACAACGTGTCCCACGTCGTGGGCTACATCCAGGGCAAAAGCCCCGAGTGGAGACCTTACGTGTTGCTCCTCAGCACCCTGAATTCCTGCGTCPig (700)
750 893760 770 780 790 800 810 820 830 840 850 860 870 880(750)
CTACAACGTGTCCCATGTCGTGGGCTATATCTGCGGTGAAAGCCCGGCGTGGAGGATCTACGTGACGCTTCTCAGCACCCTGAACTCCTGTGTCGACCCCTTTGTCTACTACTTCTCCTCCTCCGGGTTCCAAGCCGACTTTCAHuman (720)
CTATAATATGTCCCATGTGGTGGGCTATGTCAGCCGTGAGAGTCCGTCCTGGCGGAGCTACGTGCTCCTCCTCAGCACCCTCAACTCTTGTATCGACCCCCTGGTTTTCTACTTTTCTTCCTCCAAGTTCCAAGCCGACTTTCAMouse (708)
CTACAATATGTCCCACGTGGTGGGCTACGTGCGCGGTGAGAGTCCGACCTGGCGGAGCTACGTGCTTCTCCTCAGCACCCTCAACTCTTGTATTGACCCTCTGGTTTTCTACTTTTCATCCTCCAAGTTCCAAGCCGACTTTCARat (708)
CTACAACATGTCCCACATCGTGGGCTACATCCAGGGTAAAAGCCCCACGTGGAGAAGTTATGTGCTGCTCCTCAGCACCCTGAATTCCTGCGTCGACCCCCTTGTCTACTATTTCTCATCATCTGGGTTCCAAGCCGACTTCCACow (717)
CTACAACGTGTCCCACATCGTGGGCTACATCCAGGGTGAAAGCCCCACGTGGAGAAGTTACGTGCTGCTCCTCAGCACCCTGAATTCCTGCTTTGACCCCCTCGTCTACTATTTCTCATCATCTGGATTCCAAGCTGACTTCCAGoat (717)
CTACAACGTGTCCCACGTCGTGGGCTACATCCAGGGCAAAAGCCCCGAGTGGAGACCTTACGTGTTGCTCCTCAGCACCCTGAATTCCTGCGTCGACCCCCTCATCTACTACTTCTCATCCTCGGGGTTCCAAGCTGACTGCCAPig (750)
800 943810 820 830 840 850 860 870 880 890 900 910 920 930(800)
GGAGGATCTACGTGACGCTTCTCAGCACCCTGAACTCCTGTGTCGACCCCTTTGTCTACTACTTCTCCTCCTCCGGGTTCCAAGCCGACTTTCATGAGCTGCTGAGGAGGTTGTGTGGGCTCTGGGGCCAGTGGCAGCAGGAGAHuman (770)
GGCGGAGCTACGTGCTCCTCCTCAGCACCCTCAACTCTTGTATCGACCCCCTGGTTTTCTACTTTTCTTCCTCCAAGTTCCAAGCCGACTTTCATCAACTCCTGGGGAGGCTGCTCAGAACTTGTGTGCCTTGGACTCAGCAAGMouse (758)
GGCGGAGCTACGTGCTTCTCCTCAGCACCCTCAACTCTTGTATTGACCCTCTGGTTTTCTACTTTTCATCCTCCAAGTTCCAAGCCGACTTTCATCAGCTCCTGTCTAGGCTGATCAGAGCTTGTGTGCCTTGGACTCAGGAAGRat (758)
GGAGAAGTTATGTGCTGCTCCTCAGCACCCTGAATTCCTGCGTCGACCCCCTTGTCTACTATTTCTCATCATCTGGGTTCCAAGCCGACTTCCACGGATTGCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGACow (767)
GGAGAAGTTACGTGCTGCTCCTCAGCACCCTGAATTCCTGCTTTGACCCCCTCGTCTACTATTTCTCATCATCTGGATTCCAAGCTGACTTCCAGGGATTGCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGAGoat (767)
GGAGACCTTACGTGTTGCTCCTCAGCACCCTGAATTCCTGCGTCGACCCCCTCATCTACTACTTCTCATCCTCGGGGTTCCAAGCTGACTGCCAGGGGCTGCTGGGGAGGCTGACGGGGGCCTGGGGCTTTTGGCGGCAGGAAAPig (800)
850 993860 870 880 890 900 910 920 930 940 950 960 970 980(850)
TTTGTCTACTACTTCTCCTCCTCCGGGTTCCAAGCCGACTTTCATGAGCTGCTGAGGAGGTTGTGTGGGCTCTGGGGCCAGTGGCAGCAGGAGAGCAGCATGGAGCTGAAGGAGCAGAAGGGAGGGGAGG-AGCAGAG-AGCGGHuman (820)
CTGGTTTTCTACTTTTCTTCCTCCAAGTTCCAAGCCGACTTTCATCAACTCCTGGGGAGGCTGCTCAGAACTTGTGTGCCTTGGACTCAGCAAGTCAGCCTGGAACTGAAGGTAAAGAATGGAGAAGAGCCATCCAAGGAG-TGMouse (808)
CTGGTTTTCTACTTTTCATCCTCCAAGTTCCAAGCCGACTTTCATCAGCTCCTGTCTAGGCTGATCAGAGCTTGTGTGCCTTGGACTCAGGAAGTCAGCTTGGAACTGAAGGTAAAGAACGGAGAAGAGCCATCCAAGGAA-TGRat (808)
CTTGTCTACTATTTCTCATCATCTGGGTTCCAAGCCGACTTCCACGGATTGCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCTCAGGAGCTGCow (817)
CTCGTCTACTATTTCTCATCATCTGGATTCCAAGCTGACTTCCAGGGATTGCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCGCAAGAGCTGGoat (817)
CTCATCTACTACTTCTCATCCTCGGGGTTCCAAGCTGACTGCCAGGGGCTGCTGGGGAGGCTGACGGGGGCCTGGGGCTTTTGGCGGCAGGAAAGCAGCGGGAAACTGAAGAAGAGCGAAGTGGAGGGGCCGCCGCAGGAGCTGPig (850)
900 1043910 920 930 940 950 960 970 980 990 1000 1010 1020 1030(900)
GCTGAGGAGGTTGTGTGGGCTCTGGGGCCAGTGGCAGCAGGAGAGCAGCATGGAGCTGAAGGAGCAGAAGGGAGGGGAGG-AGCAGAG-AGCGGACCGACC-AGCTGAAAGAAAGACCAGTGAACACTCACAGGGCTGTGGAACHuman (870)
CCTGGGGAGGCTGCTCAGAACTTGTGTGCCTTGGACTCAGCAAGTCAGCCTGGAACTGAAGGTAAAGAATGGAGAAGAGCCATCCAAGGAG-TGTCCGAGCTAG----------------------------------------Mouse (858)
CCTGTCTAGGCTGATCAGAGCTTGTGTGCCTTGGACTCAGGAAGTCAGCTTGGAACTGAAGGTAAAGAACGGAGAAGAGCCATCCAAGGAA-TGTCCGAGCTAG----------------------------------------Rat (858)
GCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCTCAGGAGCTGTTCAACATAGAGGCTAGCTAG-----------------------------Cow (867)
GCTGGGGCGGCTGACTGGGTCCTGGGGCCCTTGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCGCAAGAGCTGTTCAATATAGAGGCCAGCTAG-----------------------------Goat (867)
GCTGGGGAGGCTGACGGGGGCCTGGGGCTTTTGGCGGCAGGAAAGCAGCGGGAAACTGAAGAAGAGCGAAGTGGAGGGGCCGCCGCAGGAGCTGTCCAATATAGACACCAGGTAG-----------------------------Pig (900)
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Figure 3.4: Alignment of FFAR3 coding sequence in six species 
 
 
 Human Mouse Rat Cow Goat Pig 
Human 100 70.5 69.8 77.0 76.8 73.7 
Mouse  100 91.4 73.6 73.1 72.1 
Rat   100 73.0 73.3 71.4 
Cow    100 96.4 83.2 
Goat     100 83.6 
Pig      100 
 
Figure 3.5: FFAR3 nucleotide sequence homology (%) between six 
species 
931 1074940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060(931)
TGGCAGCAGGAGAGCAGCATGGAGCTGAAGGAGCAGAAGGGAGGGGAGG-AGCAGAG-AGCGGACCGACC-AGCTGAAAGAAAGACCAGTGAACACTCACAGGGCTGTGGAACTGGTGGCCAGGTGGCCTGTGCTGAAAGCTAGHuman (901)
TGGACTCAGCAAGTCAGCCTGGAACTGAAGGTAAAGAATGGAGAAGAGCCATCCAAGGAG-TGTCCGAGCTAG-----------------------------------------------------------------------Mouse (889)
TGGACTCAGGAAGTCAGCTTGGAACTGAAGGTAAAGAACGGAGAAGAGCCATCCAAGGAA-TGTCCGAGCTAG-----------------------------------------------------------------------Rat (889)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCTCAGGAGCTGTTCAACATAGAGGCTAGCTAG------------------------------------------------------------Cow (898)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCGCAAGAGCTGTTCAATATAGAGGCCAGCTAG------------------------------------------------------------Goat (898)
TGGCGGCAGGAAAGCAGCGGGAAACTGAAGAAGAGCGAAGTGGAGGGGCCGCCGCAGGAGCTGTCCAATATAGACACCAGGTAG------------------------------------------------------------Pig (931)
931 1074940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060(931)
TGGCAGCAGGAGAGCAGCATGGAGCTGAAGGAGCAGAAGGGAGGGGAGG-AGCAGAG-AGCGGACCGACC-AGCTGAAAGAAAGACCAGTGAACACTCACAGGGCTGTGGAACTGGTGGCCAGGTGGCCTGTGCTGAAAGCTAGHuman (901)
TGGACTCAGCAAGTCAGCCTGGAACTGAAGGTAAAGAATGGAGAAGAGCCATCCAAGGAG-TGTCCGAGCTAG-----------------------------------------------------------------------Mouse (889)
TGGACTCAGGAAGTCAGCTTGGAACTGAAGGTAAAGAACGGAGAAGAGCCATCCAAGGAA-TGTCCGAGCTAG-----------------------------------------------------------------------Rat (889)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCTCAGGAGCTGTTCAACATAGAGGCTAGCTAG------------------------------------------------------------Cow (898)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCGCAAGAGCTGTTCAATATAGAGGCCAGCTAG------------------------------------------------------------Goat (898)
TGGCGGCAGGAAAGCAGCGGGAAACTGAAGAAGAGCGAAGTGGAGGGGCCGCCGCAGGAGCTGTCCAATATAGACACCAGGTAG------------------------------------------------------------Pig (931)
931 1074940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060(931)
TGGCAGCAGGAGAGCAGCATGGAGCTGAAGGAGCAGAAGGGAGGGGAGG-AGCAGAG-AGCGGACCGACC-AGCTGAAAGAAAGACCAGTGAACACTCACAGGGCTGTGGAACTGGTGGCCAGGTGGCCTGTGCTGAAAGCTAGHuman (901)
TGGACTCAGCAAGTCAGCCTGGAACTGAAGGTAAAGAATGGAGAAGAGCCATCCAAGGAG-TGTCCGAGCTAG-----------------------------------------------------------------------Mouse (889)
TGGACTCAGGAAGTCAGCTTGGAACTGAAGGTAAAGAACGGAGAAGAGCCATCCAAGGAA-TGTCCGAGCTAG-----------------------------------------------------------------------Rat (889)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCTCAGGAGCTGTTCAACATAGAGGCTAGCTAG------------------------------------------------------------Cow (898)
TGGCGGCAGGAGAATGGCGTGACCTCGAAGAAGAGCGAGGGAGAGGGGCCACCGCAAGAGCTGTTCAATATAGAGGCCAGCTAG------------------------------------------------------------Goat (898)
TGGCGGCAGGAAAGCAGCGGGAAACTGAAGAAGAGCGAAGTGGAGGGGCCGCCGCAGGAGCTGTCCAATATAGACACCAGGTAG------------------------------------------------------------Pig (931)
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Strategies for validating primers used for FFAR2 and FFAR3 expression 
In order to assess expression of FFAR2 and FFAR3 mRNA across the 
longitudinal axis of mouse, pig and human colon, the nucleotide coding 
regions of human, mouse, and pig were used to design species specific 
primers targeting FFAR2 or FFAR3 mRNA. Primers were designed using 
commercial available software, Primer Express Version 3.01 (Life 
Technologies). Product length was restricted to 100 base pairs of the 
intended target for use in semi-quantitative QPCR. The specificity of 
designed primers was first confirmed by NCBI nucleotide blast searches 
before obtaining the primers. 
 
Subsequently, QPCR was performed and melt curve analysis used to ensure 
formation of a single product. The product was optimised by increasing the 
concentration of template cDNA (5-50ng/µl). PCR products were visualised 
on an ethidium bromide agarose gel to confirm presence of a single band. 
Primer sets were confirmed by cloning and sequencing the product to 
determine identity. Only validated primers were used to assess expression 
profiles of SCFA receptors across the longitudinal axes of mouse, pig, and 
human colon. 
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Expression of FFAR2 and FFAR3 in mouse, pig and human colon 
Mouse colonic tissue was first used to learn semi-quantitative QPCR. Later 
similar experiments were performed using pig and human colonic tissues. 
FFAR2 mRNA expression across mouse distal intestine 
The mouse FFAR2 mRNA sequence was available from the NCBI nucleotide 
database. Primers were designed to assess relative expression of FFAR2 in 
mouse ileum and colon. 
 
 
 
 
 
 
 
 
 
Figure 3.6: Relative expression of FFAR2 mRNA across the longitudinal 
axis of mouse distal intestine. RNA was extracted from intestinal tissues of 
eight week old mice.  After RNA integrity was assessed it was used for cDNA 
synthesis. cDNA (diluted to 5µg/µl) was used in QPCR to assess FFAR2 
relative mRNA abundance. Results were normalised to ribonucleic acid 
(RNA) polymerase II and presented as mean ± standard error of the mean 
(error bars). Statistical analysis was performed by Mann-Whitney tests to 
compare unpaired columns (nsP>0.05, N = 3). Ileum (A), ascending colon (B) 
and descending colon (C). 
 
Results 
FFAR2 mRNA expression was constant from the mouse terminal ileum to 
distal colon. 
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FFAR3 mRNA expression across mouse distal intestine 
The mouse FFAR3 mRNA sequence was available on the NCBI nucleotide 
database. Primers were designed to assess relative expression of FFAR3 in 
mouse ileum and colon. The same tissue samples used to measure relative 
FFAR2 mRNA abundance in mouse intestine were employed in this analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Relative expression of FFAR3 mRNA across mouse ileum, 
ascending and descending colon. QPCR was performed to determine the 
expression of FFAR3 mRNA across the longitudinal axis of mouse intestine. 
All results were normalised using mouse RPII and presented as mean ± 
standard error of the mean (error bars). Statistical analysis was performed 
using Mann-Whitney to compare columns (nsP>0.05; N = 3). A) Ileum, B) 
ascending colon, and C) descending colon. 
Result 
There was no change in FFAR3 expression level between the terminal ileum, 
proximal colon and distal colon of mice.
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Expression of FFAR2 mRNA across pig colon 
Pig FFAR2 mRNA sequence from NCBI nucleotide database was used to 
design QPCR primers. Colonic samples were collected from 28 day old 
piglets weaned onto a commercial diet. RNA was extracted from 40 samples 
and their integrity assessed cDNA first strand synthesis performed and 
5µg/µl sample dilutions prepared and a caecal sample chosen as a common 
calibrator between all QPCR runs.  
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Relative expression of FFAR2 mRNA across the longitudinal 
axis of pig colon. Expression of FFAR2 mRNA was assessed across the 
longitudinal axis of pig colon by QPCR. All samples were normalised against 
pig β-actin and results presented as mean ± standard error of the mean 
(error bars). Statistical analysis was performed using Mann-Whitney tests to 
compare unpaired columns (nsP>0.05; N = 6). A) Caecum, B) Ascending 
colon, C) Transverse colon, D) Descending colon, E) Rectum. 
 
Results 
FFAR2 mRNA expression was found constant across the longitudinal axis of 
pig colon. 
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Expression of FFAR3 mRNA across pig colon 
Primers were designed to pig FFAR3, cloned and sequenced to confirm 
specificity. Expression of FFAR3 was assessed by QPCR using the same 
cDNA samples used to assess FFAR2 mRNA expression across the 
longitudinal axis of pig colon (Figure 3.8). As before a caecal sample was 
chosen as a common calibrator between all QPCR runs. 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Relative expression of FFAR3 mRNA across the longitudinal 
axis of pig colon. Expression of FFAR3 mRNA across the longitudinal axis 
was accessed by QPCR and all results normalised to pig β-actin. Results are 
presented as the mean ± standard error of the mean (error bars). Statistical 
analysis was performed using Mann-Whitney tests to compare unpaired 
columns (nsP>0.05; N = 6). A) Caecum, B) Ascending colon, C) Transverse 
colon, D) Descending colon, E) Rectum. 
 
Results 
No statistical significant changes in FFAR3 expression was observed across 
the longitudinal axis of pig colon. 
Expression of FFAR3 (GPR41) mRNA
across the longitudinal axis of pig colon
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Relative FFAR2 mRNA across human colon 
The Human FFAR2 mRNA sequence available on NCBI nucleotide database 
was used to design QPCR primers using primer express. QPCR primers 
were tested, cloned and target specificity confirmed by sequence analysis. 
The relative expression of FFAR2 mRNA was assessed across the 
longitudinal axis of human colon using a sample of the ascending colon as a 
common calibrator between QPCR runs. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Relative expression profile of FFAR2 mRNA across the 
longitudinal axis of human colon. Expression of FFAR2 mRNA across the 
longitudinal axis of human colon was assessed by QPCR and results 
normalised to human β-actin. Results are presented as mean ± standard 
error of the mean (error bars) and statistical analysis performed using Mann-
Whitney tests to compare unpaired columns (nsP>0.05; N = 6). A) Ascending 
colon, B) Transverse colon, C) Descending colon. 
 
Results  
FFAR2 mRNA expression remains constant across the longitudinal axis of 
human colon. 
 
Expression of FFAR2 across
the longitudinal axis of human colon [N = 6]
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Relative FFAR3 mRNA across human colon 
Human FFAR3 mRNA sequence available on the NCBI database was used 
to design QPCR primers on primer express. The successful primer set was 
cloned and specificity confirmed by sequence analysis. FFAR3 mRNA 
relative expression across the longitudinal axis of human colon; ascending, 
transverse and descending colon was assessed using the same samples 
used to test FFAR2 mRNA expression. As before a common sample from the 
ascending colon was also used as a calibrator between QPCR runs.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Relative expression profile of FFAR3 mRNA across the 
longitudinal axis of human colon. Expression of FFAR3 mRNA across the 
longitudinal axis of human colon was assessed by QPCR and results 
normalised to human β-actin. Results are presented as mean ± standard 
error of the mean (error bars) and statistical analysis performed using Mann-
Whitney tests to compare unpaired columns (nsP>0.05; N = 3). A) Ascending 
colon, B) Transverse colon, C) Descending colon. 
 
Result 
FFAR3 expression is constant across the longitudinal axis of human colon. 
Expression of FFAR3 across
the longitudinal axis of human colon [N = 3]
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Localisation of SCFA receptors by immunohistochemistry 
 
 
 
 
 
 
 
 
Figure 3.12a: Localisation of SCFA receptors in pig colon 
Six 10µM thick cryo-sections of pig colonic tissue were probed with a primary 
FFAR2 custom synthesised antibody (optimal dilution, 1: 100). To detect 
bound primary FFAR2 antibody the sections were treated with Donkey anti-
rabbit secondary antibody (IgG) conjugated to a fluorescent probe, FITC 
(optimal dilution, 1: 500 (as described in methods). Image (A) shows FFAR2 
(green triangle) 400X magnified, image (B) shows FFAR2 (green triangle) 
1000X magnified, and image (C) shows labelling was specific; no labelling 
was observed when secondary antibody was used alone (negative control), 
10X magnification. Scale bar = 10µm. 
 
Result 
In pig colon, FFAR2 is found deep within colonic crypts localised to triangular 
shaped cells, a characteristic feature of enteroendocrine cells. 
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Localisation of SCFA receptors by immunohistochemistry 
 
 
 
 
 
 
 
 
 
Figure 3.12b: Localisation of FFAR2 in human ascending colon 
Four 10µm cryo-sections from six human colonic biopsies taken from the 
ascending colon were labelled with a custom synthesised FFAR2 antibody as 
previously described (see Figure 3.12a). Image (A) shows human FFAR2 
(green triangle) at 400X magnification, image (B) is FFAR2 (green triangle) at 
1000X magnification, and image (C) is representative of a negative control 
showing no labelling in the absence of primary antibody. Scale bar = 10µm.  
 
Results 
In human colon, FFAR2 is found deep within colonic crypts localised to 
triangular shaped cells, a characteristic feature of enteroendocrine cells. 
  A B 
C  
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SCFA receptors co-localisation within enteroendocrine cells 
Enteroendocrine cells have a characteristic flask shaped appearance. To 
determine if FFAR2 and FFAR3 are indeed expressed within colonic 
enteroendocrine cells, co-expression of the receptors with chromogranin A 
(ChA), a known marker of enteroendocrine cells was assessed. 
Double immunohistochemistry was carried out using adjacent sections from 
the same tissue block. One section was probed with a primary antibody to 
ChA (Optimal dilution, 1:100) and the other section stained with custom 
synthesised antibodies targeting FFAR2 or FFAR3. These sections were 
treated with donkey anti-rabbit secondary antibodies (IgG) conjugated to 
fluorescein isothiocyanate (FITC) or indocarbocyanine (Cy3) targeting bound 
primary antibody to enable detection by immunofluorescence (full details 
described in the method section). 
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Pig colon: Co-localisation of FFAR2 and FFAR3 with ChA 
 
 
 
 
 
 
 
 
 
Figure 3.13a: A typical figure of the co-localisation of SCFA receptors 
and ChA in pig colonic tissue. Colonic tissue from four pigs was fixed in 
4% (w/v) paraformaldehyde and used to prepare two tissue blocks from each 
region of pig colon. From these tissue blocks two adjacent cryo-sections 
(10µm thick) were prepared and probed to show localisation of SCFA 
receptors (green; B and E) and ChA (red; C and F) in pig colonic tissue. 
Adjacent tissue sections were probed with donkey anti-rabbit secondary 
antibodies conjugated to either FITC or Cy3. Furthermore, to show specificity 
of antibodies, no labelling was observed in tissue sections when primary 
antibody was excluded, negative controls (images; A and D). All images are 
magnified x10 (A and D) or x1000. Scale bar = 10µm. 
 
Results 
In pig colonic tissues SCFA receptors are localised in the same cell as ChA, 
a classical marker of enteroendocrine cells. 
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Human colon: Co-localisation of SCFA receptors with ChA 
 
 
 
 
 
 
 
 
Figure 3.13b: Representative images showing co-localisation of FFAR2 
and FFAR3 with ChA in human colon. Three colonic biopsies from the 
ascending colon were fixed in 4% (w/v) paraformaldehyde to prepare frozen 
tissue blocks. 10µm thick cryo-sections were prepared from each tissue 
block. One section was probed with custom synthesis primary antibodies 
(1:100) targeting FFAR2 or FFAR3 (green; B and E), and the adjacent cryo-
section probed with (1:100) primary antibody targeting ChA (red; C and F), a 
marker of enteroendocrine cells. The tissue sections were then probed with 
donkey anti-rabbit secondary antibodies conjugated to either FITC or Cy3. 
Tissue sections not probed with primary antibody were commonly used as 
negative controls to assess none specific binding of secondary antibodies 
(images; A and D). All images are magnified x10 (A and D) or x1000 and 
possess a 10µm scale bar. 
 
Results 
In human colon the SCFA receptors, FFAR2 and FFAR3, are localised in the 
same cell as ChA, a classical marker of enteroendocrine cells.  
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Enteroendocrine cell subtype(s) expressing SCFA receptors 
There are at least 10 different endocrine cell populations producing over 20 
hormones. Their classification is based on secreted hormones and their 
location in the gastrointestinal tract (see introduction). The majority of 
endocrine cells expressed in the distal intestine are L-type and 
enterochromaffin endocrine cells. In order to determine which endocrine cell 
type in the distal intestine expresses FFAR2 and FFAR3, double 
immunohistochemistry was performed as described in Method section. It was 
shown that FFAR2 and FFAR3 were present in cells containing glucagon like 
peptide 1 (GLP-1), PYY and 5-HT. GLP-1 and PYY are expressed in L-type 
endocrine cells and 5-HT in enterochromaffin cells (see introduction) 
suggesting that FFAR2 and FFAR3 are expressed in L-type and 
enterochromaffin enteroendocrine cells. 
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Pig colon: Co-localisation of SCFA receptors with GLP-1 
 
 
 
 
 
 
 
 
 
Figure 3.14: Co-expression of FFAR2 and FFAR3 with GLP-1 in pig 
colon. Pig colonic tissue was prepared as outlined in figure 3.13a. Eight 
adjacent 10µm thick cryo-sections were prepared from frozen gelatin-
sucrose embedded blocks containing tissue from the ascending colon from 
four piglets. One section was probed with custom synthesis polyclonal 
primary antibodies (1:100) targeting a SCFA receptor (green; B and E) and 
adjacent sections with primary antibody (1:100) targeting the N-terminus of 
GLP-1 (red; C and F). These sections were then treated to detect bound 
primary antibodies using donkey anti-rabbit secondary antibodies (1:500) 
conjugated to FITC or Cy3. All images show magnification x1000. Tissue 
sections (negative controls) were treated in the absence of primary antibody 
to rule out none specific binding of secondary antibodies (images; A and D). 
Scale bar = 10µm. 
 
Results 
SCFA receptors are localised within cells containing GLP-1. 
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Pig colon: Co-localisation of SCFA receptors with 5-HT 
 
 
 
 
 
 
 
 
Figure 3.15: A typical figure showing co-localisation of FFAR2 and 
FFAR3 with 5-HT in pig colon. The same immunohistochemistry strategy 
outlined in figure 3.14 was adopted to investigate SCFA receptor localisation 
to serotonin (5-HT). Using a cryostat, eight adjacent 10µm thick sections 
were prepared from frozen gelatin-sucrose embedded tissue blocks of the 
ascending colon from four piglets. One section was probed with primary 
antibody (1:100) targeting a SCFA receptor (green; B and E) and adjacent 
sections probed for 5-HT (red; C and F). Sections were then probed with 
polyclonal donkey anti-rabbit secondary antibodies (1:500) conjugated to 
FITC or Cy3. In the absence of primary antibody tissue sections showed no 
labelling represented in images A and D (negative controls). All images have 
a scale bar of 10µm and are magnified x10 (A and D), x400 (B and C), or 
x1000 (E and F). 
 
Results 
SCFA receptors are localised within cells containing 5-HT. 
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Pig colon: Co-localisation of SCFA receptors with PYY 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: A representative figure showing co-expression of FFAR2 
and FFAR3 with PYY in pig colon. Localisation of SCFA receptors with 
PYY were assessed in line with the procedure described in figure 3.14. Eight 
adjacent 10µm thick cryo-sections were prepared from frozen gelatin-
sucrose embedded tissue blocks of the ascending colon from four piglets. 
Similar to before, one section was probed with primary antibody (1:100) 
targeting a SCFA receptor (green; B and E) and the adjacent section probed 
with primary antibody (1:100) targeting PYY (red; C and F). To assess 
localisation of SCFA receptors with PYY, two polyclonal donkey-anti-rabbit 
secondary antibodies conjugated to FITC or Cy3 were used. In the absence 
of primary antibody no labelling was observed (negative controls; E and F). 
All images possess a 10µm scale bar and magnified x10 (A and D) or x1000. 
Result 
Colonic SCFA receptors and PYY are localised to the same cell. 
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Summary and discussion 
The data presented in this chapter have shown that FFAR2 and FFAR3 are 
expressed in mouse, pig and human colon indicating the potential ability of 
these tissues to detect SCFA. Moreover, expression levels of FFAR2 and 
FFAR3 mRNA across the longitudinal axes of mouse, pig and human colon 
were similar suggesting that the colonic tissue can detect SCFA along its 
length in a comparable manner.  
At the protein level FFAR2 and FFAR3 were localised to enteroendocrine 
cells found in the colonic crypts of both pig and human tissues. Using pig 
colonic tissue, it was demonstrated that FFAR2 and FFAR3 are present in L-
type enteroendocrine cells expressing GLP-1 and PYY. SCFA receptor 
expression was also shown in enterochromaffin cells possessing 5HT. 
Since the discovery of FFAR2 and FFAR3 it has been known that FFAR3 is 
expressed at highest levels in adipose tissue and at lower levels in colonic 
tissue, while FFAR2 is present at highest levels in polymorphonuclear cells 
(Brown, et al. 2003). Localisation of FFAR2 within colonic tissue was 
reported first in rat (Karaki, et al. 2006) and subsequently in human (Karaki, 
et al. 2008). Later it was demonstrated that FFAR3 is present in human colon 
(Tazoe, et al. 2009). However, the work carried out by Karaki and colleagues 
using commercial antibodies reported localisation of these receptors to 
enteroendocrine cells, mast cells and surface absorptive epithelial cells of 
the colon. To expand Karaki and colleagues (2008) and Tazoe, et al. 2009 
results we employed custom synthesis antibodies under careful optimised 
conditions to perform immunohistochemistry. In our studies, SCFA receptors 
were exclusively localised to enteroendocrine cells of colonic crypts 
expressing PYY. 
In previous studies it was reported that PYY containing enteroendocrine cells 
contain FFAR2 but not 5-HT (Karaki et al. 2006; Karaki et al. 2008), and that 
FFAR3 is localised to enteroendocrine cells containing PYY but not FFAR2 
or 5-HT (Tazoe et al. 2009). Furthermore, it was identified that mast cells of 
the lamina propria expressed FFAR2 and 5-HT (Karaki, et al. 2006). A 
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hormone known to be released from mast cells of lamina propria (Yu, et al. 
1999) and from enteroendocrine (enterochromaffin) cells (Facer et al. 1979).  
We aimed to determine if the SCFA receptors are co-localised with GLP-1 
and 5-HT. Here we have shown that cells expressing SCFA receptors 
possess PYY, 5-HT and also GLP-1. Our findings imply that luminal SCFA 
may mediate secretion of 5-HT and the satiety hormones PYY and GLP-1. 
In summary, the work presented in this chapter has shown that: 
 
 The colon of mice, pigs and humans express FFAR2 and FFAR3. 
 Identification of FFAR3 in pig colon required cloning and sequencing 
of this receptor. 
 Abundance for FFAR2 and FFAR3 mRNA remains constant across 
the longitudinal axis of large intestine in all three species. 
 FFAR2 and FFAR3 are exclusively expressed in the crypt 
enteroendocrine cells of the intestine in pig and human colonic tissue. 
 FFAR2 and FFAR3 are present in the same enteroendocrine L-cells 
possessing GLP-1 and PYY. 
 FFAR2 and FFAR3 reside in enterochromaffin cells possessing 5HT. 
 
Together these results suggest that SCFA receptors may have a number of 
roles in gastrointestinal tract. Firstly, they may be involved in appetite control 
through release of satiety hormones, GLP-1 and PYY. Secondly, they may 
influence gut motility through release of 5-HT. This implies these receptors 
may have important roles in animal welfare and human health and wellbeing 
by influencing gut motility, suppressing appetite and controlling energy 
homeostasis. 
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Chapter Four 
Impact of dietary fibre on SCFA receptor 
expression in the colon 
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The term dietary fibre was first introduced in 1953 (Hipsley.1953). By today’s 
definitions dietary fibres include edible parts of plants and carbohydrates that 
evade digestion and absorption in the small intestine and undergo partial or 
complete fermentation in the colon. Their categorisation takes into account 
both physiochemical properties and their physiological effects. Fibres derived 
from the plant cell wall are consumed as cereals, legumes, fruit and 
vegetables. These are non-starch polysaccharides that include: cellulose, 
hemicellulose, pectin, gums, mucilage and oligosaccharides such as inulin. 
While grain (seeds and corn) and cooked potatoes, fructo-oligosaccharides, 
galacto-oligosaccharides, modified celluloses and synthetic polydextrose are 
considered as resistant starches (Mudgil and Barak. 2013).  
Introduction 
Colonic microflora utilise dietary fibre and resistant starch as an energy 
source generating SCFA as by-products of fermentation. The major SCFA 
produced are acetate, propionate and butyrate with others such as valerate 
and iso-butyrate being produced in minimal quantities. The ratio of SCFA 
produced is dependent on the type and quantity of dietary fibre consumed, 
and proportions of inhabitant bacterial populations (Hernot, et al. 2009; 
Smiricky-Tjardes, et al. 2003). Each day approximately 300mM SCFA are 
generated with only a small proportion being excreted (Hoverstad. 1986). 
Approximately 90% of SCFA produced are absorbed in the colon (Ruppin, et 
al. 1980). Butyrate is of particular importance being the major energy source 
for colonic epithelial cells, maintaining intestinal tissue homeostasis (Cuff and 
Shirazi-Beechey. 2005), and reducing intestinal inflammation (Singh, et al. 
2014).  
In the colonic lumen the majority of SCFA exist in their anionic forms, the 
transport of which across the plasma membrane requires a transporter. It has 
been shown that SCFA are absorbed across the luminal membrane of pig 
and human colon (Ritzhaupt, et al. 1998; Cuff et al. 2002) and equine colon 
(Nedjadi, et al. 2014) by the monocarboxylate transporter 1 (MCT1). 
Furthermore, it has been shown that MCT1 expression is up-regulated by 
increased luminal concentrations of butyrate (Cuff, et al. 2002).  
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The link between dietary fibre and release of satiety peptides has been 
known for over two decades. In early studies the consumption of fermentable 
carbohydrates was shown to increase plasma levels of ‘enteroglucagon’ and 
peptide YY (PYY) in correlation with crypt cell production rates (Goodlad, et 
al. 1987). Later, the ability of SCFA to induce peptide YY secretion was 
identified (Longo, et al. 1991). More recently this effect has been linked to 
SCFA receptors localised to the enteroendocrine cells of the colon. In the 
previous chapter it was shown that the two SCFA receptors, FFAR2 and 
FFAR3 were present in colonic enteroendocrine cells and co-localised with 
PYY, GLP-1 and 5-HT suggestive of their role in appetite control and gut 
motility.  
Several studies have proposed that dietary fibre enhances density of GLP-1 
containing enteroendocrine L cells (Cani, et al. 2007; Kaji, et al. 2011). 
Interestingly, Kaji and colleagues (2011) showed FFAR2 and GLP-1 to 
double in parallel, suggestive of luminal SCFA induced proliferation of 
FFAR2/GLP-1 endocrine cells. This highlights an important role of FFAR2 in 
GLP-1 production and secretion. So the aim of this study was to assess the 
potential effect of dietary fibre on luminal SCFA concentrations, expression of 
SCFA receptors, the genes encoding GLP-1, PYY and SCFA symporter, 
(MCT1). 
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The specific objectives were to assess the effect of dietary fibre on: 
Dietary trials in pigs 
1) SCFA receptor expression across the longitudinal axis of pig colon. 
2) Luminal concentrations of SCFA in pig colon. 
3) Expression of the SCFA transporter, MCT1. 
4) Expression of proglucagon and PYY expression. 
 
Three groups of twenty eight day old piglets were weaned for fourteen days 
onto a hydrolysable carbohydrate (hCHO) diet and two fermentable 
carbohydrate (fCHO) diets. Hydrolysable carbohydrates are those that are 
digested in the small intestine by pancreatic amylase and brush border 
membrane derived disaccharidases into monosaccharides, while fermentable 
carbohydrates are utilised by colonic microflora into SCFA. The information 
below provides a summary of the composition of the hCHO diet and two 
fCHO diets (full compositions are described in Methods). 
Dietary fibre studies 
 
Summary of dietary compositions 
 
 
 
 
 
 
 
hCHO 
 
30% ground wheat 
17.5% Soyabean 
 
 
 
2.6% Total fibre 
 
Digestible Energy 
15.75 
fCHO 1 
 
5 % Ground soya hulls 
0.75% Microfos inulin 
3% Nutriose wheat dextrin 
28% Starch 
7.7% Sugar 
6.6% Total fibre 
 
Digestible Energy 
 16.48 
fCHO 2 
 
5% Unmolassed beet pulp 
0.75% Microfos inulin 
3% Nutriose wheat dextrin 
28% Starch 
8% Sugar 
5.9% Total fibre 
 
Digestible Energy 
16.64 
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Effect of consumption of hydrolysable and fermentable carbohydrates 
on luminal SCFA concentrations in pig proximal colon 
 
 
 
 
 
 
 
 
 
Figure 4.1: SCFA concentrations in luminal content of the ascending 
(proximal) colon of pigs fed different forms of dietary carbohydrates. 
SCFA concentrations were measured by gas-chromatography mass 
spectroscopy as described in Methods. Data represent the mean ± standard 
error of the mean (error bars). Statistical analysis was performed by two-way 
ANOVA with Bonferroni post-test correction (***P<0.001; N = 8). Diets 
represented with coloured bars; □ control diet (hCHO), ■ fermentable diet 1 
(fCHO1) and, ■ fermentable diet 2 (fCHO2).  
 
Results 
Results show the average SCFA concentrations of the ascending colon to be 
70mM acetate (57%) > 40mM propionate (32%) > 20mM butyrate (16%) with 
low amounts of other SCFA to include: iso-butyrate, valerate and iso-valerate 
(data not shown). Statistical analysis revealed SCFA concentrations to be the 
same irrespective of the dietary type.  However, a clear statistical significant 
difference existed between the most abundant SCFA. 
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Influence of consumption of dietary carbohydrates on MCT1 expression 
 
 
 
 
 
 
 
 
 
Figure 4.2: Expression of MCT1 mRNA in the ascending colon of pigs 
maintained on different diets. RNA was isolated as described in Methods 
and MCT1 mRNA expression levels determined by QPCR. All results are 
normalised to β-actin and presented as mean ± standard error of the mean 
(error bars). Statistical analysis was performed by two-way ANOVA with 
Bonferroni post-test correction (**P<0.01; N = 6), A) hCHO (Control diet), B) 
fCHO1, C) fCHO2.  
 
Results 
These results show a 68% and 51% increase in MCT1 mRNA expression in 
response to two fermentable carbohydrate diets fCHO1 and fCHO2 
respectively, compared to the hydrolysable carbohydrate diet.  
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Effect of intake of diet containing different forms of carbohydrate on 
FFAR2 mRNA expression in the pig colon 
 
 
 
 
 
 
 
 
Figure 4.3: A typical graph showing the effect of different diets on 
FFAR2 mRNA expression in pig ascending colon. Three groups of eight 
28 day old piglets were weaned for 14 days onto two different fermentable 
carbohydrate (fCHO) diets and a hydrolysable carbohydrate (hCHO) diet. 
RNA extracted from colonic tissue was used as described in Methods for 
QPCR analysis. All samples were calibrated to a common tissue sample from 
a pig fed the hCHO diet and results normalised to pig β-actin mRNA 
expression. Results presented are samples from the pig ascending colon 
presented as mean ± standard error of the mean (error bars). Statistical 
analysis was performed by two-way ANOVA with Bonferroni post-test 
correction (ns
Results 
P>0.05; N = 6). A) hCHO, B) fCHO1, and C) fCHO2. 
The results of this study show that 1) the expression of FFAR2 mRNA in the 
proximal colon remains constant irrespective of dietary fibre. Furthermore, 2) 
consumption of dietary fibre had no effect on the expression levels of FFAR2 
in caecum, mid colon, distal colon and rectum. The figure above is 
representative of FFAR2 expression in all these regions.  
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Effect of intake of diet containing different forms of carbohydrate on 
FFAR3 mRNA in pig colon 
 
 
 
 
 
 
 
 
Figure 4.4: A typical graph showing the effect of different diets on 
FFAR3 mRNA expression in pig ascending colon. Colonic samples were 
collected from 28 day old piglets weaned for 14 days onto two fermentable 
carbohydrates (fCHO) and the hydrolysable carbohydrate (hCHO) diet. 
FFAR3 mRNA expression was assessed as described in methods. All 
samples were calibrated to a common tissue sample from a pig fed the 
hCHO diet. Data were normalised to pig β-actin mRNA expression and 
results expressed as mean ± standard error of the mean (error bars). 
Statistical analysis was performed using two-way ANOVA with Bonferroni 
post-test correction (ns
Results 
P>0.05; N = 6). A) hCHO, B) fCHO1, C) fCHO2. 
The above results show that levels of FFAR3 mRNA in pig ascending colon 
are unaffected by these dietary fibres compared to hCHO (control). In similar 
studies, the expression of FFAR3 was shown to remain unaltered across the 
longitudinal axis of pig large intestine (caecum, transverse colon, descending 
colon and rectum) and equate to measured levels in the ascending colon. 
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Effect of consumption of different diets on PYY expression 
 
 
 
 
 
 
 
 
 
Figure 4.5: Relative expression of peptide YY mRNA in the ascending 
colon of pigs fed two fCHO and the hCHO diet. The experimental setup 
was as previously described (see figure 4.4). PYY mRNA was as assessed 
as described in Methods. All samples were calibrated to a common tissue 
sample from a piglet weaned onto the hCHO diet. Results were normalised to 
pig β-actin and data presented as mean ± standard error of the mean (error 
bars). Statistical analysis performed by two-way ANOVA with Bonferroni 
post-test correction (*P<0.05, ns
Results 
P>0.05; N = 6). A) hCHO, B) fCHO1, and C) 
fCHO2. 
These results show a statistically significant 1.6 fold increase in PYY mRNA 
in response to consumption of fCHO1 compared to the hCHO diet. However, 
fCHO2 had no effect on PYY mRNA expression. 
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Effect of intake of different diets on proglucagon expression 
 
 
 
 
 
 
 
 
Figure 4.6: Relative expression of proglucagon (GCG) mRNA in pig 
proximal colon in response to different diets. All samples were calibrated 
to a common mRNA isolated from the same tissue as described above and 
normalised to β-actin mRNA. Results are presented as mean ± standard 
error of the mean (error bars). Statistical analysis was then performed by 
two-way ANOVA with Bonferroni post-test correction (ns
 
P>0.05; N = 6). A) 
hCHO, B) fCHO1, and C) fCHO2. 
Results 
Statistical analysis revealed no statistical significant increases in GCG 
mRNA in response to either fermentable carbohydrate diet in comparison to 
a hCHO diet. 
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In this chapter, the concentrations of major SCFA in the luminal content of 
pig ascending colon were not influenced by the dietary type, digestible vs 
fermentable. Average concentrations were: acetate (70mM) > propionate 
(40mM) > butyrate (20mM). A similar ratio was observed across the 
proximal-distal axis of pig colon, however declined aborally with lowest SCFA 
concentrations present in freshly voided faeces (data not shown).  
Summary and discussion 
The proton coupled SCFA symporter (MCT1) was shown to be up-regulated 
in response to intake of dietary fibre, while expression of SCFA receptors, 
FFAR2 and FFAR3 remained constant. Furthermore, while fCHO2 had 
minimal impact on PYY and GCG mRNA expression; fCHO1 was found to 
increase PYY mRNA expression relative to a hCHO diet without affecting 
pro-glucagon expression, the pre-cursor of the satiety peptide GLP-1. 
SCFA concentrations 
It is difficult to interpret SCFA concentrations measured in the colonic lumen 
due to the dynamic nature of the environment. SCFA are continually being 
produced, absorbed, and excreted. For these reasons, SCFA measurements 
reported here are solely representative of SCFA concentrations at a 
particular time-point. In our studies measurements of acetate (70mM) > 
propionate (40mM) > butyrate (20mM) were observed in pig proximal colon 
(Figure 4.1). This is inconsistent with SCFA levels reported from the colonic 
content of human cadavers; 60mM acetate: 20mM propionate: 20mM 
butyrate, a 3:1:1 ratio (Cummings. 1987). This discrepancy can be attributed 
to sample source, sample freshness and perhaps the impact of death on the 
dynamics of the colonic lumen. Therefore our results provide a more 
accurate ex-vivo snap shot. Dietary fibres are known to produce differential 
profiles of SCFA production which have been demonstrated through in-vitro 
fermentation studies (Hernot, et al. 2009; Aguirre, et al. 2014), and also 
reported in colonic content of animal models such as rats (Adam, et al. 
2014). This discrepancy might partly be explained by 1) interspecies 
variation (rodent versus pig), and 2) an enhanced uptake of luminal SCFA. 
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MCT1  
Our results provide evidence that dietary fibres up-regulate MCT1 mRNA 
expression in the colon (figure 4.2), consistent with previous reports (Kirat, et 
al. 2009; Woodward, et al. 2012). MCT1 expression is localised to the 
colonic luminal membrane and is up-regulated in response to butyrate in a 
dose-time dependent manner, while acetate and propionate show no effect 
(Cuff, et al. 2002). This up-regulation occurs through activation of 
transcription and enhanced mRNA stability increasing MCT1 mRNA and 
protein abundance leading to an increase in SCFA transport across the 
colonic luminal membrane (Cuff, et al. 2002). Furthermore, luminal sensing 
of butyrate was been shown to activate GPR109A to cause short-term up-
regulation of MCT1 (Borthakur, et al. 2012). However, the downstream 
signalling pathway by which butyrate activates GPR109A to upregulate 
MCT1 has not been identified. However, it is evident that increased luminal 
SCFA in particular butyrate enhances the SCFA absorptive capacity of the 
colon (Cuff, et al. 2002). Together, this implies that dietary fibre enhances 
SCFA production (particularly butyrate), causing the up-regulation of luminal 
MCT1 expression and increases SCFA absorption. This may provide an 
explanation for our observation of steady state SCFA concentrations 
irrespective of dietary fibre (figure 4.1). 
 
SCFA receptors 
The data presented in this chapter suggests that dietary fibre has no effect 
on expression levels of FFAR2 (Figure 4.3) and FFAR3 (Figure 4.4) in pig 
colon. This is in contrast to previous work that has reported an increase in L-
type endocrine cell number possessing FFAR2 in response to intake of 
dietary fibre in the rat colon measured by immunohistochemistry (Kaji, et al. 
2011). To determine whether differences existed between mRNA and protein 
level recent work in our laboratory has demonstrated that dietary fibre had no 
effect on the number of L-type cells possessing FFAR2 in pig colon (Al-
Rammahi and Shirazi-Beechey. unpublished). Explanations for this 
discrepancy includes: 1) interspecies variation (pig versus rat) and 2) types 
of dietary fibre having different effects, or 3) the immunohistochemical 
method and antibody type used by Kaji, et al. (2011). 
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A recent study has addressed this discrepancy, assessing the impact of 
different types of soluble fibres on expression of SCFA receptors (Adam, et 
al. 2014). FFAR2 mRNA was found to be up-regulated in response to fructo-
oligosaccharide but not pectin or oat β-glycans (in distal ileum). Similarly, in 
the proximal colon of rat FFAR3 mRNA increased in response to fructo-
oligosaccharide and pectin but not oat β-glycans (Adam, et al. 2014). 
However, overall the conclusion of this study was that there were no 
consistent changes in SCFA receptor gene expression. These results 
therefore complement our own observation indicating that the expression of 
SCFA receptors is not influenced by dietary fibre. This implies that luminal 
receptors act as sensors to respond to luminal SCFA. Stimulation may elicit 
changes in gene expression and hormone secretion, the latter acting locally 
or at distant sites to influence various physiological processes. 
 
Satiety peptides GLP-1 and PYY  
Previous studies have demonstrated dietary fibres to have a proliferative 
effect on the intestinal epithelium increasing crypt cell production (Goodlad, 
et al. 1987). This increases the number of each cell lineage and 
subsequently, the number of endocrine L-type cells (Cani, et al. 2007; Kaji, et 
al. 2011). Furthermore, fibre has been shown to promote L-type cell 
differentiation doubling the number of endocrine cells containing GLP-1 
(Cani, et al. 2007). This may provide an explanation for the increase in pro-
glucagon observed in previous studies (Cani, et al. 2004; Cani, et al. 2005). 
However, these results are contradictory to our own findings where the 
proglucagon transcript remains constant irrespective of dietary fibre type 
(Figure 4.6). Potential explanations for these discrepancies include 1) 
species variation (pig versus rat), and 2) different types of dietary fibre 
having differing effects. 
The satiety hormones GLP-1 and PYY are found co-localised in human 
primary L-type endocrine cells (Habib, et al. 2013), with recent evidence 
demonstrating their localisation within separate storage organelles which 
may provide explanation for their selective secretion profiles (Cho, et al. 
2014). In our studies we observe a differential impact of dietary fibre on 
expression of pro-glucagon (gene encoding GLP-1) and PYY mRNA. We 
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observed a 1.6 fold increase in PYY mRNA in response to fCHO1 but not 
fCHO2 when compared to hCHO diet (Figure 4.5). PYY transcript up-
regulation is consistent with previous studies that have shown pectin derived 
from Soya Hulls enhances PYY transcript (Kirat, et al. 2009), and resistant 
starch enhances both transcript expression and secretion of PYY and GLP-1 
(Zhou, et al. 2008). Recently, soluble fermentable fibres fed to rats for four 
weeks were shown to have no effect on PYY and GLP-1 mRNA expression 
but increased their levels in circulation (Adam, et al. 2014), in a dose-
dependent manner (Adam, et al. 2015). This demonstrates that the mode of 
action of some fibres may regulate GLP-1 and PYY secretion independently 
of their effect on gene transcription. This is complementary to our own 
observations suggesting that secretion of PYY and GLP-1 may be regulated 
at post-transcriptional / post-translational levels. 
Overall this chapter has provided evidence to show that in response to 
dietary fibre: 
1) FFAR2 and FFAR3 mRNA expression remains unaltered. 
2) Steady state concentrations of SCFAs remain unaltered. 
3) the SCFA transporter (MCT1) is up-regulated. 
4) the peptide YY mRNA is up-regulated. 
5) the proglucagon (GLP-1) mRNA is unaffected. 
Together, there is accumulating evidence linking dietary fibre to increased 
levels of circulating satiety peptides that suppress appetite, reduce body 
weight and adiposity (Parnell, et al. 2012; Adam, et al. 2014; Adam, et al. 
2015). The SCFA receptor, FFAR2 is believed to have a dominant role in 
secretion of satiety hormones involved in appetite control and energy 
homeostasis (Kaji, et al. 2011; Tolhurst, et al. 2012; Lin, et al. 2012). 
Therefore, the SCFA receptors have important roles and maybe vital for 
animal welfare and human health and wellbeing. Interestingly, localisation of 
FFAR2 in the colon makes the SCFA receptor aborally accessible for 
manipulation and has the potential as a therapeutic target.  
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In 2003, two orphan GPCR (GPR41 and GPR43) were recognised as SCFA 
receptors by several independent studies (Brown, et al. 2003; Le Poul et al. 
2003), and later renamed FFAR2 and FFAR3 (Stoddart, et al. 2008). In these 
early studies it was recognised that FFAR2 and FFAR3 share coupling with 
the pertussis toxin sensitive inhibitory G-protein, G
Introduction 
αi/o signalling, while FFAR2 
also possessed dual coupling to the G-protein, Gq/11 
Monocarboxylates activate SCFA receptors in high µM to low mM 
concentrations with FFAR2 and FFAR3 displaying distinct activity profiles. 
The activity profiles of SCFA receptors in terms of carbon chain length for 
FFAR2 are: C2=C3>C4>C6>C5>C1 and for FFAR3; C3=C4=C5>C6>C2 with 
C1 demonstrating no activity (Hudson, et al. 2013; Brown, et al. 2003; Le 
Poul, et al. 2003). Interestingly, different activity profiles have been reported 
for murine FFAR2 and FFAR3 compared to human SCFA receptors (Hudson, 
et al. 2012). However, a small selection of carboxylic acids with SCFA 
receptor activity have now been identified (Schmidt, et al. 2011), and an ago-
allosteric modulator of FFAR2 synthesised (Lee, et al. 2008; Wang, et al. 
2010), providing useful tools to differentiate between these closely related 
SCFA receptors. 
pathway.  Despite this 
difference both receptors share similar sequence homology; FFAR3 shares 
53% similarity and 43% identity to FFAR2 (Brown, et al. 2003). Common 
endogenous ligands activate these receptors leading to: 1) inositol 1,4,5-
triphosphate formation, 2) ERK1/2 activation, 3) inhibition of cAMP 
accumulation, and 4) intracellular calcium release (Le Poul, et al. 2003). 
Based on immunohistochemical studies presented in this thesis (chapter 3) 
and those by Karaki, et al. (2008), Tazoe, et al. (2009) and Kaji, et al. (2011) 
there is a common agreement that SCFA receptors are expressed in L-type 
enteroendocrine cells. In 2011, it was proposed that FFAR2 plays a role in 
SCFA induced GLP-1 secretion. This was based on findings that the number 
of endocrine cells containing GLP-1 and FFAR2 increased equally in 
response to dietary fibre (Kaji, et al. 2011). FFAR2 involvement was 
supported in subsequent studies involving FFAR2 knockout mice (Tolhurst, 
et al. 2012). In light of these propositions we aimed to clarify the involvement 
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of the SCFA receptor, FFAR2 in SCFA induced GLP-1 secretion using L-type 
enteroendocrine cell lines. 
The objective of this chapter was to: 
1) Determine SCFA induced receptor activation. 
2) Characterise candidate L-type enteroendocrine cell lines. 
3) Assess SCFA induced GLP-1 secretion from selected cell lines. 
4) Evaluate involvement of FFAR2 in SCFA induced GLP-1 secretion. 
 
In order to determine the function of FFAR2 and FFAR3 (SCFA receptors) 
independently, two engineered HEK293 Flp-In
SCFA induced activation of the SCFA receptors  
TM TRExTM
SCFA, acetate, propionate, butyrate and the allosteric modulator of FFAR2, 
4-CMTB (Lee, et al. 2008), were used to stimulate HEK293 Flp-In
 systems were 
generated with inducible FFAR2 or FFAR3 expression (see Methods). 
Engineered in-vitro systems are programmed to express a known receptor 
for activity characterisation (Brown, et al. 2003; Le Poul, et al. 2003). In 
contrast some cell lines of cancerous origin express both SCFA receptors 
simultaneously making single receptor characterisation difficult. It has been 
shown that activation of SCFA receptors lead to changes in intracellular 
calcium (Tolhurst, et al. 2012). Therefore the latter property was used as a 
read out for receptor activation in subsequent experiments.  
TM TRExTM 
FFAR2 or FFAR3 cells that had grown to confluence over two days on 96 
well plates. FFAR2 or FFAR3 expression was induced using doxycycline 20 
hours before assessment. A short-time before measurements cells were 
loaded with a fluorescent dye (FLUO-4 AM) to detect changes in intracellular 
calcium. This allowed receptor activation to be assessed by measuring 
changes in fluorescence detected on molecular devices FLEX Station III (as 
described in Methods). 
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A complication between the two in-vitro systems was that they shared similar 
ligands, a feature which made differentiation between the cell systems 
difficult. For this reason it was necessary to include a cell line specific marker 
as an internal control, and to use a number of novel orthosteric agonists for 
FFAR2 and FFAR3 (Schmidt, et al. 2011).  
Assessment of intracellular calcium in engineered cell lines 
The FFAR2 agonists tested included: 4-CMTB (Wang, et al. 2010), and tiglic 
acid (Schmidt, et al. 2011). A range of concentrations of 4-CMTB, tested 
against a vehicle control, did not lead to any detectable receptor activation. 
Similarly, tiglic acid tested at a range of concentrations (1µM to 1mM) was 
tested against a vehicle control but did not induce calcium responses. 
Two reported FFAR3 agonists were also tested (1µM to 1mM); a 
concentration of 100µM 3-pentenoic acid activated both FFAR2 and FFAR3. 
However, a concentration of 1mM 1-methylcyclopropane carboxylic acid 
demonstrated FFAR3 specific activation. The latter was subsequently used in 
all further experiments. 
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Determining SCFA induced activation of the SCFA receptor, FFAR2 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: SCFA activation of FFAR2. 
HEK293-Flp-InTM TRExTM
 
 cells with inducible expression of FFAR2 were 
stimulated with increasing concentrations of SCFA, acetate, propionate and 
butyrate (dissolved in Tyrode’s buffer). Tyrode’s buffer was used alone in 
each experiment as a negative control. Relative fluorescent units (RFU) were 
calculated by measuring changes in fluorescence divided by the detectable 
base line fluorescence. Results are presented as a non-linear regression 
dose (log) response curves with least square ordinary fit (Hill slope = 1) from 
three independent assays. Data points represent the mean ± standard error 
of the mean, (n = 9). Acetate (red), propionate (green) and butyrate (blue). 
Results 
Acetate, propionate and butyrate activate FFAR2 which is reflected as 
changes in intracellular calcium concentration, with the order of activation 
potency, acetate = propionate > butyrate. 
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Determining SCFA induced activation of the SCFA receptor, FFAR3 
 
 
 
Figure 5.2: SCFA activation of FFAR3. 
HEK293-Flp-InTM TRExTM
 
 cells with induced expression of FFAR3 were 
stimulated with increasing concentrations of acetate, propionate and butyrate 
(prepared in Tyrode’s buffer). Tyrode’s buffer alone was used as a negative 
control in each experiment. The resulting change in fluorescence was used to 
calculate the RFU as described previously. Results are presented as non-
linear regression dose (log) response curves with least square ordinary fit 
(Hill slope = 1). Data from three independent assays are presented as mean 
± standard error of the mean (n = 9). Acetate (Red), Propionate (Green) and 
Butyrate (Blue). 
Results 
It was demonstrated that acetate, propionate and butyrate tested activate 
FFAR3 as seen by changes in intracellular calcium concentration, with the 
order of activation potency, propionate > butyrate = acetate. 
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Effect of butyrate and 4-CMTB on FFAR2 activity 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: A typical scatterplot demonstrating activation of FFAR2 by 
4-CMTB in the presence of increasing butyrate concentrations. 
HEK293 Flp-InTM TRExTM FFAR2 cells were loaded with FLUO-4 AM (as 
described in Methods) and challenged with; A) buffer alone, B) 10µM ATP (a 
known stimulant), C) 10µM 4-CMTB alone, D) 10mM butyrate, E) 10mM 
butyrate with 10µM 4-CMTB, F) 20mM Butyrate with 10µM 4-CMTB, G) 
40mM Butyrate with 10µM 4-CMTB. Changes in intracellular calcium were 
measured to calculate RFU. Results are presented as mean ± standard error 
of the mean (error bars). Statistical analysis was performed using Mann-
Whitney tests to compare columns (**P<0.01, ***P<0.001, ns
 
P>0.05; N = 3).  
Results 
In response to extracellular ATP there was an increase in intracellular 
calcium, indicating cell viability (positive control). Furthermore, there was 
enhancement in intracellular calcium in response to extracellular butyrate. 
However, increasing butyrate concentrations supplemented with 4-CMTB led 
to highest increase in intracellular calcium concentrations. There was no 
effect on intracellular calcium concentration when cells were exposed to 
FFAR2 specific agonist (4-CMTB) alone.  
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Effect of monocarboxylates on FFAR2 activation in the presence or absence of 4-CMTB  
 
 
 
 
 
Carbon Chain 
Length 
Monocarboxylate 
(pH 7.4) 
Monocarboxylate  
(Log EC50) 
Monocarboxylate 
(mM) 
with 4-CMTB 
(Log EC50) 
with 4-CMTB 
(mM) 
C1 Formate -0.96 >100 -2.36 4.40 
C2 Acetate -2.35 4.40 -2.93 1.20 
C3 Propionate -2.13 7.40 -2.30 5.00 
C4 Butyrate -1.79 16.2 -2.48 3.30 
C5 Valerate -2.04 9.10 -3.48 0.30 
C6 Hexanoate -1.86 13.8 -2.70 2.00 
C
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Figure 5.4: Effect of various monocarboxylates in the presence and absence of 4-CMTB on FFAR2 activity. 
HEK293-Flp-InTM TRExTM
 
 cells with induced FFAR2 expression were stimulated by a range of monocarboxylates either alone or 
supplemented with 10μM 4-CMTB, and effects on intracellular concentrations were assessed. Relative fluorescence units (RFU) 
were used to calculate and plot non-linear regression dose (log) response curves with least squares ordinary fit, (Hill slope = 1). 
Data are presented as Log EC50 values and the equivalent concentration, (N = 3). EC50 = concentration required to elicit half the 
maximal dose response. 
Results 
The order of potency of various monocarboxylates to induce intracellular calcium changes, when used alone were 
C2>C3>C5>C6>C4>C1. Inclusion of 4-CMTB with monocarboxylates supported intracellular calcium changes in the order of 
C5>C2>C6>C4>C1>C3. 
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Monocarboxylate induced FFAR3 activity in response to a FFA2 specific agonist, 10µM 4-CMTB 
 
 
Carbon Chain 
Length 
Monocarboxylate 
(pH 7.4) 
Monocarboxylate 
(Log EC50) 
Monocarboxylate 
(mM) 
with 4-CMTB 
(Log EC50) 
with 4-CMTB 
(mM) 
C1 Formate 5.08 NA 5.48 NA 
C2 Acetate -2.40 4.03 -2.22 6.04 
C3 Propionate -2.97 1.07 undetermined undetermined 
C4 Butyrate -2.98 1.05 -3.47 0.34 
C5 Valerate -3.36 0.44 -3.15 0.71 
C6 Hexanoate -3.29 0.52 -3.14 0.72 
C
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Figure 5.5: FFAR3 activity in response to monocarboxylates in the presence and absence of 10μM 4-CMTB 
Dose response curve analysis of monocarboxylates alone or supplemented with 10μM 4-CMTB in HEK293-Flp-InTM TRExTM
 
 cells 
with induced FFAR3 expression, assessed by changes in intracellular calcium. Relative fluorescent units used to represent  the 
detected change in fluorescence over the fluorescent base line were used to plot a non-linear regression dose (log) response curve 
with least squares ordinary fit (Hill slope = 1). These data were used to above to show the concentration required to elicit half the 
maximal dose response as log EC50 values and equivalent millimolar concentrations. Data are presented as an average of three 
experiments of three technical replicates (N = 3). 
Results 
The results indicated that formate (either alone or with 4-CMTB) had no effect on stimulation of FFAR3. However, other 
monocarboxylates stimulated FFAR3 with the order of potency; Hexanoate > Valerate > Butyrate = Propionate > Acetate. Inclusion 
of 4-CMTB with these monocarboxylates had no additional effect on intracellular calcium concentrations. 
 
Collectively, the calcium assay data has shown that there is a differential selectivity for ligands between FFAR2 and FFAR3 in terms 
of carbon chain length, and various known agonists.  
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The second objective of this chapter was to identify and characterise suitable 
in-vitro cell lines and assess their ability to secrete gut hormones in response 
to exposure to SCFA. Four enteroendocrine L-type cells, originating from 
cancerous tissues, have been proposed to secrete satiety hormones 
following nutrient stimulation. These include the two small intestinal derived 
cell lines 1) murine STC-1 cells (Saitoh, et al. 2007) 2) human duodenal 
derived HUTU-80 cells (Rozengurt, et al. 2006), and colonic derived cell lines 
1) murine GLUTag cells (Drucker, et al. 1992) and 2) human NCI-H716 cells 
(Reimer, et al. 2001; deBruine, et al. 1992). The STC-1 cell line was 
disregarded in studies presented in this thesis, due to their small intestinal 
origin and their ability to secrete CCK but not GLP-1 (Daly, et al. 2013). While 
the murine GLUTag and human NCI-H716 cell lines originating from the 
colonic epithelium (Drucker, et al. 1992; de Bruine, et al. 1992), were 
considered suitable for studies on GLP-1 release. Expression of FFAR2 and 
FFAR3 were assessed in GLUTag and NCI-H716 cells, using mouse ileal 
and colonic tissues and human colonic tissue as positive controls 
respectively (see Figure 5.6a & b). The results indicate that GLUTag and 
NCI-H716 cells express both FFAR2 and FFAR3. 
Characterisation of in-vitro enteroendocrine L-type cells 
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FFAR2 and FFAR3 expression in native intestinal tissues and the 
GLUTag cell line. 
 
Figure 5.6a: Expression of FFAR2 and FFAR3 in mice intestine and 
GLUTag cell line. A representative image of products from RT-PCR 
reactions using primers (mouse specific) designed for RT-PCR to show the 
presence of Mouse FFAR2 (Expected: 460bp) and Mouse FFAR3 (Expected: 
229bp) in the ileum and colon of C57/BL6 mice (positive controls) and murine 
derived GLUTag cells. No none-specific primer artefacts were observed 
under reaction conditions in the absence of starting template, negative 
control (data not shown). Lane: 1) Mouse Ileum, 2) Mouse Colon, 3) GLUTag 
cells show FFAR2 expression and 4) Mouse Ileum, 5) Mouse Colon and 6) 
GLUTag cells to represent FFAR3 expression. 
Result 
Sequence analysis revealed that the SCFA receptors, FFAR2 and FFAR3 
are expressed by the GLUTag cell line, mouse ileum and colonic tissue. 
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FFAR2 and FFAR3 expression in native intestinal tissues and the NCI-
H716 cell line. 
 
 
 
 
 
 
Figure 5.6b: FFAR2 and FFAR3 expression in human colonic tissue and 
NCI-H716 cells. A typical image of products from RT-PCR reactions using 
human specific QPCR primers to demonstrate the presence of FFAR2 
(expected: 79bp) and FFAR3 (expected: 72bp) in human colonic tissue 
(positive controls) and the human derived NCI-H716 cell line. Reactions 
absent of starting template (negative controls) revealed none-specific primer 
artefacts downstream of sample take-off values and shown above. Human 
FFAR2: 1) Human colonic biopsy, 2) NCI-H716 cells, 3) negative control, and 
FFAR3: 4) Human colonic biopsy, 5) NCI-H716 cells, 6) negative control.  
 
Results 
Sequence analysis revealed that the SCFA receptors, FFAR2 and FFAR3 
are expressed by the NCI-H716 cell line and human colonic tissue. 
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Further characterisation of the GLUTag and NCI-H716 cell lines  
In order to generally characterise candidate cell lines; NCI-H716, and 
GLUTag cells, mRNA expression of various nutrient sensors (G-protein 
coupled receptors): free fatty acid receptors 1, 2 and 3 (FFAR1, FFAR2, 
FFAR3); taste 1 receptor family members T1R1, T1R2, T1R3; bile acid 
receptor (TGR5); peptone receptor (GPR93); long and medium chain fatty 
acid receptor (GPR120); cannabinoid receptor (GPR119), intestinal nutrient 
transporters: Na+
 
/glucose co-transporter 1 (SGLT1), monocarboxylate 
transporter 1 (MCT1) and satiety hormones: peptide YY (PYY), glucagon 
gene encoding for GLP-1 (GCG); transient receptor potential ion channels 
TRPA1 (receptor for phyto-nutrients or plant extracts) and TRPVI (capsaicin 
receptor) were also investigated. Human and mouse colonic tissues were 
used as positive controls. For comparison the expression profile of the above 
intestinal luminal membrane proteins and gut hormones were also assessed 
in HUTU-80, a human duodenal derived cell line.  In the light of not having 
available human duodenal tissues, this cell line provided a positive control for 
some of the membrane proteins known to be expressed in the small but not 
large intestine (e.g. SGLT1). Results summarised in Figure 5.7 (next page). 
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Assessment to determine expression for various receptors, gut 
hormones and nutrient transporters in native human and mouse 
intestinal tissues and enteroendocrine cell lines. 
 
Target Human NCI-H716 HUTU-80 GLUTag Mouse 
      
FFAR1 + + + ND ND 
FFAR2 + + + + + 
FFAR3 + + + + + 
      
T1R1 + + + + + 
T1R2 + + + + + 
T1R3 + + + + + 
      
TGR5 + + + ND ND 
GPR93 + + + ND ND 
GPR120 + + - ND ND 
GPR119 + + + ND ND 
      
PYY + + - + + 
GCG + + + + + 
      
MCT1 + + + - + 
SGLT1 - - + - - 
      
TRPA1 + + + + + 
TRPV1 + + + + + 
 
 
 
Figure 5.7: Expression of mRNA encoding for intestinal membrane 
proteins and genes encoding for satiety hormones assessed by RT-
PCR. Human or mouse colonic tissues were used as positive controls for 
human derived NCI-H716 cell line and murine derived GLUTag cells,  
respectively. Expression levels are denoted as; (+) = expressed and (-) = not 
expressed. ND = not determined, Human = human colon, mouse = mouse 
colon. 
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Having characterised GLUTag and NCI-H716 cell lines, the next aim was to 
determine their potential to secrete GLP-1 in response to butyrate.  
 
 
GLP-1 secretion from GLUTag cells in response to butyrate and FFAR2 
agonist stimulation 
 
 
 
 
 
 
 
 
Figure 5.8: Butyrate and 4-CMTB induced GLP-1 secretion from GLUTag 
cells. Cells were grown to confluence in 24 well plates and stimulated for two 
hours in the presence of 10mM butyrate or 10μM 4-CMTB and compared to 
the cells exposed to Hanks Balanced Salts Solution, HBSS (used as control). 
Secretion of GLP-1 was measured as described in methods. The amount of 
GLP-1 released following stimulation is presented as percentage of control. 
The data represent the mean ± standard error of the mean (error bar). 
Statistical analysis was performed using One-way ANOVA with Bonferroni 
post-test correction (*P< 0.05 and ***P<0.001; N = 6). A) HBSS buffer alone 
B) 10mM butyrate in HBSS buffer, and C) 10µM 4-CMTB in HBSS buffer. 
 
Results 
Butyrate induced a 1.71- fold increase in GLP-1 secretion and 10μM 4-CMTB 
induced a 2.36 fold increase in GLP-1 release, compared to the control.  
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To determine if growth conditions would influence the expression of FFAR2 
and FFAR3, NCI-H716 cells were grown on Matrigel or in suspension and 
expression levels of SCFA receptors were determined. 
 
mRNA Human Colon 
NCI-H716 
Matrigel 
NCI-H716 
Suspension 
FFAR2 1 22 4 
FFAR3 1 59 106 
 
Figure 5.9: Impact of growth conditions on levels of FFAR2 and FFAR3 
mRNA expression in NCI-H716 cells. mRNA abundance for FFAR2 and 
FFAR3 in human colonic tissue was considered as 1. Expression levels of 
the receptors in NCI-H716 grown either on MatrigelTM
 
 or in suspension were 
compared against that in human tissue. Data presented as an average level 
of expression normalised to human RPII.  
Results 
The results show that NCI-H716 cells grown on Matrigel provide a more 
favourable condition; with enhanced levels of FFAR2 expression and 
reduced levels of FFAR3 in cells grown on Matrigel. Furthermore, it is known 
that NCI-H716 cells grown on Matrigel secrete GLP-1 in response to glucose 
(Jang, et al. 2007). 
 
Therefore, in order to determine functionality of NCI-H716 cells they were 
exposed to different concentrations of glucose known to evoke GLP-1 
release (Figure 5.10). 
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Glucose induced GLP-1 secretion from NCI-H716 cells 
 
 
 
 
 
 
 
 
Figure 5.10: Glucose induced GLP-1 secretion from NCI-H716 cells.  
NCI-H716 cells grown on MatrigelTM to confluence were exposed for two 
hours to glucose at concentrations of 25mM (B) and 50mM (C) or A) buffer 
alone (vehicle control). Data are presented as percentage of vehicle control 
to represent mean ± standard error of the mean (error bars). Statistical 
analysis was performed by one-way ANOVA with Bonferroni post-test 
correction (**P<0.01, ns
 
P>0.05; N = 4). 
Results 
Exposure of NCI-H716 cells to glucose either at 25mM or 50mM, 
concentrations known to evoke GLP-1 release from these cells (Jang, et al. 
2007) resulted in GLP-1 secretion. The amount of GLP-1 release was similar 
at 25mM and 50mM glucose. 
 
Having shown that glucose elicits GLP-1 release, the effect of SCFA on the 
ability of NCI-H716 cells to secrete GLP-1 was determined. 
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GLP-1 secretion from NCI-H716 cells in response to SCFA stimulation 
 
 
 
 
 
 
 
 
 
Figure 5.11: SCFA induced GLP-1 secretion from NCI-H716 cells.  
NCI-H716 cells grown on MatrigelTM were pre-conditioned for four hours in 
low glucose DMEM before two hour stimulation with glucose free Tyrode’s 
buffer (Vehicle control); supplemented with 50mM glucose (Glu), 10mM 
acetate (Act), 10mM propionate (Prop), 10mM butyrate (But), 10mM butyrate 
+10µM 4-CMTB (But + 4-CMTB), or 10µM 4-CMTB alone (Negative control). 
Glucose (50mM) was used as a positive control to show cell functionality. 
GLP-1 secretion data, expressed as percentage of vehicle control are 
presented as the mean ± standard error of the mean (error bar). Statistical 
analysis was performed using Mann-Whitney tests to compare unpaired 
columns (*P<0.05, **P<0.01, ***P<0.001, ns
 
P>0.05; N = 6). 
Results 
Glucose and butyrate alone induced a twofold increase in GLP-1 release. 
Acetate, propionate and 4-CMTB failed to elicit a response. Butyrate 
supplemented with 4-CMTB enhanced GLP-1 secretion by ≈100% compared 
to butyrate alone and 3.3 fold in relation to vehicle control. 
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In order to determine that the cells had maintained their membrane integrity 
following two hour incubation with various compounds, the following 
strategies were used. 
Cellular integrity of NCI-H716 cells following two hour stimulation 
Firstly, a bioluminescence ViaLightTM
  
 assay was employed to measure 
intracellular levels of ATP. Since cell injury leads to rapid decrease of 
intracellular ATP and loss of cell membrane integrity. The cell viability was 
assessed based on a linear relationship between ATP content and the 
luciferase enzyme catalysing formation of light (see Methods). 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Assessment of NCI-H716 cell viability following SCFA 
stimulation. NCI-H716 cells were grown and treated under the experimental 
conditions used to measure GLP-1 secretion (see figure 5.11). For two hours 
cells were exposed to stimulants; Tyrode’s buffer containing no glucose 
(vehicle control), supplemented with 10% Ethanol (Negative control), 50mM 
Glucose (Glu), 10mM Acetate (Ace), 10mM Propionate (Prop), 10mM 
Butyrate (But) or 10µM 4-CMTB. Supernatants were collected and cells 
harvested to measure remaining intracellular levels of ATP in accordance to 
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the manufacturer’s instructions of a ViaLightTM assay. Data are expressed as 
percentage of vehicle control and presented as the mean ± standard error of 
the mean (error bar). Statistical analysis was performed by Mann-Whitney 
tests to compare unpaired columns (***P<0.001, ns
Results 
P>0.05; N = 3). 
NCI-H716 cells exposed to stimulants retained high levels of intracellular 
ATP, demonstrating that NCI-H716 cells remain viable following two hour 
exposure to all stimulants. However, in NCI-H716 cells exposed to 10% 
ethanol (negative control), ATP content was reduced indicating loss of cell 
membrane viability. 
 
Furthermore, levels of lactate dehydrogenase (LDH), a classical marker of 
cellular cytoplasm were determined (see Methods). The rationale is that in 
cells in which the plasma membrane has been disrupted, “leaky cells”, one 
can detect LDH compared to cells retaining their plasma membrane integrity. 
To induce leaky membranes, cells were incubated with 0.2% Triton-X100 to 
induce loss of cell membrane integrity. This led to significant and measurable 
levels of LDH. However, no LDH was detected in supernatants from NCI-
H716 cells that were incubated with various tested compounds for two hours 
(data not shown). This indicates that effects of various agents were not 
through non-specific effects. 
 
In order to determine if exposure of NCI-H716 cells to SCFA leads to 
intracellular calcium release, cells were exposed to various concentrations of 
SCFA, and intracellular calcium was measured using a FLEX station as 
described in Methods.  
SCFA induced intracellular calcium release in NCI-H716 cells  
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Measurement of intracellular calcium in NCI-H716 cells upon SCFA 
stimulation 
 
 
 
 
 
 
 
 
 
Figure 5.13: SCFA induced intracellular calcium changes in NCI-H716 
cells. Changes in intracellular calcium were detected upon stimulation of 
confluent cells pre-loaded with the fluorescent probe, FLUO-4 AM. Results 
are shown as relative fluorescent units (RFU) representing the measured 
change in fluorescence over the observed fluorescent baseline. Data are 
presented as the mean ± standard error of the mean (error bars). Statistical 
analysis was performed using Mann-Whitney tests to compare columns 
(*P<0.05, ***P<0.001; N = 5). A) Control (Buffer alone), B) 100mM Acetate, 
C) 100mM Propionate, D) 40mM butyrate. 
Results  
100mM Acetate, 100mM propionate and 40mM butyrate induced intracellular 
calcium mobilisation in NCI-H716 cells compared to cells exposed to buffer 
alone. The SCFA order of potency was acetate = propionate > butyrate. 
Concentrations of SCFA selected were based on previous results (Figure 
5.1).
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Measurement of intracellular calcium in NCI-H716 cells upon SCFA 
stimulation in presence of 10µM 4-CMTB 
 
 
 
 
 
 
 
 
 
Figure 5.14: Intracellular calcium changes in response to SCFA and 4-
CMTB stimulation. SCFA were supplemented with 4-CMTB and used to 
stimulate confluent NCI-H716 cells grown on MatrigelTM
Results 
 (pre-loaded with 
FLUO-4 AM). Cell responses are shown as relative fluorescent units (RFU), 
representing the detected change in fluorescence over the baseline 
fluorescent signal. Results are presented as mean ± standard error of the 
mean (error bars). Statistical analysis was performed using Mann-Whitney 
tests to compare columns (*P<0.05, *** P<0.001; N = 3). A) Control (Buffer 
alone), B) 10µM 4-CMTB, C) 100mM Acetate with 10µM 4-CMTB, D) 100mM 
Propionate with 10µM 4-CMTB, and E) 40mM Butyrate with 10µM 4-CMTB. 
SCFA supplemented with 4-CMTB evokes significant increases in 
intracellular calcium concentration. In the presence of 4-CMTB the SCFA 
order of potency is changed to: Propionate > Acetate > Butyrate compared to 
using each SCFA alone; acetate = propionate > butyrate (see Figure 5.13). 
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Ligand activation of SCFA receptors 
Summary and discussion 
In 2003, several recombinant cell systems were used to show human SCFA 
receptors may have differential responses to SCFA (Le Poul, et al. 2003). 
These differences were that the activation of FFAR2 by acetate was equal to 
propionate, whilst at FFAR3; propionate was more stimulatory compared to 
acetate (Le Poul, et al. 2003). In the work presented here, human HEK293-
Flp-InTM TRExTM cells with inducible expression of either FFAR2 or FFAR3 
were used to assess the order of SCFA potency at activating the SCFA 
receptors. Our initial findings were consistent with work by Le Poul, et al. 
(2003) and Brown and colleagues (2003). However, extending our studies to 
include monocarboxylates of up to a carbon chain length of six carbons 
demonstrated the order of potency at FFAR2 to be; C2>C3>C5>C6>C4>C1 
(Figure 5.4) while for FFAR3; C5>C6>C4>C3>C2 with C1 having no effect 
on human FFAR3 activity (Figure 5.5). The latter result contradicts those 
previously reported by Brown and colleagues (2003) and Le Poul, et al. 
(2003). However, they are supportive of results published by Hudson and 
colleagues (2012). These differences might be explained by changes in 
constitutive expression of SCFA receptors between batches of cells 
(Hudson, et al. 2012), measurable by incorporation of [35
Orthosteric agonists are ligands that bind and activate receptors through an 
orthosteric binding pocket to elicit intracellular signalling cascades dependent 
on the attached G-protein, a response that can be enhanced in accompany 
of an allosteric agonist. An allosteric agonist can function as a positive or 
negative allosteric modulator of orthosteric agonists by binding to an 
allosteric binding pocket on the receptor. 4-CMTB was the first synthetic 
potent selective agonist of both mouse and human FFAR2 (Lee, et al. 2008). 
Pharmacological investigations have shown that 4-CMTB acts as an ago-
S]GTPγS assays 
(Stoddart and Milligan. 2010), and/or 2) possibly by expression of 
unidentified or an unexpected SCFA receptor, such as the odorant SCFA 
receptor, Olfr78 identified by Pluznick and colleagues (2013), or 3) in-vitro 
system used and/or the cell based assay employed.  
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allosteric modulator functioning at a distinct site, ‘allosteric binding pocket’, to 
endogenous SCFA; the latter stimulate SCFA receptors at an ‘orthosteric 
binding pocket’ within FFAR2 (Smith, et al. 2011). Our results confirm 4-
CMTB to be selective for FFAR2 over FFAR3 in line with findings of Lee, et 
al. (2008), enhancing SCFA activity of FFAR2 as a positive allosteric 
modulator (Smith, et al. 2011), altering the order of potency at FFAR2: 
C5>C2>C6>C4>C1>C3 (figure 5.5). Inconsistent with reports (Smith, et al. 
2011), in our studies 4-CMTB did not act as an ago-allosteric agonist when 
used alone. Potential explanations included: 1) species differences (Hudson, 
et al. 2012), 2) difference in signalling pathway responsive to 4-CMTB and 
SCFA (Smith, et al. 2011), and 3) the cell based assay employed. 
However, SCFA and 4-CMTB do not share a common binding site on FFAR2 
(Smith, et al. 2011). This needs to be kept in mind for interpretation of results 
when 4-CMTB has been used to assess functions of SCFA receptors. To 
assist in differentiation between SCFA receptors and influence of 4-CMTB, 
efforts have been made to identify novel orthosteric activators of FFAR2 
(Hudson, et al. 2013) and allosteric ligands of FFAR3 (Hudson, et al. 2014).  
SCFA induced GLP-1 Secretion 
Our in-vitro studies demonstrated that 10mM butyrate induces GLP-1 
secretion from murine GLUTag cells (Figure 5.8) and human NCI-H716 cells 
(Figure 5.11) following two hour stimulation. A complementary observation 
has been published for the NCI-H716 cell line following overnight incubation 
with butyrate (Yadav, et al. 2013). The latter study reported highest levels of 
GLP-1 release at a concentration of 2mM butyrate and decreasing at higher 
butyrate concentrations. This study has also reported that in response to 2 
mM butyrate there is an increase in expression of pro-glucagon and FFAR3 
mRNA in NCI-H716 cells (Yadav, et al. 2013). This is in contrast to our 
observation. We have shown that pro-glucagon and FFAR3 mRNA 
expression is not affected by exposure of NCI-H716 to butyrate. 
The ability of butyrate to induce GLP-1 secretion has been demonstrated in 
wild type mice (Lin, et al. 2012), and mixed primary cultures from murine 
colon (Tolhurst, et al. 2012). Mixed primary cultures from the colon of FFAR2 
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knockout mice were compared to cultures from wild type mice. It was 
demonstrated that secretion of GLP-1 in response to propionate and acetate 
significantly reduced in cultures from FFAR2 knockout mice. It has been 
proposed that both receptors may be involved, with FFAR2 having the most 
dominant role in GLP-1 secretion (Tolhurst, et al. 2012). In another study, it 
was shown that FFAR3 knockout mice had reduced levels of plasma GLP-1 
following ingestion of butyrate (Lin, et al. 2012). However, involvement of 
FFAR2 was not taken into account in this study. 
Tolhurst and colleagues (2012) reported that acetate, propionate and 
butyrate (1mM) induced GLP-1 secretion from mixed primary cultures from 
murine colon. However, the GLUTag cell line was unresponsive to 1 to 
10mM acetate, propionate and butyrate (Tolhurst, et al. 2012). These 
observations are consistent with our findings where acetate and propionate 
(10mM) failed to induce GLP-1 secretion from either GLUTag or NCI-H716 
cells. The reasons why acetate and propionate do not induce GLP-1 release 
are not known. It has been suggested that this may be due to low expression 
levels of FFAR2 in GLUTag cells or low concentrations of SCFA used in this 
study. 
It should be noted that although acetate and propionate do not induce GLP-1 
release from cell lines, we have observed that butyrate elicits secretion of 
GLP-1. It can be proposed that in NCI-H716 there is higher binding affinity 
for butyrate on the receptor compared to that for propionate or acetate. 
Alternatively, one may propose that acetate and propionate do not bind to 
the receptor.  To answer these questions competition studies with high 
concentrations of acetate and propionate (100mM) in the presence of low 
concentrations of butyrate (1-10mM) need to be carried out.  
N
 
iacin receptor (GPR109A) has been shown to be responsive to butyrate. 
However, to date no studies have been carried out to assess expression of 
GPR109A in enteroendocrine L cells and its potential involvement in GLP-1 
secretion.   
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Our results provide supportive evidence for the role of FFAR2 in SCFA 
induced GLP-1 secretion. This is demonstrated by observations that a 
specific agonist of FFAR2, 4-CMTB, induces GLP-1 secretion from GLUTag 
cells (Figure 5.8), and has a synergistic effect on butyrate induced GLP-1 
secretion from NCI-H716 cells (Figure 5.11). The observation that 4-CMTB 
alone can activate FFAR2 in GLUTag cells leading to GLP-1 release, but 
needing to be combined with butyrate to exert this effect in NCI-H716 cells 
requires further investigations. While one can come up with a number of 
models, extensive research is required to answer these different cellular 
responses. 
Signalling pathways downstream of receptor activation 
Previous studies have shown nutrient induced GLP-1 secretion to be 
accompanied with changes in intracellular calcium concentrations in murine 
GLUTag cells (Parker, et al. 2012) and human NCI-H716 cells (Le Neve and 
Daniel. 2011). This pathway is linked to SCFA activation of FFAR2 working 
via the Gq pathway (Tolhurst et al. 2012). Tolhurst, et al. (2012) reported that 
acetate, propionate and CFMB (FFAR2 agonist) induces calcium responses 
in cultures of primary colonic L cells. This is consistent with involvement of 
FFAR2 and Gq
In our findings, the addition of 4-CMTB to SCFA had a synergistic effect in 
increasing intracellular calcium concentrations which may imply involvement 
of FFAR2. It would have been worth measuring calcium responses at lower 
SCFA concentrations. 
 pathway.  
Regarding the G proteins involved in signal transduction, FFAR2 couples to 
Gq and Gi/o whilst FFAR3 works in association with the Gi/o pathway. There 
is experimental evidence that the Gq pathway participates in FFAR2 induced 
GLP-1 release (Tolhurst, et al. 2012), and that propionate induced GLP-1 
secretion is not significantly reduced by pertussis toxin suggesting minimal 
involvement of the Gi pathway. It has been proposed that gustducin knockout 
mice secrete low levels of GLP-1 compared to wild-type littermates following 
SCFA stimulation (Li, et al. 2013). Whilst the latter findings suggested that 
gustducin may participate in the pathway leading to GLP-1 release, it does 
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not provide any evidence supporting the participation of FFAR2 in this 
pathway. GLP-1 is secreted in response to a number of luminal nutrients 
such as fat and carbohydrates independently of any involvement of FFAR2 
(or FFAR3).  
So the most acceptable model is to propose that activation of FFAR2 via 
luminal butyrate (or 4-CMTB) stimulates Gq pathway. The Gq protein works 
via phospholipase C (PLC) and inositol 1, 4, 5-trisphosphate (IP3) pathways. 
IP3 binding to IP3
 
 receptors, particularly calcium channels in the endoplasmic 
reticulum causes the cytosolic concentration of calcium to increase, leading 
to a cascade of intracellular events resulting in cell depolarization and 
release of GLP-1 (Alberts, et al. 2002), illustrated in figure 5.15 (next page). 
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Figure 5.15: An illustration of a proposed model of butyrate induced 
GLP-1 secretion. Butyrate and 4-CMTB stimulate FFAR2 causing activation 
of the Gαq 
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pathway. Stimulation of protein lipase C (PLC) cleaves 
phosphatidylinositol 4, 5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol trisphosphate (IP3). While DAG is recruited to the plasma membrane 
stimulating protein kinase C (PKC), IP3 triggers activation of IP3 receptors 
on smooth endoplasmic reticulum to cause release of intracellular calcium 
stores. Ultimately, cell depolarisation evokes glucagon like peptide 1 (GLP-1) 
release into the blood stream and causes activation of specific receptors on 
afferent neurons relaying signals to appetite centres of the brain. 
Butyrate & 4-CMTB 
173 
 
 
 
 
 
 
 
 
 
 
Chapter Six 
FFAR2 involvement in butyrate induced 
GLP-1 secretion 
 
 
 
 
 
 
 
 
 
Chapter Six 
174 
In 2011, it was proposed that FFAR2 has an important role in SCFA induced 
secretion of GLP-1 (Kaji, et al. 2011). Subsequently various studies 
assessed the roles of FFAR2 and FFAR3 in SCFA induced GLP-1 secretion 
(Tolhurst, et al. 2012; Lin, et al. 2012). Tolhurst, et al (2012) used various 
strategies such as using 1) primary L-cells isolated from intestines of mice in 
which genes for FFAR2 and FFAR3 were deleted (knockout mice), 2) an 
agonist of FFAR2 (S)-2-(4-chlorophenyl)-
Introduction 
N-(5-fluorothiazol-2-yl)-3-
methylbutanamide (CFMB) and 3) pertussis toxin (PTX) an inhibitor of the 
inhibitory G-protein (Gi) and concluded that FFAR2-dependent Gαq 
 
pathway 
may have a dominant role in SCFA induced GLP-1 release (Tolhurst, et al. 
2012). This conclusion was based on findings that 1mM propionate induced 
GLP-1 secretion was not significantly reduced by PTX treatment, and FFAR2 
specific agonist enhanced changes in intracellular calcium strongly implicate 
involvement of FFAR2 mediated pathways (Tolhurst, et al. 2012). However, 
in this study involvement of FFAR2 was suggested for acetate, propionate 
but not butyrate (Tolhurst, et al. 2012). Butyrate induced GLP-1 secretion 
has been demonstrated in NCI-H716 cells (Yadav, et al. 2013), and shown to 
be reduced in FFAR3 knockout mice (Lin, et al. 2012). However, this latter 
study did not take into account involvement of FFAR2. Therefore our studies 
aimed to bridge this gap assessing involvement of FFAR2 in butyrate 
induced GLP-1 secretion. 
Alternative strategies to differentiate between the roles of these receptors 
involved in SCFA-induced gut hormone release include the use of specific 
antagonists of SCFA receptors and RNA interference technology. However, 
availability of SCFA receptor antagonists is currently limited to β-
hydoxybutyrate, a reported FFAR3 antagonist (Kimura, et al. 2011), and 
RNA interference has only been used to show SCFA induced inhibition of 
adipocyte differentiation through FFAR2 (Hong, et al. 2005). No such 
strategy has been used to assess involvement of FFAR2 in intestinal satiety 
hormone release. 
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RNA interference (RNAi) is a highly conserved sequence specific gene 
silencing mechanism naturally occurring in organisms (Elbashir, et al. 2002). 
It is now possible to silence genes in-vitro using human cell models 
(Elbashir, et al. 2001). Today, this technology is considered a valuable tool 
for in-vitro functional studies with capacity to selectively knockdown genes 
both short-term and long-term (Chen and Jianping. 2012). Importantly, short-
term gene silencing has had successes in the NCI-H716 cells with reports 
elucidating involvement of GPCR nutrient receptors in GLP-1 secretion via 
short interference RNA, siRNA (Kim, et al. 2014; Lauffer, et al. 2009). To our 
knowledge no attempt has been made to elucidate the involvement of 
FFAR2 in butyrate induced GLP-1 secretion using in-vitro NCI-H716 cells. 
To this end, the objectives of this chapter were to: 
1) Assess expression of SCFA receptors at protein level in NCI-H716 
cells. 
2) Use siRNA to knockdown FFAR2 expression in NCI-H716 cells. 
3) Assess FFAR2 involvement in butyrate induced GLP-1 release. 
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In order to determine if the human L-type endocrine cells (NCI-H716) 
express FFAR2 and FFAR3, western blot analyses using specific antibodies 
to these receptors were carried out. 
Expression of SCFA receptors at protein level in NCI-H716 cells 
 
Western blot analysis of FFAR3 in the NCI-H716 cell line 
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Figure 6.1: Western blots of FFAR3 protein expression in NCI-H716.  
Representative images of four PVDF membranes from 12% (v/v) SDS-PAGE 
(1mm) gels loaded with 40µg protein (15µl) per lane of prepared PNMFs. 
Following the protocol described in methods, primary antibody was incubated 
overnight at 4°C (1:500) in TBS-MT (top) or TBS-CT (bottom). Then 
membranes were probed with secondary antibodies as described in 
methods. Immuno-blots were prepared by exposing the film for 2 minutes 
(left) and 5 minutes (right). AAC1 cells are a model of epithelial cells that do 
not express FFAR3 (Lane 2: negative control), while HT-29 cells contain 
FFAR3 expression (Lane 3: positive control). Lane 4 represents NCI-H716 
cells grown in suspension while PNMFs of NCI-H716 cells grown on Matrigel 
are presented in Lane 5. PageRulerTM
 
 was used as an indicator of molecular 
weight (Lane 1). 
Results:  
FFAR3 protein was detected in NCI-H716 cells grown in suspension and 
grown on Matrigel in comparison to the expression levels in colonic epithelial 
AAC1 cells that do not express FFAR3 (negative control), and the HT-29 
cells that do express FFAR3 (positive control). Bands of an expected size of 
approximately 37kDa were detected but also bands of ≈45kDa were 
observed. 
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Western blot analysis of FFAR2 in the NCI-H716 cell line 
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Figure 6.2: Western blots of FFAR2 protein expression in NCI-H716 
cells. Representative images of four PVDF membranes of 12% SDS-PAGE 
gels (1mm) loaded with 40µg protein (15µl) lane-1 of prepared PNMFs. 
Following the protocol described in methods, primary antibody (FFAR2) was 
incubated overnight 4°C (1:500) in TBS BSA-T. Then membranes were 
washed and probed with secondary antibody as described in methods. The 
above immuno-blots were prepared by exposure to film for 1 minute (A), 2 
minutes (B), 5 minutes (C) and 10 minutes (D). As before; AAC1 cells not 
expressing FFAR2 were used as a negative control (Lane 1), HT-29 cells 
expressing FFAR2 was used as a positive control (Lane 2). PNMFs from 
NCI-H716 cells grown in suspension (Lane 3), and NCI-H716 cells grown on 
MatrigelTM (Lane 4) were assessed for expression of FFAR2 protein using 
PageRulerTM
 
 (Lane 5) as an indicator of molecular weight.  
Results 
FFAR2 was detected (expected size 37kDa) in NCI-H716 cells in suspension 
and cells grown on MatrigelTM
 
 in relation to negative control (AAC1 cells) but 
much lower than a positive control (HT-29 cells). Also, bands of ≈45kDa and 
>70kDa were observed. 
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Three siRNA (21-oligonucleotide) duplexes specific for FFAR2 were used for 
initial assessment. Cells were seeded onto Matrigel the night before forward 
transfection as previously described. Cells were transfected with 100nM of 
siRNA duplex using Lipofectamine
Knockdown of FFAR2 expression using siRNA in NCI-H716 cells 
® 
 
3000 (as described in methods). 
Following 48 hours cells of siRNA treatment were harvested for RNA 
isolation. Expression levels of FFAR2 were assessed by QPCR as described 
in methods. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Screening of siRNA duplexes for FFAR2 knockdown.  
FFAR2 knockdown was assessed by QPCR using samples from NCI-H716 
cells transfected with siRNA duplexes compared to a scrambled siRNA 
duplex (negative control). All samples were normalised to β-actin reference 
control. Results are presented as mean ± standard error of the mean (error 
bar). Statistical analysis was performed Mann-Whitney tests to compare 
columns (*P<0.05; N = 3). A) Control, B) siRNA duplex I, C) siRNA duplex II, 
D) siRNA duplex III. 
 
Results 
All three siRNA duplexes caused a statistically significant knockdown of 
FFAR2; 26.4% duplex I, 20.4% siRNA duplex II and 23.5% duplex III. 
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Since all three siRNA duplexes demonstrated ability to knockdown FFAR2 
expression to a similar level, the time dependent effect was investigated.  
Time-dependent kinetics of FFAR2 knockdown 
 
 
 
 
 
 
 
 
 
Figure 6.4: Time-dependent kinetics of FFAR2 knockdown 
Time-dependent kinetics of FFAR2 mRNA knockdown in transfected NCI-
H716 cells were analysed by QPCR at a 24 hour time interval against a time 
matched negative control for 96 hours. All samples were normalised against 
a human β-actin loading control. Results are presented as mean ± standard 
error of the mean (error bar). Statistical analysis was performed by Mann-
Whitney tests (*P<0.05, ns
Results 
P>0.05; N = 3). A) Time matched Control, B) 24 
hours, C) 48 hours, D) 72 hours, and E) 96 hours. 
FFAR2 mRNA expression was reduced by 12.8% (24 hours), 25.6% (48 
hours), 22.8% (72 hours) and 26.5% (96 hours) compared to a time-matched 
negative control (scrambled siRNA). The time point of 72 hours was used in 
subsequent experiments. 
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Effect of increased concentrations of siRNA on FFAR2 knockdown  
 
 
 
 
 
 
 
 
 
Figure 6.5: Concentration-dependent knockdown of FFAR2.  
NCI-H716 cells grown on MatrigelTM were transfected with increasing 
concentrations of FFAR2 siRNA duplex II using Lipofectamine® 3000 in 
accordance to manufactures instructions. After 72 hours cells were 
harvested for RNA isolation and then processed as described in methods for 
QPCR. FFAR2 knockdown was compared to time-matched control 
(scrambled siRNA). All samples were normalised against human β-actin 
loading control. Results are presented as mean ± standard error of the mean 
(error bars). Statistical analysis assessment was performed using Mann-
Whitney tests to compare columns (*P<0.05, **P<0.01, ns
 
P>0.05; N = 3). A) 
Scrambled siRNA (time-matched control), B) 100nM, C) 200nM, D) 400nM. 
Results 
NCI-H716 cells grown on MatrigelTM
A 
 were treated with FFAR2 siRNA for 72 
hours using concentrations; 100nM, 200nM and 400nM. QPCR analysis 
revealed statistically significant reductions in relative abundance of FFAR2 
mRNA by 18% (100nM), 45% (200nM) and 35% (400nM). However, no 
statistically significant reduction was observed in FFAR2 expression between 
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200nM and 400nM. Therefore, all subsequent experiments were performed 
using 200nM siRNA targeting FFAR2 knockdown.  
The effect of inhibition of FFAR2 expression in butyrate-induced GLP-1 
secretion was determined in cells in response to butyrate. 
FFAR2 involvement in SCFA induced GLP-1 secretion 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: FFAR2 involvement in butyrate induced GLP-1 secretion. 
FFAR2 siRNA was transfected into NCI-H716 cells using Lipofectamine®
 
 
3000 in accordance to manufacturer’s instructions (as described in methods). 
After 72 hours cells were preconditioned for 4 hours in low glucose DMEM 
before 2 hour exposure to 10mM butyrate. Supernatants were collected and 
used to measure GLP-1 secretion in A) cells transfected with scrambled 
siRNA, B) cells transfected with FFAR2 specific siRNA, C) cells transfected 
with scrambled siRNA and exposed to 10mM butyrate and D) cells 
transfected with FFAR2 specific siRNA and exposed to 10mM butyrate. 
Results are presented as mean ± standard error of the mean (error bars). 
Statistical analysis was performed using Mann-Whitney tests to compare 
columns (**P<0.01; N = 4). 
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Results 
10mM butyrate induced a 262% increase in GLP-1 secretion from cells 
transfected with scrambled siRNA in comparison to control cells exposed to 
Tyrode’s buffer following 72 hours treatment with scrambled siRNA. In NCI-
H716 cells transfected with FFAR2 siRNA there was less GLP-1 secretion. 
However, this reduced response was not statistically significant.  
 
Membranes isolated from NCI-H716 cells grown in suspension and on 
Matrigel expressed FFAR2 and FFAR3 proteins. However, the expression 
levels were lower in cells grown on Matrigel compared with those present in 
suspension. 
Summary and discussion 
RNA interference was used to determine involvement of FFAR2 in butyrate 
induced GLP-1 secretion. After NCI-H716 cells were treated 72 hours with 
siRNA targeting FFAR2 or scrambled siRNA (control) cells were stimulated 
two hours with Tyrode’s buffer alone or supplemented with 10mM butyrate. 
Assessment of siRNA treated cells revealed a statistically significant 
reduction in FFAR2 mRNA (45%) compared to scrambled siRNA treated 
cells. Furthermore, measurement of GLP-1 secretion provided suggestive 
evidence of reduced GLP-1 release from FFAR2 siRNA treated cells. 
FFAR2 and FFAR3 protein expression in NCI-H716 cells 
In this chapter it has been shown FFAR2 and FFAR3 proteins are expressed 
in the NCI-H716 cell line, the experimental enteroendocrine cell line used in 
this study. FFAR3 protein expression is less abundant than in HT-29 cells 
(positive control). Furthermore, FFAR3 protein expression appeared more 
prominent than FFAR2 (Figure 6.1 and Figure 6.2) in NCI-H716 cells. 
Although further evidence is necessary to support this observation it is in line 
with evidence from the in-vitro murine GLUTag cells; another L cell model 
with low levels of FFAR2 expression (Tolhurst, et al. 2012), and enhanced 
levels of FFAR3. This may be a common feature of SCFA receptors in 
enteroendocrine cell lines which have a cancerous origin compared to 
normal cell lineages (Wu, et al. 2012). Growing NCI-H716 cells on Matrigel 
further reduced expression of FFAR2 and FFAR3 at protein level. This might 
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be attributed to the ability of Matrigel to influence gene expression and its 
role in NCI-H716 cell differentiation (de Bruine, et al. 1992; Kleinman and 
Martin. 2005). 
The apparent molecular weight of FFAR2 and FFAR3 is 37kDa. However, 
using western blot analysis in NCI-H716 cells, a number of bands with a 
range of molecular weights were detected (Figure 6.1 and Figure 6.2). These 
results are consistent with findings from reports using pig (Li, et al. 2014) and 
human colonic tissues (Karaki, et al. 2008; Tazoe, et al. 2009), and they may 
be due to different forms of the same protein, or non-specific binding of the 
antibody. It has been proposed that larger size bands may be due to protein 
modifications after translation, a common feature shared among GPCR. One 
such modification is N-link glycosylation that provides GPCR molecular 
stability, promotes cell surface expression and can modulate ligand binding 
activity (Trombetta. 2003). To provide an example, the structure of FFAR3 
has N-linked glycosylation site (N166) in the ECL2. It also has other 
modification sites such as one PKC site (S216), two combined PKA/PKC 
phosphorylation sites (T328/329) and a palmitoylation site (C295) at the C 
terminus (Sawzdargo, et al. 1997). In 2009, FFAR3 localised to the colonic 
lumen was confirmed to be N-linked glycosylated possessing several other 
yet undetermined modifications (Tazoe, et al. 2009). A noteworthy 
observation is that both apparent theoretical and modified protein bands are 
present. One interpretation would be that NCI-H716 possesses modified 
SCFA receptors at the cell membrane but also unmodified proteins within 
intracellular stores, such as the Golgi apparatus and/or endoplasmic 
reticulum (Tazoe, et al. 2009). This could be confirmed with organelle 
markers or comparing brush border membrane fractions (BBMFs) with 
PNMFs used within this thesis. A feature of NCI-H716 differentiation is 
reduced levels of modified protein of both SCFA receptors suggesting that 
MatrigelTM
 
 may reduce levels of SCFA receptors on the cell surface 
membrane.  
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RNA interference: FFAR2 knockdown in human NCI-H716 cells  
Several rodent studies have implicated involvement of FFAR2 in SCFA 
induced GLP-1 secretion (Kaji, et al. 2011; Tolhurst, et al. 2012). NCI-H716 
cells were shown to secrete GLP-1 in response to butyrate (Yadav, et al. 
2013), complimentary to our own observation (Figure 6.6). However, to date 
no investigations have been carried out to identify the mechanism involved in 
SCFA induced GLP-1 secretion from human NCI-H716 cells. For this reason 
our objective was to evaluate the involvement of FFAR2 in butyrate induced 
GLP-1 secretion by long or short-term RNA interference.  
Long-term interference (shRNA) 
Our initial focus was to induce permanent FFAR2 knockdown using shRNA. 
This involved generation of a stable NCI-H716 cell population demonstrating 
FFAR2 knockdown under antibiotic selective pressure (Lanza, et al. 2013). 
This strategy used five FFAR2 plasmids containing a puromycin resistance 
gene and FFAR2 targeted shRNA which were transfected into NCI-H716 
cells. Several optimisations were made to establish a delivery platform (poly-
L-lysine), the transfection strategy (Lipofectamine® 3000) and the necessary 
puromycin concentration (4µg/ml) needed for effective selective pressure. 
Following optimisations and ten weeks of culture, five puromycin resistant 
cultures were identified with differing degrees of FFAR2 knockdown. The 
most successful transfection strategy (low-speed centrifugation) 
demonstrated approximately 60% knockdown, an enhancement of ≈25% 
from forward transfection. This is complimentary to a report that showed low 
speed centrifugation to improve siRNA transfection efficiency in suspended 
cells (Majumdar, et al. 2014). However, plating these cells onto Matrigel for 
48 hours under conditions used to measure GLP-1 secretion caused an 
increase in FFAR2 transcript when compared to cells treated with a 
scrambled control. This observation can be attributed to Matrigel’s effect on 
gene expression (de Bruine, et al. 1993; Kleinman and Martin. 2005). In 
hindsight, given protein expression of the SCFA receptors in suspended NCI-
H716 cells is greater than NCI-H716 cells grown on MatrigelTM. It would have 
been worth exploring Poly-D-lysine as an alternative platform to perform 
these knockdown studies and investigate butyrate induced GLP-1 secretion. 
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Attention shifted toward an alternative strategy to knockdown FFAR2. To this 
end, given the reported success of FFAR2 knockdown using siRNA (Hong, 
et al. 2005), and using siRNA in our laboratory to investigate amino acid 
induced CCK secretion from STC-1 cells (Daly, et al. 2013), attention shifted 
toward short-term FFAR2 knockdown using siRNA targeting FFAR2. 
FFAR2 knockdown; siRNA optimisation  
In our initial assessment using three siRNA duplexes, there was 
approximately 20% reduction in FFAR2 expression in all cases under 
experimental conditions (Figure 6.3). By increasing siRNA concentration to 
200nM, FFAR2 knockdown was enhanced by approximately 45% when NCI-
H716 cells were cultured on Matrigel for 72 hours (Figure 6.5). In hindsight, 
further optimisation to reach 70-80% knockdown would have been desirable. 
This might have been achieved by 1) pooling siRNA duplexes, 2) assessing 
siRNA duplexes from other suppliers, 3) and/or using a poly-L-lysine platform 
instead of MatrigelTM
Our results show that 10mM butyrate induces a 262% increase in GLP-1 
secretion from NCI-H716 cells compared cells treated with scrambled siRNA. 
In cells transfected with FFAR2 specific siRNA there was a 45% decrease in 
FFAR2 mRNA expression with a 28% reduction in total GLP-1 secreted. This 
result suggests FFAR2 is involved in butyrate induced GLP-1 secretion. This 
is supported by SCFA induced changes in intracellular calcium which are 
enhanced in the presence of a FFAR2 allosteric modulator (previous 
chapter). However, statistical analysis indicated the level of FFAR2 
knockdown was not significant, making results inconclusive. Further 
experiments are needed to increase sample numbers to provide clarification. 
Our finding that 4-CMTB (agonist of FFAR2, see previous chapter) induces 
GLP-1 release is supportive of a role for FFAR2 in butyrate induced GLP-1 
release. Further work is warranted to clarify the role of human FFAR2 in 
GLP-1 secretion using NCI-H716 cells or another human in-vitro model, such 
as the HUTU-80 cell line using siRNA.  
.  
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In summary, this chapter has used NCI-H716 cells to show that: 
• FFAR2 and FFAR3 proteins are expressed in NCI-H716 human 
enteroendocrine cell line. 
• RNA inference caused a reduction in FFAR2 mRNA 
• FFAR2 is a good candidate for butyrate induced GLP-1 secretion from 
enteroendocrine cells. 
Together, these results suggest FFAR2 could be involved in butyrate 
induced GLP-1 secretion. However, further work is required to 
understand the shortfall and limitations in siRNA technology used in this 
study.  
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In recent years, dietary fibres have been shown to be involved in 
suppression of appetite and weight management. This has renewed 
research interest in the role of fibres in controlling obesity. Dietary fibre is not 
hydrolysed in the small intestine and reaches the large intestine. Colonic 
microflora utilise fibre as an energy source for fermentation yielding 
monocarboxylates. The three major monocarboxylates commonly termed 
short chain fatty acids (SCFA) are acetate, propionate and butyrate. These 
SCFA contribute to energy homeostasis and appetite control through multiple 
pathways and SCFA receptors.  
General discussion and future directions 
In the colon, butyrate provides energy for colonic epithelial cells with ability to 
increase SCFA transport by up-regulating the expression of 
monocarboxylate transporter 1 (MCT1) in a dose and time dependent 
manner. The underlying mechanism is through increasing MCT1 
transcription, mRNA stability (Cuff et al. 2002), and luminal activation of the 
SCFA receptor, GPR109A (Borthakur, et al. 2012). 
It has been reported that luminal SCFA induce hormone secretion through 
FFAR2 (Tolhurst, et al. 2012) and FFAR3 (Lin, et al. 2012). Following 
absorption, propionate is a precursor of glucose production in the liver, 
influencing feeding behaviour through hepatic vagal afferent nerves 
(Mithieux. 2014). While acetate is utilised by peripheral tissues, where it 
stimulates leptin secretion from adipocytes (Zaibi, et al. 2010), and has a 
central role in appetite control (Frost, et al. 2014). Butyrate and propionate 
are reported to protect against diet induced obesity in a FFAR3 independent 
mechanism (Lin, et al. 2012), implying FFAR2 involvement.  
SCFA have been shown to stimulate GLP-1 secretion from murine primary L 
cell cultures (Tolhurst, et al. 2012), rodents (Lin, et al. 2012; Psichas, et al. 
2014), and the NCI-H716 cell line (Yadav, et al. 2013). The involvement of 
SCFA receptors, FFAR2 and FFAR3, in SCFA-induced GLP-1 secretion are 
supported in studies involving knockout mice (Tolhurst, et al. 2012; Lin, et al. 
2012). However, the contribution of FFAR2 and FFAR3 remains a matter of 
debate. In 2012, evidence was provided to support involvement of the 
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FFAR2-Gαq
Work presented in this thesis has shown that FFAR2 and FFAR3 expression 
levels are constant across the longitudinal axes of mouse, pig and human 
colon. This suggests that colonic regional expression of these receptors is 
similar across mammalian species. Immunohistochemistry has demonstrated 
SCFA receptor localisation deep in colonic crypts within enteroendocrine 
cells, and co-localised with hormones, GLP-1, PYY and 5-HT. This suggests 
that SCFA may induce secretion of multiple hormones which provides 
potential areas of future research in gut motility, appetite control and energy 
homeostasis. These studies will have important impact to animal welfare and 
human health and wellbeing. 
 pathway in GLP-1 secretion (Tolhurst, et al. 2012). While 
another report suggested that FFAR3 is needed for maximal butyrate-
induced GLP-1 secretion (Lin, et al. 2012). However, participation of 
GPR109A in butyrate induced GLP-1 secretion remains undetermined.  
In pig colon luminal SCFA concentration and abundance of SCFA receptors 
were shown to remain constant irrespective of dietary type (digestible vs 
fermentable). However, the expression of SCFA transporter (MCT1) was 
enhanced in response to dietary fibre allowing the potential for enhanced 
uptake of SCFA. Furthermore, it was found that dietary fibre had a differential 
impact on satiety peptide expression, enhancing PYY mRNA while having no 
influence on GLP-1 precursor, proglucagon mRNA. Current research 
investigating the impact that different types of dietary fibre have on gut 
physiology, appetite control and energy homeostasis may in the future see 
dietary fibre become an intervention against the rising incidence of obesity.  
The use of in-vitro cell lines demonstrated 1) SCFA induced activation of 
FFAR2 and FFAR3, 2) the specificity of 4-CMTB for FFAR2 and its ability to 
enhance potency of SCFA action. Butyrate was shown to induce GLP-1 
secretion from murine GLUTag cells and human NCI-H716 cells. Attempts 
were made to determine involvement of FFAR2 in butyrate induced GLP-1 
secretion from NCI-H716 cells using siRNA technology. However, results 
were inconclusive, indicating the need of further work to elucidate roles of 
SCFA receptors; FFAR2, FFAR3 or GPR109A in GLP-1 secretion. 
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Identification of the receptor involved will enable elucidation of the 
downstream signal transduction pathway involved in SCFA induced satiety 
hormone release. The work presented in this thesis is a small step toward 
understanding the SCFA receptor involvement and the pathway participating 
in GLP-1 secretion.  
It is worth highlighting that butyrate induced GLP-1 secretion was reported to 
involve FFAR3 in mice (Lin, et al. 2012), indicating consideration ought to be 
made for FFAR3 involvement in NCI-H716 cells. Furthermore, butyrate fed to 
wild-type mice was shown to stimulate secretion of PYY and GIP (Lin, et al. 
2012). It has been reported that butyrate induced GIP secretion occurred in a 
FFAR3-indepentent pathway (Lin, et al. 2012), suggestive of FFAR2 
involvement in GIP secretion from K-type cells or perhaps L/K-type cells.  
There are recent reports indicating that SCFA receptors are localised to 
enteroendocrine cells throughout the gastrointestinal tract. For example, 
SCFA receptors have been shown to be expressed in duodenal I cells, that 
secrete CCK (Sykaras, et al. 2012). However, studies have shown that 
SCFA are unable to evoke CCK secretion from the intestinal cell 
(McLaughlin, et al. 1999). It is suggested that SCFA receptors may detect 
SCFA levels circulating within the blood (Sykaras, et al. 2012).  
Duodenal SCFA receptors were reported to induce luminal bicarbonate 
secretion and enhance levels of GLP-2 in portal blood (Akiba, et al. 2014). 
Furthermore, acetate and propionate were shown to activate FFAR3 
provoking secretion of GLP-2 causing bicarbonate release. Activation of 
FFAR2 induced secretion of 5-HT increasing bicarbonate levels through 
activation of muscarinic and 5-HT receptor (Akiba, et al. 2014). 
In the stomach, FFAR2 and FFAR3 have been shown to be localised to a 
cluster of tuft cells within the gastric groove (Eberle, et al. 2014), FFAR2 was 
demonstrated to be localised to X/A cells where stimulation inhibits ghrelin 
secretion through a Gα i/o pathway (Engelstoft, et al. 2013). Whether SCFA 
induce leptin secretion from P cells of the stomach remains to be 
determined. 
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These studies provide evidence that the SCFA receptors may not be limited 
to the colon and therefore provide ample future research opportunities to 
understand the roles of SCFA receptors within the gastrointestinal tract and 
other tissues. Together, future work will help elucidate their importance in 
appetite control, energy homeostasis and animal welfare and human health 
and wellbeing. 
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